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Abstract 
Ultraviolet radiation (UVR) in solar light is important for skin biology. It is 
involved in the development acute and chronic skin inflammation, aging and 
cancer, causing erythema, tanning and local or systemic immunosuppression. 
Omega-3 polyunsaturated fatty acids (n-3 PUFA) are considered anti- 
inflammatory and could reduce the damage caused by overexposure to UVR. 
Although, n-3 PUFA have been considered as photoprotective agents, their 
exact mechanisms of action is not completely understood. 
The aim of the work is to determine the effect of UVR and the n-3 PUFA 
eicosapentaenoic acid (EPA), or docosahexaenoic acid (DHA) on human skin 
cells (in vitro study), specifically on: cell viability, apoptosis and their metabolism 
through the cyclooxygenase and lipoxygenase pathways. Also, to study the 
cellular incorporation and effect of n-3 PUFA on the fatty acid profile of skin 
cells. A clinical study was undertaken to assess the incorporation of n-3 PUFA 
supplements in human skin.   
A clinical study was performed in 40 healthy women (active group) 
supplemented with 4g/day of EPA (70%) and DHA (10%) and 40 healthy 
women (placebo group) supplemented with 4g/day of glyceryl tricoprylate 
coprate (GTCC). After 3 months, both blood samples and skin punch biopsies 
were collected and analysed for fatty acids by gas chromatography (GC). 
HaCaT keratinocytes and 46BR.1N fibroblasts were cultured and treated with 
10 and 50µM of either EPA, or DHA or oleic acid (OA) for 72h and exposed to 
15 and 50 mJ/cm2. Cell viability was measured by the MTT assay and cell 
apoptosis by a colorimetric method, at 24h post UVR. Cells and culture media 
were analysed by GC and liquid chromatography tandem mass spectrometry 
(LC/ESI-MS/MS) to assess cellular fatty acids and production of eicosanoids. 
II 
 
The clinical a study showed that in RBC saturated fatty acids (SFA) 
(44.27±7.43%) were the main fatty acid group followed by n-6 PUFA 
(29.61±5.53%). While in dermal tissue monounsaturated fatty acids (MUFA) 
(58.90±9.80%) was the main fatty acid group followed by SFA (27.06±6.78%).  
A significant increase in EPA, DHA and docosapentaenoic acid (DPA) was 
observed in RBC but only EPA was significantly increased in the dermis post n-
3 PUFA supplementation.                            .                                                                    
The viability of HaCaT keratinocytes and 46BR.1N fibroblasts decreased post 
UVR and this was further reduced post PUFA treatment. Cell apoptosis 
increased when cells were exposed to UVR and further increased when cells 
were treated with EPA and DHA.                                .                                                  
In HaCaT keratinocytes MUFA (54.22±8.82%) was the main fatty acid group 
followed by FAS (37.11±.9.16%), while SFA (51.94±8.68%) was the main group 
followed by MUFA (27.07±4.79) in 46BR.1N. Treated both cells with EPA and 
DHA showed significant increased in cellular EPA, DPA and DHA.                                                                                                                          
46BR.1N fibroblasts produced higher levels of prostaglandins (PG) compared to 
HaCaT keratinocytes: PGE2 and PGD2 were the main PG in both HaCaT 
(7.96±3.18 and 1.48±1.19 pg/million cell; respectively) and 46BR.1N with 
(44.2±23.00 and 17.1±9.71 pg/million cell; respectively). Significant increase in 
PGE1 and PGE2 occurred when cells were exposed to 15mJ/cm
2 UVR. 
Treatment with n-3 PUFA decreased the level of PGE1 and PGE2, and increase 
production PGE3 at the baseline and post UVR. Both cell lines produced 
hydroxy fatty acids and the concentration of these mediators was higher in 
46BR.1N than HaCaT. The concentrations of these mediators were significant 
increased post UVR: treatment with n-3 PUFA decreased the level of HODE 
and HETE, and increase production of HEPE and HDHA at baseline and post 
UVR.  
Overall, n-3PUFA treatment led to increases in the content of EPA and DHA on 
RBC, dermal tissue and human skin cell lines. EPA and DHA in skin cell lines 
appear to offer protection by increasing cellular apoptosis, decreasing 
inflammatory mediators specifically PGE2 and 12-HETE, and increasing anti-
inflammatory mediators such as PGE3, 15-HEPE and 17-HDHA.   
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1.1. Skin 
          The skin is a complex multilayered organ with several specialized 
appendages   (Freinkel and Woodley, 2001). The skin is identified as the largest 
and one of the most important organs in the body (Bos, 2005). It is about 1.8 m2 
in surface area, 1.2 mm in average thickness, and can weigh up to 4.7kg with 
blood and 4.2 kg without blood. The thickness varies and it can be extremely 
thin in some areas of the body, such as the eyelids and postauricular area.  
Overall skin constitutes 6% of body weight (Goldsmith, 1990). Skin has 
important roles and functions in the human body, due to the variety and unique 
combination of cells of which it is made. The skin protects the body from 
external environmental influences, such as chemical, physical and bacterial 
damage (Madison, 2003) and harmful rays including ultraviolet radiation (UVR) 
(Creidi et al., 1994) (Figure1.1). 
 
 Figure.1.1. Schematic of the structure of human skin (Taken from Kendall and 
Nicolaou, 2013). 
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The skin consists of three layers: the epidermis or outer layer, the dermis or 
middle layer and the subcutaneous tissue or bottom layer (Figure 1.1). Each 
layer comprises specialised cells, and  each has its own role and function.  
1.1.1. Epidermis  
         The epidermis is the external layer of the skin and acts as a physical 
barrier between the body and the environment. The thickness of the epidermis 
is about 0.8 – 1.4 mm (Gawkrodger, 2008). The epidermis does not contain 
blood vessels; therefore it is nourished from the dermis by diffusion. Four types 
of cells are important for the function of the epidermis: keratinocytes, 
melanocytes, Langerhans cells and Markel cells. The epidermis is divided into 
four layers: stratum basale (SB), stratum spinosum (SS), stratum granulosum 
(SG) and stratum corneum (SC) (Figure 1.2). 
 
  
Figure.1.2. Schematic representation of human epidermis (Taken from 
ww.biomedexperts.com). 
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1.1.1.1. The layers of the epidermis  
1.1.1.1.1. The stratum basale layer  
          The stratum basale layer (Figure1.2) is a germinative layer that is 
generally described as single layer of columnar basal cells (Graham-Brown and 
Bourke, 2007). Every basal cell divides by mitosis every four days to generate 
new basal cells. The new basal cells constantly push older cells up to the skin 
surface. The stratum basale cells are attached to the basement membrane by 
hemidesmosomes (Heyden et al., 1992). 
1.1.1.1.2. The stratum spinosum layer  
            The stratum spinosum layer (Figure 1.2) is directly above the basal layer. 
In this layer, keratinocytes become polyhedral after they lose their columnar 
shape, and their ability to produce the amount and types of keratin is also 
increased (Mottaz and Zelickson, 1975). Lipid-enriched lamellar bodies (LB) 
(keratenosomes, membrane-coating granules) appear first in this layer. The 
cells begin to become flat and elongated in the upper layers of the stratum 
spinosum, and migrate to the stratum granulosum.  
1.1.1.1.3. The stratum granulosum layer  
         The stratum granulosum (Figure 1.2) is above the stratum spinosum layer. 
Granule cells can be recognised by their basophilic keratohyalin granules and 
lamellar bodies which are biochemically composed of lipids. The lipid content of 
lamellar bodies is secreted into the intercellular spaces of the deeper stratum 
corneum (Freinkel and Woodley, 2001). Keratinocytes lose the ability to 
differentiate and as a result, cornified cells appear (Candi et al., 2005, Ishida-
Yamamoto and Iizuka, 1998). 
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1.1.1.1.4. The stratum corneum layer  
          The outer layer of the epidermis is the stratum corneum (Figure1.2). It 
plays an important role in maintaining life as the barrier of the skin. Moreover it 
is involved in the regulation of transepidermal water loss. The stratum corneum 
contains lipid secreted by lamellar bodies. The corneocytes become flat and not  
nucleated as a result of the final step of the differentiation of keratinocyte 
(Proksch et al., 2008). Although corneocytes are not alive, they are still 
biochemically active and are linked and connected together by intracellular 
lipids (Tobin, 2006, Marks et al., 2006). There is a complex mixture of lipid and 
proteins between the corneocytes. Keratinocyte secreted enzymes metabolise 
and break down the intracellular lipids to produce a lipid mixture that contains 
fatty acids (15%), cholesterol (25%) and ceramides (50%) of the total lipid mass. 
The lipid mixture is important for the skin's epidermal barrier (Holden et al., 
2002).  
1.1.1.2. Epidermal cells 
1.1.1.2.1. Epidermal keratinocytes  
          Keratinocytes are the major type of cell in the epidermis. They constitute 
approximately 95% of all cells found in the epidermis (Rook and Burns, 2004, 
Lippens et al., 2009). They form several layers from the epidermal base 
membrane to the skin surface. Keratinocytes are responsible for the production 
and maintenance of the stratum corneum layer. Furthermore, they participate in 
immunological and inflammatory processes (Forslind et al., 2004).  
         Keratinocytes exist in the stratum basale and then migrate from the basal 
layer to reach the skin surface. As they migrate, they produce different types of 
6 
 
keratins, which are insoluble proteins that help to protect the skin. Keratins type 
5 and type 14 are produced by the keratinocytes in the stratum basale layer of 
the epidermis (Heyden et al., 1992). In the stratum spinosum, the ability of 
keratinocytes to produce keratins is increased as well as their ability to produce 
different types of keratins. At the terminal stage of keratinocyte differentiation 
keratins type 1 and type 10 are the main keratins produced (Heyden et al., 
1992). Once the keratinocytes reach the granular epidermal layer, keratohyalin 
granules and filaggrins appear and the cells become corneocytes. The main 
types of keratins secreted at this stage are type 6 and type 16. 
1.1.1.2.2. Melanocytes  
          During early fetal development, melanocytes are derived and migrate into 
the skin from the neural crest (Erickson and Goins, 1995). They are located in 
the stratum basal layer of skin. They comprise 1-2% of the epidermal cell 
population and constitute about 5-10 % of the cell population in the basal layer. 
The main function of melanocytes is to synthesise melanin (Gawkrodger, 2008). 
Two main types of melanin are produced by melanocytes the red/yellow 
pheomelanin and the black/brown eumelanin. The synthesis of melanin takes 
place in the melanosomes. Once melanin is produced the melanosomes are 
transferred into the neighbouring keratinocytes (Kobayashi et al., 1998). The 
number and size of melanosomes is important in determining skin pigmentation. 
They are larger in black skin than in white skin. Each mature melanocyte can 
make contact with about 30–40 keratinocytes to make the epidermal–melanin 
unit (De Luca et al., 1988). Ultraviolet irradiation is the main factor that 
stimulates melanin production (Graham-Brown and Burns, 2007, Gawkrodger, 
2008). Melanin protects cells from UVR damage by a) absorbing electro-
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magnetic radiation of this wavelength and b) acting as a scavenger of free-
radicals which are produced by UVR (Prota, 1997). Melanocytes are also able 
to produce a wide range of signalling molecules, such as melanocortin peptides 
(Wakamatsu et al., 1997), cytokines (Förster E et al., 1991), serotonin 
(Johansson et al. 1998), catecholamines (Iyengar B and Misra RS 1987) and 
eicosanoids (Masoodi et al., 2010, Gledhill et al., 2010). 
1.1.1.2.3. Langerhans cells    
          Langerhans cells are generally found in the epidermis and in hair follicles 
within the outer root sheet (Baumann et al., 2003). They are epidermal dendritic 
cells and Birbeck granules  are characteristic of them (Musso et al., 2008).  
Langerhans cells were identified by Langerhans in 1868  (Langerhans, 1885). 
As they are not linked to other cells by desmosomes, they can move and 
migrate from the skin to the immune system (lymph nodes). It is thought that 
they are able to internalise and process foreign antigens and transport them to 
the skin lymph nodes where cutaneous immune responses are initiated 
(Cumberbatch et al., 2003). Langerhans cells migration and maturation is 
mainly controlled by cytokines that are secreted by the cells themselves end 
those secreted by surrounding keratinocytes (Griffiths et al., 2005). Also, in 
response to UVR, LCs migrate to the lymph nodes (Dandie et al., 2001, Allan et 
al., 2006).           
1.1.1.2.4. Merkel cells    
          Merkel cells were first described by Merkel FS in 1875; these large cells 
are found in the basal layer of the epidermis (Sidhu et al., 2005). The number of 
Markel cells is low compared to keratinocytes. Merkel cells are associated with 
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nerve terminals, forming a Merkel cell-neuron complex, which acts as a 
mechanoreceptor (Baumann et al., 2003).  
1.1.2. Dermis 
          The dermis is found directly under the epidermis (Figure1.1). It varies in 
thickness from 0.6 mm in eyelids to 3 mm in the back of the palms and the 
soles of the feet (Gawkrodger, 2008). The dermis is composed of two layers. 
The upper papillary layer contains reticulin fibres, elastin and collagen. This 
layer is adjoined to the epidermis (Washington et al., 2001). The lower reticular 
layer has fewer reticulin fibres, and an elastin and collagen network that 
provides structural support. Like any connective tissue, the dermis has many 
types of cells: fibroblasts which synthesise collagen, elastin and, ground 
substance, mast cells or mastocytes (which are placed near the blood vessels) 
and histocytes which are a kind of macrophage. In contrast to the epidermis, 
sensitive nerve endings and small blood vessels are found in the dermal layer 
(Starr, 2008). 
 1.1.2.1. Dermal fibroblasts 
         Fibroblasts are one of the most important cells in the skin (Sorrell and 
Caplan, 2004). They synthesise all the components of the protein matrix: 
collagen, elastin and ground substance. They also, produce enzymes such as 
collagenases and gelatinases, which are responsible for degradation and 
remodelling of the collagen matrix (Soter and Baden, 1984). Collagen  makes 
up 90% of the total dermal protein and about 70-80% of the skin’s total dry 
weight (Hunter, 2002). There are at least 25 types of collagen and about half of 
them are present in the skin. Collagen type I (85–90%) is the most abundant  
followed by collagen type III (8–11%) and collagen type V (2–4%) (Uitto, 1989). 
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Elastin is the second protein produced by fibroblasts. It constitutes about 2% of 
the skin’s total dry weight and most of it is located in the dermis (Rosenbloom et 
al., 1993). 
1.1.2.2. Mast cells 
          Mast cells are considered secretory cells that are found in all dermal 
regions but are most commonly present in the upper dermis (Soter and Baden, 
1984). Mast cells have an important role in inflammatory and allergic reactions, 
and they secrete bioactive mediators such as histamine, cytokines and 
eicosanoids such as prostaglandin D2 (PGD2) (Dawicki and Marshall, 2007, 
Wedemeyer et al., 2000). It has been reported that UVR induces the migration 
of mast cells from skin to draining lymph nodes (Byrne et al., 2008). 
1.1.3. Subcutaneous layer 
         The subcutaneous layer is situated below the dermal layer (Figure1.1). It 
is composed of connective and adipose tissue which is connected with the 
dermis’s connective tissue. Through this layer the skin is stabilised and 
connected to the underlying body structure. At the same time, this 
subcutaneous layer separates the skin from the deep fascia, which is situated 
around the muscles (Premkumar, 2004).The adipose tissue serves as an 
energy storage reservoir and insulator.  
          In addition to all these cells, skin also has neural, vascular and lymphatic 
systems, sensory nerve receptors, free terminals and hair follicle endings. 
Extensive vasculature housed in the dermis helps to regulate body temperature, 
to deliver oxygen and nutrients, and to remove toxins and waste products. Skin 
also has many glands such as the sebaceous gland, which is responsible for 
secreting sebum which serves to maintain the pH of the skin surface at around 
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5. Another major gland in the skin is the sweat gland, which is found in almost 
every part of the skin and produces sweat. Sweat production is a control 
mechanism useful for maintaining the homeostasis of the body.   
1.2. Ultraviolet radiation and human skin 
          The sun is the main source of UVR reaching the surface of the earth. 
More than 98% of UVR in the sunlight is blocked by the earth’s ozone layer. 
The wavelength range of UVR is longer than X-ray-s and shorter than visible 
light (400 – 700nm), ranging, typically from 100 to 400 nm (Figure 1.3). The 
UVR band can be subdivided into three ranges: UVA 315 – 400 nm, UVB 280 – 
315 nm and UVC 100 – 280 nm (Ghetti et al., 2006, Ohnaka, 1993). The ozone 
layer is able to absorb most UVR with a wavelength of less than 295 nm. 
Therefore, UVC does not reach the earth’s surface and only UVB and UVA are 
important in respect to human skin. Depending on the type and amount of UVR, 
humans can experience either a beneficial or a harmful effect (Ohnaka, 1993).  
            UVB is considered the most destructive form of UVR because it is 
plentiful in the environment. UVB radiation is mainly absorbed by the epidermis 
and upper dermis. However, UVA, with its longer wavelength can penetrate 
deeper through the epidermis to reach the dermis (Costin and Hearing, 2007).  
UVB has enough energy to cause direct damage to cellular DNA. Harmful 
effects can include erythema, cataracts, and the development of skin cancer. 
UVA can also cause DNA damage primarily through the generation of reactive 
oxygen species (ROS) (Kvam and Tyrrell, 1997). Moreover, both UVA and UVB 
stimulate the production of melanin and induce apoptosis of melanocytes and 
keratinocytes an effect that has been recognised as a protective mechanism in 
the skin (Bowen et al., 2003). In general, UVB and UVA contribute to freckling 
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and skin wrinkling and can induce skin carcinogenesis in a number of ways: 
directly by generation of DNA photoproducts or indirectly by releasing mediators 
that cause oxidative damage to DNA (Ravanat et al., 2001, Lee et al., 2013a). 
 
 
 
Figure.1.3. Wavelength ranges of the electromagnetic radiation spectrum (Stroebel 
and Richard. 2009) 
 
1.2.1. Effect of ultraviolet radiation on DNA  
          DNA absorbs UVR with a wavelength of about 260nm and the absorption 
is decreased at increased wavelength up to about 300nm. This wavelength 
range is within the UVB range, and UVB is responsible for direct DNA damage 
in the cells (Taylor, 1994). The cyclobutane pyrimidine dimers (CPD) and 
thymine dimers are the major DNA photoproducts generated after absorbance 
of UVR. CPD and the (6-4) pyrimidine pyrimidon photoproduct ((6-4) (PPs) have 
a role in the development of skin cancer. Specific mutations from these 
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products lead to UVR fingerprint which includes CC      TT and C    T (Ravanat 
et al., 2001). It has been suggested that formation of dimers especially CPD, by 
UVR led to keratinocytes releasing immunosuppressive mediators such as IL-
10 and TNF-α (Walker and Young, 2007). The repair mechanism of CPD leads 
to stimulation of skin pigmentation which protects the DNA from  further damage 
(Bestak and Halliday, 1996). 
1.2.2. Effects of ultraviolet radiation on photoimmunosuppression 
          UVR has the ability to inhibit the immune system of the skin not only 
locally but also systemically. Local immunosuppression relates to the 
circumstance where the antigen is applied to the irradiated skin site, while 
during the process of systemic immunosuppression the antigen is away from a 
skin site that has been irradiated (Chung et al., 1986). High doses of UVB are 
needed to reduce immunity at distant non-exposed sites, while much lower 
doses are required to induce local photoimmunosuppression. Furthermore, it is 
recognised that local photoimmunosuppression by UVB is caused even at 
suberythemal doses (Young, 2003, Vink et al., 1996). Various mechanisms may 
be involved in systemic and local immunosuppression. On the other hand UVR 
has a restricted ability to penetrate  the skin and generates systemic 
immunosuppression through stimulation of soluble mediators and cytokines, 
such as IL-10, IL-4 and IL -13,  (Schwarz et al., 1996, Loser et al., 2007) and 
tumor necrosis factor alpha (TNF-α) (Werth et al., 2003) and lipid mediators 
such as platelet activating factor (PAF) and prostaglandin E2 (PGE2) . 
          With regard to both systemic and local immunosuppression, it is 
recognised that the immune system can be compromised by UVR in an antigen-
specific way through the creation of immune tolerance; antigen specific Tregs 
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may be identified in the draining LNs of the skin, as well as the spleen, after 
UVR (Schwarz, 2008, Schwarz, 2005). The immunosuppressive impacts of UV-
exposure in the specific case of humans can be seen through various examples, 
including reduced contact hypersensitivity (CHS) responses, as well as the re-
activation of herpes simplex as a result of direct sun exposure (Damian et al., 
2011). 
1.2.3. Effect of ultraviolet radiation on urocanic acid 
           Studies on the UVR effects and absorption by the components of the skin 
indicated that in addition to DNA, urocanic acid (UCA) is an important 
photoproduction in the skin. UCA is synthesised by keratinocytes during the 
process of keratinisation (Noonan and Defabo, 1992). After interaction with 
UVR, trans-UCA, which is the major skin UCA isomer, is converted to cis-UCA 
isomer (De Fabo and Noonan, 1983). Several studies suggest that cis-UCA is 
one of the immunosuppression mediators induced by UVB (Noonan and Defabo, 
1992, McLoone et al., 2005). Morover, it has been found that cis-UCA has a 
significant effect on both local and systemic CHS immunosuppression after 
UVR (Vanstrien and Korstanje, 1995). The mechanism of cis-UCA action is still 
unclear but it has been reported to act on  cells through histamine-like receptors 
or platelet activating factor receptor (Beissert et al., 1997, Walterscheid et al., 
2006). Finally, upregulation of the immunomodulatory mediators such as PGE2, 
TNF-α and IL-6 was found after human keratinocytes were treated with cis-UCA 
(Kaneko et al., 2009). 
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1.2.4. Activation of apoptosis by ultraviolet radiation  
          Apoptosis is a protective mechanism that minimises and prevents the 
malignant transformation of cells with irreparable DNA damage. Apoptosis can 
be induced by protein p53 (p53), which activates transcription by up-regulating 
the expression of pro-apoptotic genes such as Bax and Fas. Also, p53 down-
regulates the expression of anti-apoptotic genes such as Bcl-2. Over all, 
apoptosis in response to UVR induced damage is regulated at least in part by 
p53, p2, Bax and Bcl-2 pathways.  
        The effect of UV on the induction of apoptosis may depend on the dose 
and type of cell. Figure 1.4 shown an outline of the main ways of UVR induced 
apoptosis: (İ) following DNA damage, p53 is activated and leaks to mitochondria 
cytochrome c. (İİ) UVR can activate several cell membrane death receptors 
which then activate the caspase pathways. (İİİ) Activation of membrane death 
receptors by UVR leads to activation of caspase 8, which cleaves cytosolic Bid 
to its truncated active form (tBid). tBid can then be transferred to the membrane 
of mitochondria. This would induce the translocation and the oligomerisation of 
Bax or Bak. These proteins activate the release of cytochrome C from the 
mitochondria (Bang et al., 2003, Ashkenazi and Dixit, 1998). (iv) Finally, UVR 
can induce apoptosis by increase ROS generation, which can than change the 
structure and function of several molecules (Lee et al., 2013). All these 
apoptotic pathways are balanced by activation of the E2F1 transcription factor, 
which is up regulated in response to DNA damage and promotes DNA repair 
(Berton et al., 2005). 
         In the epidermis, apoptosis plays an important role in controlling the 
development of erythema which occurs after sun exposure (Kraemer, 1997). 
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The peak sunburn appears 24h post UVR exposure and within several days it 
gradually declines (Okamoto et al., 1999). The dead cells may be replaced by 
hyperproliferative cells, leading to epidermal hyperplasia. This implies that UV-
induced apoptosis and hyperplasia are closely linked, tightly regulated and that 
deregulation of these pathways may lead to skin cancer development 
(Melnikova and Ananthaswamy, 2005).  
 
 
Figure.1.4. Mechanism of UVR induced apoptosis (taken from Lee et al., 2013a). (İ) 
UVR induced DNA damage, p53 is activated and leaks to mitochondria cytochrome c. 
(İİ) UVR can activate a membrane death receptors (extrinsic pathway). (İİİ) Activation 
of membrane death receptors by UVR leads to activation intrinsic pathway. (iv) UVR 
induces apoptosis by increase ROS generation.  
Apaf-1= Apoptotic protease activating factor 1 
CD95= Cluster of differentiation 95  
FADD = Fas associated death domain  
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1.2.5. Skin pigmentation and ultraviolet radiation. 
           Pigmentation is one mechanism of skin protection against UVR. Through 
the barrier of keratinocytes that contain melanin, melanin functions as a 
photoprotector by absorbing UVR (Thody et al., 1993). There are many 
variations in human skin pigmentation including racial, regional, and individual, 
and these are affected by environmental factors such as different degrees of 
exposure to UVR. Skin colour depends on constitutive pigmentation and 
facultative pigmentation. Based on this skin has been classified into six skin 
prototypes, as shown in Table1.1 (Fitzpatrick, 1988). The classification is based 
on the ability of individuals to undergo melanogenesis (tanning) in response to 
sun or UVR exposure. Skin type I refer to individuals who always burn easily 
and do not tan in response to UVR. Meanwhile skin type VI represents people 
who are deeply pigmented, have very dark skin and almost never burn when 
exposed to UVR.  
Table.1.1. Classification of human skin phototypes (Fitzpatrick, 1988).  
Skin 
type Skin colour Sunburn Tanning 
Skin 
cancer 
I White High Very poor High 
II White High Poor High 
III Light Brown Moderate Good Moderate 
IV Moderate Brown Low Very good Low 
V Dark Brown Very low Very good Very low 
VI Black Never Deep pigmentation Very low 
                        
17 
 
1.2.6. Skin response to acute UVR exposure    
          The acute effects of UVR from natural (sunlight) and artificial (lamps) 
sources are a major worry for human health. The major acute effects of UVR on 
normal human skin are: sunburn inflammation (erythema), tanning, and local or 
systemic immunosuppression (Matsumura and Ananthaswamy, 2004). 
          Erythema is an acute injury that occurs after extreme exposure to UVR. 
When the  superficial blood vessels of the dermis dilate, the rate of blood flow 
increases in the skin, and this leads to redness of the skin (Diffey, 1991). This is 
apparent from about four hours after exposure and is maximal at about 24 
hours (Young et al., 1996, Rhodes et al., 2009). Excessive exposure to UVR 
may lead to epidermal and dermal oedema, pain, and even blistering (Taylor 
and Sober, 1996).  
          Immediate tanning occurs within 5-10 min of UVR exposure and lasts for 
12 hours before fading. Delayed tanning persists for weeks to months and 
occurs as a consequence of melanocytes stimulation and production of new 
melanin (Diffey, 1991).  
          Hyperplasia of the epidermis also occurs as a result of repeated exposure 
to the sun, which stimulates epidermal cell hyperproliferation and produces 
epidermal thickening. Thickening of the stratum corneum layer increase three-
fold within one to three weeks, and about three fold- to five-fold within seven 
weeks. Skin thickness returns to normal about one to two months after 
exposure to irradiation has ceased. The increased thickening of the skin allows 
better protection against UVR (Diffey, 1991, Soter, 1990). 
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1.2.7. Skin response to chronic UVR exposure    
           It is clear that any excessive exposure to UVR can lead to damage of the 
human skin structure (Leyden, 1990). In the long-term, this damage can lead to 
photoageing and carcinogenesis, through chronic inflammation and DNA 
damage.  Photoaging or dermatoheliosis refers to the structural changes in the 
skin resulting from frequent sun (UVR) exposure rather than the passing of time 
alone (Taylor and Sober, 1996). There are many clinical signs of photoaging 
such as, dryness, deep wrinkles, accentuated skin furrows, sagging, loss of 
elasticity, mottled pigmentation and telangiectasia (Leyden, 1990).  
          Photoaging appears in the epidermis as epidermal hypertrophy with 
keratinocyte disarray and hypertrophy of sebaceous glands and the dermal 
matrix (Young, 1990). Photoaging also leads to an increase in dermal 
thickening due to the presence of massive quantities of thickened, tangled and 
degraded elastic fibres. Overall, UVR is a complete carcinogen, able to initiate 
and promote cancer, DNA damage and immunosuppression (Ziegler et al., 
1994). 
1.3. Fatty Acids  
          Fatty acids are carboxylic acids that contain between 2-30 carbons. The 
hydrocarbon chain terminates with a carboxyl group at one end and methyl 
group at the other. The carboxyl group can form ester links with alcohols, such 
as cholesterol forming cholesterol esters, and glycerol forming various 
acylglycerols. Fatty acids with carbon chain lengths of between 12 and 22 are 
the most common in animal cells. Fatty acids can be saturated or unsaturated 
depending on the presence of double bonds in the carbon chain. Unsaturated 
fatty acids can be divided into two groups: monounsaturated fatty acids (MUFAs) 
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which contain only one double bond and polyunsaturated fatty acids (PUFAs) 
which contain two or more double bonds.  PUFAs are also described by the 
position of the last double bond relative to the terminal carbon of the acyl chain. 
Following a popular shorthand notation, omega -3 polyunsaturated fatty acids 
that have the last double bond on the 3rd carbon from the end of the acyl are 
described as n-3 PUFA. Omega 6 polyunsaturated fatty acids with the last 
double bond on the 6th carbon from the end of the acyl chain are described as 
n-6 PUFA.  
1.3.1. Fatty acid biosynthesis  
          Fatty acids are supplied through diet which is considered the main and 
most important source for the provision of essential fatty acids. However, many 
fatty acids are produced by endogenous synthesis that occurs mainly in the liver. 
Fatty acid biosynthesis takes place in the cytosol starting with acetyl-CoA which 
is formed from pyruvate or by β-oxidation of the fatty acids in the mitochondria. 
Acetyl-CoA reacts with oxaloacetate to give citrate, which has to be transported 
from the mitochondria to the cytosol where it is transformed back to acetyl-CoA. 
Following the reaction catalysed by acetyl-CoA carboxylase, malonyl-CoA is 
formed and the acyl chain starts growing by the addition of 2-C up to a length of 
16C (palmitic). This occurs with the help of the multi functioning enzyme fatty 
acid synthase (Mayne, 1994).  
          There are some tissues which contain enzymes that produce short chain 
saturated acids: for example, the mammary gland of some species can produce 
fatty acids containing 8 to 10 carbons. The biosynthesis of fatty acids longer 
than palmitic acid occurs through additional reactions leading to elongation and 
desaturation of the acyl chain. 
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1.3.2. Biosynthesis of unsaturated fatty acids  
            Most monounsaturated fatty acids are synthesised by the addition of     
a single double bond to a saturated fatty acid this reaction occurs typically 
between carbons number 9 and 10 by the action of the enzyme delta (∆) 9 
desaturase. For example, stearic acid (C18:0) is transformed into the 
monounsaturated fatty acid oleic acid (OA,18:1n-9) (Figure 1.5). All eukaryotes 
and some bacteria can form PUFA. Plants can synthesise PUFA by adding a 
new double bond between the existing double bond and terminal methyl group, 
whereas animal desaturases normally introduce a new double bond between an 
existing double bond and the carboxyl group. Insertion of a new double bond 
between carbons 12 and13 (counted from the carboxyl carbon) of OA yields 
linoleic acid (LA,18:2 n-6) and the enzyme that catalyses this reaction is called 
∆ 12 desaturase (Figure 1.5). LA yields α-linolenic acid (ALA,18:3 n-3) by the 
addition of a double bond between carbons 15 and 16 by ∆ 15 desaturase 
(Minich, 1999, Newsholme and Leech, 2009). The human body cannot produce 
fatty acids which contain at least two double bond positioned from C9 and 
above, because the ∆ 12 and ∆ 15 desaturases are absent. As a result LA and 
ALA cannot be synthesised de novo and must be obtained from the diet 
(Edwards and O'Flaherty, 2008). LA and ALA are known as essential fatty acids. 
LA is the parent fatty acid of the n-6 PUFA family and ALA is the parent fatty 
acid of the n-3 PUFA. The pathway of desaturation and elongation occurs in the 
liver. LA is converted to γ -Linolenic acid (GLA, 18:3 n-6) by ∆ 6 desaturase and 
is then elongated to dihomo γ-linolenic (DGLA, 20:3 n-6). Arachidonic acid (AA, 
C20:4 n-6) is generated from DGLA by a ∆ 5 desaturase. A summary of these 
biosynthetic pathways is shown in Figure 1.5. 
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n-9 fatty acids                                
Stearic acid (C18:0) 
             ∆ 9-desaturase                                           
                                                     n-6 fatty acids                                 n-3 fatty acids 
 Oleic acid       ∆ 12 desaturase              Linoleic acid       ∆ 15 desaturase       α-linolenic acid 
C18:1n-9            Plants only                    C18:2n-6            Plants only                C18:3n-3  
          ∆ 6-desaturase                                        ∆ 6-desaturase                                        ∆ 6-desaturase                
                    
C18:2 n-9                                γ -Linolenic acid                                  Stearidonic acid 
                                                       C18:3 n-6                                          C18:4 n-3 
          Elongase        Elongase                                              Elongase 
C20:2 n-9                                   Dihomo-γ-linolenic                        Eicosatetraenoic acid 
                                                        C20:3 n-6                                         C20:4 n-3   
        ∆ 5-desaturase                                        ∆ 5-desaturase                                         ∆ 5-desaturase                
                    
Mead acid                               Arachidonic acid                            Eicosapentaenoic acid 
 C20:3 n-9                                      C20:4 n-6                                          C20:5 n-3 
          Elongase                                                  Elongase                                             Elongase 
C22:3 n-9                              Docosatetraenoic acid                    Docosapentaenoic acid 
                                                         C22:4 n-6                                         C22:5 n-3   
          Elongase                                                  Elongase                                                       Elongase 
 
24:3 n-9 24:4 n-6                                            24:5 n-3 
        ∆ 6-desaturase                                         ∆ 6-desaturase                                              ∆ 6-desaturase                
 
24:4 n-9 24:5 n-6                                              24:6 n-3 
          β -oxidation                                               β -oxidation                                                   β -oxidation 
 
Docosatetraenoic acid             Docosapentaenoic acid                Docosahexaenoic acid 
       C22:4 n-9                                 C22:5 n-6                                         C22:6 n-3   
 
 
Figure.1.5. Outline of the major pathways involved in the biosynthesis of polyun-
saturated fatty acids  
DIET 
Strecker pathway 
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1.3.3. Omega-3 polyunsaturated fatty acids  
       Dietary n-3 PUFAs have properties important for health and disease, such 
as cardiovascular neuronal development, and regulation of plasma lipid levels 
and immune function (Aarsetoey et al., 2012). Intake of n-3 PUFAs leads to 
their distribution to virtually every cell in the body, with effects on membrane 
composition and function, eicosanoid synthesis, and signalling, as well as the 
regulation of gene expression(Salem et al., 2001). The n-3 PUFAs that are 
important in human nutrition are: ALA, EPA  and DHA (Lands, 1992). Several 
animal studies reported that the relative levels of n-6 and n-3 PUFA can be 
regulated by altering the balance of LA and ALA in the diet (Blank et al., 2002). 
The endogenous synthesis of n-3 PUFA from ALA is independently regulated 
by transcription factors or changes in the expression of the biosynthetic 
enzymes and also depends on substrate competition for existing enzymes 
rather than an increase in their mRNA expression (Tu et al., 2010). It has also 
been reported that a diet rich in LA can lead to inhibition of DHA synthesis 
(Gibson et al., 2013). Oily fish such as mackerel, salmon, sardines, anchovies 
and herring are the main sources of the long chain n-3 PUFA EPA and DHA. 
Lower amounts of n-3 PUFA are found in other fish such as tuna. Vegetable oils 
such as soybean and canola are a rich source of ALA. (Gerster, 1998). In 
addition to diet, endogenous synthesis is another source of n-3PUFA. EPA is 
elongated to DPA, further elongated to C24:6 n-3 and through the β oxidation is 
converted to DHA. The levels of DPA in circulation correlate with EPA level not 
with the fish consumption, in contrast high DHA levels correlate with dietary 
consumption, not with endogenous synthesis (Pawlosky et al., 2001). This 
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means that DPA comes from exogenous EPA and DHA, both of which depend 
on nutrition. 
1.4. Eicosanoids and related lipid mediators 
          Eicosanoids were first identified by Kurzrok and Leib of Columbia 
University in 1930, as a chemical that had an effect on cervical muscle cramps. 
In the mid-1930s, Euler discovered that human semen contained active 
compounds which, when injected, can contract or relax smooth muscle and 
affect blood pressure (Kurzrok. and Lieb., 1930). The biosynthetic pathways for 
eicosanoid production were discovered by Bergstrom, Samuelsson, and their 
associates in the early 1960s (Bergstrom and Sjovall., 1962). Eicosanoids are 
autacoids that are not stored but produced when needed (Velzing-Aarts et al., 
1999, Yilmaz, 2001). The eicosanoids have physiological effects on many 
biological systems such as the cardiovascular system, brain, eye, lung, kidney 
and skin (Bishop-Bailey et al., 2002, Ishihara et al., 2004). 
            There are two main families of eicosanoids: prostanoids which include 
prostaglandins, prostacyclins, and thromboxanes, and the leukotrienes 
(Velzing-Aarts et al., 1999). Oxidation of the C20:0 PUFA AA, EPA and DGLA, 
generates eicosanoids. When the parent fatty acid has 22 carbons (22 = 
docosa), the family of lipid mediators produced is termed docosanoids. When 
the precursor fatty acid has 18 carbons (18 = octadeca) the family is called 
octadeconoids. Three groups of enzymes contribute to the formation of 
eicosanoids and related lipid mediators: cyclooxygenases (COX-1 and COX-2), 
lipoxygenases (LOX) and cytochrome P450 oxidases (Funk, 2001, Ciccoli et al., 
2005). 
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         Biosynthesis of eicosanoids depends on the availability of free PUFA 
which depends on the capacity of the enzymes that remove them from 
membrane phospholipids. It is also influenced by dietary intake. Increased 
intake of foods rich in n-3 PUFA tends to decrease membrane AA content in 
favour of increased n-3 PUFA. Eicosanoid synthesis is precisely controlled. An 
effective way of regulation is through the expression of eicosanoids biosynthetic 
enzymes, which can be either down-regulated or up-regulated (Brock and 
Peters-Golden, 2007).  
1.4.1. The role of phospholipases in lipid mediator production 
          Phospholipases (PL) have an important role in eicosanoid and lipid 
mediator production. The first step in the biosynthesis of eicosanoids is the 
hydrolysis of membrane glycerophospholipids to release AA and other PUFA 
(Figure 1.6). There are many types of phospholipases but phospholipase A2 
(PLA2) is the most relevant enzyme (Dennis, 1987). The production of free AA 
is highly regulated and is balanced between two competing reactions, 
reacylation and transfer into various phospholipid pools by acyltransferases and 
transacylases, and phospholipid hydrolysis by PLA2 (Chilton et al., 1996).  
         More than 15 different mammalian PLA2 enzymes have been identified 
and they differ in their intracellular localisation and biochemical characteristics. 
The three major types are: secretary phospholipase A2 (sPLA2), cytosolic Ca
2+ 
dependent phospholipase A2 (cPLA2) and Ca
2+ independent cytosolic 
phospholipase A2 (iPLA2)(Dennis, 1994).  
        Among the PLA2 types, sPLA2 is a secretable isoform, with a low molecular 
mass of 13-18 kDa and it requires a millimolar concentration of Ca2+ for catalytic 
activity (Fuentes et al., 2002, Chen et al., 1994). Several sPLA2 subtypes have 
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been described in various cells: sPLA2 isoforms have been detected in 
keratinocytes but at low level mRNA including; sPLA2-s-IIA, -IID, -V, and –X. 
However, only sPLA2-X has been identified as being secreted by keratinocytes 
(Schadow et al., 2001). It has also been reported that sPLA2-X stimulates both 
tyrosinase activity and dendricity in melanocytes and this is mediated by 
lysophosphatidylcholine (Scott et al., 2006). Ca2+independent cytosolic 
phospholipase A2 (iPLA2), does not require Ca
2+ for catalytic activity. iPLA2 is 
similar in size (83-85 kDa) and shares the same intracellular location with cPLA2 
(Six and Dennis, 2000). Although Ca2+ is not required for the enzymatic action 
of iPLA2, it is reportedly up-regulated by calcium or calcium-dependent factors 
in some cell models (Murakami and Kudo, 2004). 
 
 
 
Figure.1.6. Outline of the biosynthetic pathway of prostanoids (taken from 
Waltenberger et al., 2011) 
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Cytosolic Ca2+ dependent phospholipase A2 (cPLA2) has a molecular mass of 
85 kDa and is present in many cells and tissues. cPLA2 was first discovered in 
platelets and macrophages. Ca2+ is required for cPLA2 activation and is 
necessary for binding to membranes (Kramer and Sharp, 1997, Clark et al., 
1995). cPLA2 plays an important role in releasing AA specifically from the sn-2 
position of membrane phospholipids for eicosanoids production (Balsinde et al., 
1995) and also has a role in the lysophospholipid regulation. cPLA2 has been 
considered a target for the development of anti-inflammatory drugs. cPLA2 
contributes to the long-term generation of AA preceding eicosanoid production 
in differentiated human keratinocytes (Sjursen et al., 2000). 
1.4.2. Prostanoids 
         The term prostanoids is used to describe the following eicosanoids: 
prostaglandins (PG), prostacyclin (PGI), and thromboxanes (TX). All 
prostanoids are derived from the unstable PGH2 through the action of many 
different prostanoid syntheses (Figure1.6). Prostanoids are involved in the 
inflammatory response. Prostaglandins are oxygenated C20-PUFA that contain 
a five-member ring; in prostacyclin there is a bridge of oxygen between the C6 
and C9 and thromboxane has a bicyclic oxane-oxetane ring structure. TXA2 is 
unstable and converts to the stable TXB2. The number of double bonds in 
prostanoids depends on the precursor of fatty acid. Series-1 prostanoids have 
only one double bond and derive from DHGLA. Series-2 prostanoids have two 
double bonds and derive from AA. The series-3 prostanoids have three double 
bonds and derive from EPA. In general, AA-derived eicosanoids are considered 
to have pro-inflammatory effects, whereas EPA and DHGLA derived 
eicosanoids have anti-inflammatory effects (Cowing and Saker, 2001). Figure 
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1.7 shows the structures of three types of prostaglandins E (PGE) and 
prostaglandins F (PGF) and their precursor PUFA.      
               
 
Figure.1.7. Structures of series 1,2 and 3 of PGE and PGF and their precursor 
polyunsaturated fatty acid (taken from lipidlibrary.aocs.org) 
1.4.2.1. The role of cyclooxygenase in prostanoid production 
          Cyclooxygenase (COX) was first purified in 1976 and cloned in 1988. It is 
the key enzyme in the biosynthesis of prostaglandins (Vane et al., 1998). There 
are two isoforms of COX; cyclooxygenase-1 (COX-1) and cyclooxygenase-2 
5c,8c,11c,14c-eicosatetraenoic acid 
(arachidonic acid, AA) 
 
5c,8c,11c,14c,17c-eicosatetraenoic acid 
(EPA) 
 
8c,11c,14c-eicosatrienoic acid (dihomo-
γ-linolenic acid, DGLA) 
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(COX-2). The enzymes are also known as endoperoxide prostaglandin H 
synthases-1 (PGHS-1) and -2 (PGHS-2). The structure of the active site in both 
COX-1 and COX-2 is very similar. However, it is larger in COX-2 than in COX-1 
(Smith et al., 2000). COX-1 is constitutively expressed in cells that produce 
prostaglandins involved in homeostasis. COX-2 is an inducible enzyme and can 
be up regulated in response to various stimuli. The presence of hydroperoxide 
at catalytic level is required for cyclooxygenase reaction (Kulmacz et al., 1994). 
However, COX-2 can be activated at 10 times lower hydroperoxide 
concentration than COX-1 (Tsai et al., 1995). In addition to AA, both COX-1 and 
COX-2 can metabolise EPA and DGLA to form prostanoids. The COX reaction 
adds two molecules of oxygen to AA to form prostaglandin G2 (PGG2). Then, by 
a peroxidase reaction PGG2 is converted to prostaglandin H2 (PGH2) which is 
very unstable. Once PGH2 is produced it is converted to a number of important 
biological mediators such as PGE2, PGD2 and PGI through the action of 
prostanoid synthases (Tsai et al., 1995, Kurumbail et al., 2001, Malkowski et al., 
2001) (Figure 1.6).  
          Cyclooxygenase can be inhibited by non-steroidal anti-inflammatory 
drugs (NSAIDs) such as aspirin and ibuprofen. Among all NSAIDs only aspirin 
can modify both COX-1 and COX-2 and inhibit it by acetylation of a serine 
residue positioned in the catalytic site of the enzyme (to Ser529 of COX-1 and 
Ser516 of COX-2). Inhibition or inactivation of COX leads to the inhibition of  PGs 
and TX production (Loll et al., 1995).  
1.4.2.2. The role of prostanoid synthases  
          Prostaglandin D synthases (PGDS) catalyse the isomerisation of the 
endoperoxide PGH2 to PGD2. Two types of PGDS have been identified: the 
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haematopoietic type PGDS (H-PGDS) and the lipocaline type PGDS (L-PGDS) 
(Urade and Hayaishi, 1999).  
        Prostaglandin E synthase (PGES) forms PGE. Three types of PGES have 
been characterised: the cytosolic PGES (cPGES) (Tanioka et al., 2000) and two 
isoforms of the membrane-bound PGES (mPGES) (Jakobsson et al., 1999): 
known as mPGES-1 and mPGES-2 (Tanikawa et al., 2002). In most tissues the 
generation of PGE2 involved in cellular homeostasis occurs via the action of 
COX-1 and cPGES. However when PGE2 is generated in response to a pro-
inflammatory stimulus, this occurs via the coordinated up-regulation and 
functional coupling of COX-2 and mPGES (Stichtenoth et al., 2001, Mancini et 
al., 2001). This can occur by common signalling, such as nuclear factor kappa B 
(NF-kB). Furthermore, the expression of mPGES-2 is induced under 
pathological conditions (e.g. cancer) and interacts with COX-2 (Park et al., 2006, 
Samuelsson et al., 2007). 
          There are two isoforms of the prostaglandin F synthase (PGFS): PGFS-I 
(lung-type) and PGFS-II (liver-type) (Suzuki et al., 1999). However the 
biosynthesis of PGF2 can occur via three pathways: directly from PGH2, or from 
PGE2 or PGD2. PGH 9-,11-endoperoxide reductase (PGH 9,11ER) catalyses 
the formation of PGF2α from PGH2; PGE 9-ketoreductase (PGE9-KR) catalyses 
the formation of PGF2α from PGE2; and PGD 11-ketoreductase (PGD11-KR) 
catalyses the formation of 9α,11β-PGF2α from PGD2 (Suzuki-Yamamoto et al., 
1999).  
          Prostacyclin (PGI2) is formed from PGH2 by the enzyme prostacyclin 
synthase (PGIS).  PGI2 is unstable and hydrolysed nonenzymatically to the 
inactive metabolite 6-keto-PGF2α (Liou et al., 2000, Hara et al., 1994). PGIS is 
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widely expressed in human tissues particularly in the endothelial cells. 
Futhermore, in endothelial cells the expression and production of both PGIS-
mRNA and PGIS-protein can by induced by TNFα and some inflammatory 
cytokines. Finally, thromboxane A synthase (TXAS) converts PGH2 to TXA2 
which is also unstable and is nonenzymatically converted to TXB2. 
The cyclopentenone prostaglandin PGJ2 is produced by spontaneous 
dehydration of PGD2. Similarly, PGJ2 isomerises to form Δ
12-PGJ2 and then 
goes through a secondary dehydration to15-deoxy-Δ12,14-PGJ2.  
1.4.2.3. The role of prostanoid receptors 
          Prostanoids have many functions and mediate physiological and 
pathophysiological processes in various organs, tissues and cells. They act via 
specific G-protein-coupled receptors. These are described as follows: DP for 
PGD, EP1, EP2, EP3 and EP4 for PGE; FP for PGF; TP for TX; and IP for PGI 
(Breyer et al., 2001). In addition, there are two isoforms of FP (FPA and FPB), 
and TP (TPα and TPβ), and eight of EP3 which only different in their C-terminal 
and are generated through alternative splicing. Moreover, PGJ2 and 15-deoxy- 
12,14-PGJ2 (15d-PGJ2) activate the PPAR nuclear receptors. The effect of 
prostanoid receptor activation on cell function is mediated by different 
intracellular signalling pathways. EP2, EP4 and IP receptors are coupled to G-
protein s (Gs) and can activate adenyl cyclase which increases production of 
intracellular cyclic adenosine monophosphate (cAMP). However, via Gq EP1 
and FP activate phosphatidylinositol metabolism. Finally, TP acts through two 
types of G-protein, Gq and Gl3, which activate phospholipase C. Although both 
TP isoforms are coupled to phospholipase C activation, TPα stimulates adenyl 
cyclase, whereas TPβ inhibits it (Hatae et al., 2002).   
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          Prostaglandins can have opposing effects depending on their signal 
transduction pathways and specific receptors. For example, PGE2 has 
vasoconstrictive effects when acting through EP1 or EP3 receptors but it has a 
vasodilator effect when acting via EP2 or EP4 receptors (Tang et al., 2000). 
Also, PGE2 can be pro-inflammatory and anti–inflammatory depending on its 
interactions with one of the EP receptors (Gualde and Harizi, 2004). Moreover, 
a low level of PGE2 decreases proliferation of human keratinocytes by 
stimulating EP3 receptor, whereas a high level of PGE2 stimulates proliferation 
by activation of the EP2 receptor. It has been found that deletion of EP2 
receptor can protect against UVR induced carcinogenesis, but it increases 
tumour aggressiveness (Brouxhon et al., 2007).  
1.4.2.4. Prostanoid deactivation 
          Prostanoids are locally formed and function close to the site of synthesis. 
They are deactivated within the same or neighbouring cells before they are 
released into the circulation as inactive metabolites. These catabolic 
mechanisms are important for the regulation of biological activities. There is one 
catabolic pathway that is common for most prostanoids and occurs via two 
steps: a) The PG uptake across the membrane by a carrier prostaglandin 
transporter (PGT). b) When the PG enters the cell, cytoplasmic oxidation to the 
15(s)-hydroxyl group by the 15-hydroxyprostaglandin dehydrogenase (15-
PGDH) (Figure1.8). 15-keto- and 13,14-dihydro-15-keto PGs are formed as a 
result of hydrogenation and reduction reactions (Tai et al., 2002). It has been 
reported that about half of PGE2 that is taken up by the epithelial monolayer is 
oxidized to 13, 14-dihydro, 15-keto-PGE2 (Nomura et al., 2004). 
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Figure.1.8. Schematic diagram of the deactivation pathway of PGE2. COX-1/-2 
=Cyclooxygenase -1/-2. PGES= Prostaglandin E synthase. 15-PGDH=15 – hydroxy-
prostaglandin dehydrogenase. 
1.4.3. Isoprostanes 
          The isoprostanes (IsoPs) are prostaglandin-like compounds formed 
through non-enzymatic pathways by free radical or reactive oxygen species 
(ROS) (Morrow et al., 1990). A number of peroxidation products are formed as 
a result of lipids being attacked by free radicals and AA is converted to PGH2-
like intermediates which are converted to prostaglandin-like compounds 
(isoprostanes) (Morrow et al., 1994). The most studied IsoPs are the F2-IsoP 
that contain a ring type F similar to PGF2α. According to the position of the 
hydroxyl group in the chain the F2-IsoP can be: 5-F2-IsoP, 8-F2-IsoP, 12-F2-IsoP 
or 15-F2-IsoP. Furthermore, in vitro prostaglandin F3-like compounds (F3-IsoP) 
are generated from EPA (Gao et al., 2006) and prostaglandin F4-like 
compounds (F4-IsoP) from DHA (Musiek et al., 2004).  
1.4.4. Lipoxygenase derived lipid mediators 
          Lipoxygenases (LOX) are a family of enzymes that oxygenate PUFA to 
specific hydroperoxide products. There are many types of LOX found in human 
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cells: 5-LOX, 12S-LOX, 12R-LOX, 15-LOX and the epidermal LOX type 3 
(eLOX3) (Yu et al., 2003, Kinzig et al., 1999, Krieg et al., 2001). LOX act by the 
addition of two oxygens to polyunsaturated fatty acids to produce unstable 
hydroperoxides which are than reduced to hydroxy fatty acids such as 
leukotrienes (LTs), lipoxins (LXs) and other bioactive lipids (Kuhn and O'Donnell, 
2006). Oxygenation of PUFA by LOX can generate an array of mono- and 
polyhydroxy fatty acids (Figure1.9): AA produces hydroxyeicosatetraenoic acids 
(HETEs), LTs, and LXs (Vance and Vance, 2002). Oxygenation of EPA by LOX 
generates hydroxy eicosapentaenoic acids (HEPEs) and E-series resolvins 
(RvEs). DHA produces hydroxy docosahexaenoic acids (HDHAs), D-series 
resolvins (RvDs), protectins (PDs) and maresins (MAR). LA forms 
hydroxyoctadecadienoic acids (HODEs) and DGLA forms hydroxyeicos-
atrienoic acids (HETrE’). 
 
Figure.1.9. Schematic diagram of the biosynthesis of hydroxyl fatty acid (taken from 
www .lipidlibrary. aocs.org )  
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1.4.4.1. Leukotrienes 
          The name leukotriene derives from the original discovery of white blood 
cells (polymorphonuclear leucocytes). Leukotriene biosynthesis depends on the 
availability of free-AA.  By the action of 5-LOX arachidonic acid is metabolised 
to 5(s)-hydroxyperoxyeicosatetraenic acid (5(S)-HPETE). The nuclear 
membrane protein, 5-lipoxygenase activating protein (FLAP) is required to 
translocate the cytosolic 5-LOX to the nuclear membrane (Ferguson, 2012, 
Woods et al., 1993). 5(S)-HPETE is rapidly reduced to 5(s)-
hydroxyeicosatetraenic acid (5(S)-HETE). 5(s)-HETE is then metabolised to 
leukotriene A4 (LTA4). LTA4 is unstable and readily forms LTB4. LTB4 is also 
conjugated with GSH to give the peptide leukotriene LTC4 which has an 
important role in regulating acute inflammatory responses (Wada et al., 2006) 
(Figure 1.10). LTC4 is transported out of the cells and metabolised to LTD4, and 
then to LTE4, which are then secreted in the urine (O'Donnell, 1999). LTA4 can 
undergo non-enzymatic reactions to form diHETEs (Vance and Vance, 2002). 
 
Figure.1.10 Schematic diagram of the biosynthesis leukotrienes (taken from 
www .lipidlibrary. aocs.org )  
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1.4.4.2. Lipoxins  
         Lipoxins are trihydroxy-eicosatetraenoic acids that derive from arachidonic 
acid (Serhan, 1994). They are structurally similar to leukotrienes and appear to 
have some complementary biological activities. The biosynthesis of lipoxins can 
occur by many biosynthetic pathways involving LOX activation as shown in 
(Figure 1.11). A) LTA4 is generated by the action of 5-LOX, and then LTA4 is 
reduced by the action of 12-LOX to generate LXA4 and LXB4. B) The 15-HPETE 
is generated by 15-LOX. Then, 5-LOX can convert 15-HPETE to a 15(6)-epoxy-
tetraenoic intermediate that is further metabolised by LOX to form LXA4 and 
LXB4. The aspirin-triggered lipoxin 15-epiLXA4 is formed throughout COX-2 and 
5-LOX (Takano et al., 1997). LXA4 is biologically active and, anti-inflammatory, 
and has recently been found to have neuroprotective effects in brain ischemia. 
LXA4 also inhibits the up regulation of both LTB4 and LTC4 (Wu et al., 
2012).                                                                                                      . 
 
 
Figure 1.11 Diagram of the biosynthesis of lipoxins (Taken from Levy and Serhan, 
2003) 
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1.4.4.3. Resolvins, Protectins and Maresins  
          Resolvins or ‘resolution-phase interaction products’ were discovered by 
Serhan et al in resolving inflammatory exudates (Serhan et al., 2002). 
Resolution of inflammation is the removal of leukocytes and debris from 
inflamed area, enabling the tissue the return to homeostasis. Rather than being 
a passive process, resolution is now considered an active biochemical and 
metabolic process. Compounds derived from EPA are resolvins of the E series 
(RvE) while those formed from DHA are termed either resolvins or protectins (or 
neuroprotectins) (PD) of the D series (RvD) or Maresins (MaR) (Bannenberg et 
al., 2005, Serhan et al., 2000). 
         Figure 1.12 shows the biosynthetic pathways involved in the conversion of 
EPA to RvE1 and RvE2. Via the action of acetylated COX-2, EPA is oxygenated 
at the C18 position to form 18R-HEPE. By the action of 5-LOX, 18R-HEPE is 
oxygenated to form 5S-hydro (peroxy)-18RHEPE. The 5S-hydroperoxy group in 
5S-hydro (peroxy)-18RHEPE is converted to a 5,6-epoxide intermediate to form 
RvE1or is reduced to a 5S-hydroxyl group to form RvE2 (Serhan et al., 2002, 
Hong et al., 2003). Resolvins act to reduce the cellular inflammation in many 
ways, including: transporting chemicals and inflammatory cells to the sites of 
inflammation, inhibiting the inflammatory production, and stimulating the 
expression of molecules involved in anti-inflammatory actions (Dona et al., 2008, 
Serhan, 2007). 
          DHA is converted into D-series resolvins. In the absence of aspirin, COX-
2 converts DHA to 13S-hydroxy-DHA (13S-HDHA) while 15-LOX converts DHA 
to 17S-hydroxy-DHA (17S-HDHA). 17S-HDHA is the precursor of four types of 
D-series resolvins: RvD1, RvD2, RvD3 and RvD4. In the presence of aspirin, 
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17(R)-hydroxy docosahexaenoic acid (17R-HDHA) is generated from DHA by 
the action of aspirin-acetylated cyclooxygenase-2. 17R-HDHA is further 
metabolised by 5-LOX to produce 17-epi-RvD1 (17R-RvD1), also known as 
aspirin-triggered (AT) RvD1 (Serhan et al., 2002, Hong et al., 2003, Sun et al., 
2007) (Figure 1.13).  
          Two receptors are known to be involved in the action of RvE1: G-protein-
coupled receptors GPCR chemokine-like receptor 1 (CMKLR1 or ChemR23) 
(Arita et al., 2005) and the leukotriene B4 receptor (BLT1) (Arita et al., 2007).  
 
 
 
Figure.1.12 Pathways for biosynthesis of RvE from EPA (taken from Serhan et al., 
2002) 
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Figure.1.13 Pathways for biosynthesis of RvD from DHA (taken from Serhan et al., 
2002). 
          Protectins (Neuroprotectins) (PD) were discovered in brain tissue as a 
response to aspirin treatment. 17S-HDHA is converted by the action of LOX to a 
16(17)-epoxide and then to the 10,17-dihydroxy docosatriene (10R,17S-DT or 
PD1 or NPD1). In the early stages of neural diseases and neural injury NPD1 is 
synthesised and acts as a initial protective signal of cell homeostasis (Bazan, 
2013, Zhao et al., 2011) (Figure 1.14). 
 
Figure.1.14 Pathways for biosynthesis of PD1 and NDP1 from DHA (taken from 
Serhan and Petasis, 2011) 
39 
 
Finally, maresins (MaR) are dihydroxy DHA derivatives coined from 
macrophages. By the action of 12-LOX. DHA is converted to 14-hydroperoxy-
docosahexaenoic acid (14S-HDHA) which is reduced to generate 7S,14S-
diHDHA (Serhan et al., 2009). Their biosynthetic pathway is shown in Figure 
1.15. 
 
Figure.1.15. Pathways for biosynthesis of maresins from DHA (taken from Stables and 
Gilroy, 2011)  
1.4.5. Cytochrome p450-derived lipid mediators 
          Cytochrome P450 (CYP) is a family of epoxygenases and monooxyg-
enases that can oxidise PUFA to produce many types of eicosanoids, including 
epoxides, midchain hydroxy fatty acids and dihydroxy fatty acids. CYP can 
oxidise  AA to  produce epoxyeicosatrienoic acids (EETs) and oxidation can 
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happen at any of the four double bonds of AA, giving  5,6-, 8,9-, 11,12- and 
14,15-EET (Campbell and Harder, 1999, Spector et al., 2004). By the action of 
soluble epoxide hydrolase (sEH) EETs are converted to dihydroxyeicosatrienoic 
acids (DHETs) (Capdevila et al., 1988, Capdevila et al., 2000). EET species are 
found in heart, liver, kidney and plasma and include the AA species  8,9-, 11,12-
 ,14,15-EET (Karara et al., 1992) (Figure 1.16). Epoxyeicosatrienoic acids 
function primarily as autocrine and paracrine mediators in the cardiovascular 
and renal systems and also have anti-inflammatory effects in the vasculature 
and kidney. Many potentially beneficial actions of EETs are attenuated upon 
conversion to DHETs, which are not essential under normal conditions (Spector 
and Norris, 2007). Furthermore, EETs have been found to increase 
angiogenesis and tumour progression, while DHETs inhibit angiogenesis, 
tumour progression and metastasis (Zhang et al., 2013). Monooxygenases 
convert AA to hydroxyeicosatetraenoic acids such as 20-hydroxyeicosatetr-
aenoic acid (20-HETE). 20-HETE is a pro-inflammatory mediator that stimulates 
production of cytokines and chemokines such as IL-8, IL-13 and PGE2 (Ishizuka 
et al., 2008). 20-HETE can also stimulate endothelial cell proliferation and 
migration. In the circulation, 20-HETE acts as a vasoconstrictor (Miyata and 
Roman, 2005). 
          EPA and DHA are also metabolised by CYP450 in human and animal 
tissues. CYP450 convert EPA to give: epoxyeicosatetraenoic acids (EEQs) and 
8,9-, 11,12- 14,15-, 17,18-DHET and mono- hydroxyeicosapentaenoic acids 
(20- and 19-HEPE) whereas CYP450 convert DHA to epoxydocosapentaenoic 
acids (EDPs) 7,9- ,10,1- ,13,14- ,16,17-and 19,20- EDP and mono-
hydroxydocosa-hexaenoic acids (22- and 21-HDoHE) (Van Rollins et al., 1988). 
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Figure.1.16 Metabolism of arachidonic acid by cytochrome P450 oxygenases (taken 
from Vriens et al., 2005).  
 
1.5. Eicosanoids in skin inflammation   
           The skin, specifically the epidermis is a very active site of lipid synthesis 
in the body (Feingold, 1991). Keratinocytes are able to synthesise most of the 
fatty acids and this may increase during normal epidermal differentiation. FAs 
are found esterified in triglycerides, phospholipids, glycosyl-ceramides and 
ceramides, which have multiple roles in the epidermis such as formation of the 
epidermal permeability barrier (Uchida and Holleran, 2008). They also function 
as molecules for energy generation and storage as well as potent signalling 
molecules that can activate the nuclear hormone receptors (Schmuth et al., 
2007) and peroxisome proliferators-activated receptors (Sertznig et al., 2008). 
Skin lipids have many biological roles ranging from structural to protective 
(Kendall and Nicolaou, 2013). 
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          Eicosanoids have pro-inflammatory and immunoregulatory activities in 
human skin. They also play a role in the regulation and differentiation of the 
epidermis. PGs specifically PGE1, PGE2 and PGD2 have been shown to boost 
keratinocytes proliferation (Pentland and Needleman, 1986). In contrast, 
fibroblasts are less responsive to PG pathway activators, whereas keratinocytes 
can activate fibroblasts to produce prostacyclin which is a paracrine 
prodifferentiating agent for keratinocytes (Baden et al., 1992).  
          In human keratinocytes, PGE2 and PGF2α are the major PGs and their 
concentrations are increased after UVB exposure (Black et al., 1981, Storey et 
al., 2007). PGE2 is the main prostaglandin identified following UVB exposure in 
cultured human epidermal keratinocytes (Miller et al., 1994). PGD2 has been 
found to be a major PG in epidermal melanocytes and FM55 melanoma cells. 
The regulation of PGD2 in FM55 occurs by the action of α-melanocyte-
stimulating hormone and is not related to melanin production (Masoodi et al., 
2010). It has also been reported that PGD2 can inhibit the growth of human 
melanoma cells (Bhuyan et al., 1986) and the ability of Langerhans cells to 
migrate (Angeli et al., 2001).  
          DGLA, directly generated from dietary arachidonic acid, is normally found 
in small amounts in the human epidermis. GLA is also converted to DGLA in the 
human epidermis by the action of an elongase (Huang and Ziboh, 2001). It is 
metabolised by epidermal cyclooxygenase to series 1 prostaglandins, PGE1 
and also by 15-lipoxygenase to 15-HETrE (Miller and Ziboh, 1988).  
          12-HETE was first reported in human skin in 1975 (Hammarstrom et al., 
1975). 12-HETE has been reported to be a major AA product in normal human 
skin (Nugteren and Kivits, 1987). Moreover, it is mainly formed in the upper 
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layer of skin epidermis (Henneicke-von Zepelin et al., 1991). The level of 12-
HETE increased in cutaneous inflammatory (Black et al., 1985) and post UVR 
exposure (Grundmann et al., 2004, Rhodes et al., 2009).  
         It has been reported that LA is the main PUFA in human skin and it has a 
role in the maintenance of the epidermal water barrier. By the action of 15-LOX, 
LA is converted to 13-HODE which is then incorporated into the epidermal 
ceramides and phospholipids (Cho and Ziboh, 1994). It has also been reported 
that expressions of 5-LOX and LTB4 concentration were significantly higher in 
skin suction of systemic sclerosis patients compared with the control. 
Furthermore, LTB4 has been found to be higher in cultures of human fibroblast 
patients (systemic sclerosis) compared with the control (Kowal-Bielecka et al., 
2001).   
1.5.1. Eicosanoids and atopic dermatitis 
         Atopic dermatitis (AD) is identified as a chronic allergic inflammatory 
disease and is characterised by abnormal skin barrier formation (Oyoshi et al., 
2009). Epidermal keratinocytes play a role in atopic dermatitis by their ability to 
both produce inflammatory mediators and to respond to inflammatory and 
allergenic stimuli (Albanesi, 2010). Atopic dermatitis is characterised by 
increased activity of PLA2 (Schafer and Kragballe, 1991). PGD2 is involved in 
AD as a result of activating Langerhans cells and mast cells which are the main 
cutaneous producers of PGD2 (Matsushima et al., 2011). Although 5-LOX and 
LTB4 have been shown to be involved in AD in animal models LOX-derived 
mediators are less involved in AD compared to COX-derived mediators (Honda 
et al., 2010). PGI2 is considered vasoactive while, PGE2 is immunosuppressive 
and LTB4 may be involved in the biochemical processes leading to atopic 
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dermatitis (Fogh et al., 1989, Nakajima et al., 2010). Finally, PUFAs such as 
EPA, DHA and GLA may be able to improve atopic dermatitis. PUFAs 
incorporated in membrane phospholipid can change the profile of eicosanoids 
resulting in a modiﬁed function of inﬂammatory cells (Gueck et al., 2004).  
1.5.2. Eicosanoids and psoriasis 
          Psoriasis is a chronic inflammatory and proliferative skin disease, with 
genetic and environmental aetiologies (Bhalerao and Bowcock, 1998). In 
general, psoriasis is characterised by abnormalities in skin lipids, increased 
production of inflammatory mediators such as IFN-γ, TNF-α and IL-12, and 
excessive growth and aberrant differentiation of keratinocytes (Lowes et al., 
2007, Pietrzak et al., 2010). Psoriasis is also associated with multi organ 
complications and abnormalities such as increased risk of cardiovascular 
abnormalities, dyslipidemia, atherosclerosis, diabetes mellitus type 2, obesity, 
cerebral stroke, cancer, osteoporosis, and depression (Pietrzak et al., 1998, 
Nijsten and Wakkee, 2009).  
         It has been reported that levels of free AA and 12-HETE are increased in 
psoriasis. In contrast, the increase in PGE2 and PGF2α levels is less prominent 
(Grabbe et al., 1984). Increases in sPLA2, cPLA2 and pityriasis lichenoides 
chronica (PLC) activity in psoriatic skin have been shown by many studies, 
which may explain the increases in AA (Andersen et al., 1994, Cunningham et 
al., 1985, Sjursen et al., 2000). Furthermore, PGE2 and PGF2α are low 
compared with free AA, possibly due to the presence of a natural inhibitor of 
COX in psoriatic skin (Ikai, 1999). AA can be metabolised by other pathways 
such as the 5- and 12-LOX pathways. No increase in 5-LOX production is found 
in peripheral polymorphonuclear leukocytes and platelets in psoriasis (Vila et al., 
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1990, Sola et al., 1991). However, the low 5-LOX activity in epidermal 
keratinocytes suggests that 5-LOX products may be formed through 
transcellular pathways involving dermally infiltrating neutrophils (Fordhutchinson, 
1993).  
         12-HETE is the predominant eicosanoid found in psoriasis and it is raised 
due to increased AA production and not because of 12-LOX activation. 12-LOX 
activity in uninvolved psoriatic skin was no higher than in normal skin. Specific 
inhibitors for 12-LOX and PLA2 showed improvement in psoriasis treatment 
(Burke, 2001). 15-LOX can produce many anti-inflammatory mediators, and 15-
HETE is the predominant product in normal dermis. 15-HETE can inhibit 5- and 
12-LOX product formation (Kragballe and Voorhees, 1987),  counteracting the 
chemotactic potency of 12-HETE and LTB4 (Kragballe et al., 1986) and acting 
as a substrate for the formation of lipoxins (Serhan et al., 2003). 
Supplementation with n-3 PUFA specifically EPA can reduce AA-derived HETE 
and increase the concentration of anti-inflammatory n-3 PUFA derivatives such 
as 15-HEPE and 15-HETrE (Mayser et al., 2002, Ricketts et al., 2010, Burke, 
2001). 
1.5.3. Eicosanoids and sunburn 
      Sunburn is a skin response to UVR which is the major environmental factor 
contributing to skin damage. Sunburn is characterised clinicallyby erythema and 
histologically by dermal inﬁltration of neutrophils and lymphocytes, and 
keratinocyte apoptosis. Some of the soluble mediators contributing to these 
changes include nitric oxide (NO) and cytokines (Rhodes et al., 2001, Rhodes 
et al., 2009). UVR, specifically UVB has been found to increase COX and LOX 
mediators in the skin. Through the generation of ROS, UVR can activate gene 
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expression, transcription factors and signalling cascades in skin cells  (Hruza 
and Pentland, 1993). UVR can also stimulate the activation and expression of 
cPLA2 in keratinocytes (in vitro), and in human and animal skin (Chen et al., 
1996). Studies in animal skin cells reported that mRNA expression of both 
prostaglandin synthases and receptors are increased after exposure to UVR 
(Carsberg et al., 1995). Many eicosanoids including PGE2, 12-HETE, 15-HETE 
and 13-HODE have been found to be upregulated by UVR (Honda et al., 2009, 
Rhodes et al., 2009, Nicolaou et al., 2012). Moreover, work with human skin 
sections and keratinocytes showed that 15-HETE produced by the dermis layer 
can inhibit 12-HETE in the epidermis layer (Yoo et al., 2008). Furthermore, 
PGE2 can arbitrate the primary inflammatory phase and may later take part in 
the reduction of inflammation and the tissue repair stage. 12-HETE can also be 
involved in keratinocyte and fibroblast mediated healing events, whilst 15-HETE 
and 13-HODE may assist in restricting pro-inflammatory signals (Pentland and 
Needleman, 1986, Ruzicka, 1992).  
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1.6. Aims and objectives of the project 
         The main function of the skin is to protect the body against harmful factors 
such as chemicals, bacteria, UVR and pollution. UVR is the most important 
factor in the development of erythema, DNA damage, immunesuppression and 
skin cancer. The toxic effects of UVR from natural sources and artificial lamps 
are concern for human health. UVR affects lipid metabolising enzymes, 
modulates their expression and stimulates the production of bioactive lipids by 
skin cells (Takashima and Bergstresser, 1996, Yoo et al., 2008). Lipid 
mediators are derived from cellular membranes as a result of activation of 
membrane phospholipase A2 by UVB in particular the n-6 PUFA AA and n-3 
PUFA EPA (Rhodes et al., 1994). Skin has biochemical and immunological 
features that can protect the body against UVR. Diet has been recognised as a 
safe method of protecting the skin and creating an anti-inflammatory 
environment.  n-3 PUFA has been suggested as having a beneficial role in skin 
health and disease (Sies and Stahl, 2004).  
          The hypothesis is that n-3 PUFA especially EPA and DHA can protect 
skin cells against UVR through the formation of novel lipid mediators. Therefore, 
the purpose of this study was to measure and evaluate this protective effect 
using a model system comprising HaCaT keratinocytes and 46BR.1N 
fibroblastic cells. The cells were treated with fatty acids and UVR. Furthermore, 
samples from a clinical study were used in order to assess the effect of oral n-3 
PUFA supplementation on skin fatty acids. The subjects were supplemented 
with n-3 PUFA for 3 months.  
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The specific objectives of this project were as follows: 
A) To investigate the effect of UVR dose on cell viability and establish a dose 
suitable for the in vitro study. 
B) To assess the toxicity of n-3 PUFA on the cell lines used in this study and 
decide on a suitable dose for the in vitro treatments. 
C) To assess the effect of UVR or/and n-3 PUFA on HaCaT and 46BR.1N cell 
apoptosis. 
D) To assess the effect of n-3 PUFA on the fatty acid profile of the cell lines 
used in the study. 
E) To measure the eicosanoids produced by HaCaT and 46BR.1N cells and the 
effect of UVR and n-3PUFA on them.  
F) To assess the systemic effect of n-3 PUFA on skin lipids using red blood 
cells and skin samples through supplementation in a clinical study. 
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Chapter 2. Materials and Methods 
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2.1. Cells and clinical samples  
2.1.1. Cell lines 
          The HaCaT human keratinocyte cell line was provided by Dr S. Britland of 
the University of Bradford. The 46BR.1N human fibroblast cell line was 
purchased from The European Collection of Cell Culture (ECACC). 
2.1.2. Clinical samples 
2.1.2.1 Participants 
          All aspects of the work described in section 2.1.2 were undertaken by 
Prof L.E Rhodes and her group at Manchester University. Seventy nine (79) 
healthy female volunteers with nickel allergy were recruited for the study. 
Volunteers were eligible to take part if they were aged between 18-60 years and 
of sun reactive skin type I or II. Volunteers were excluded from the study if they 
were taking n-3 PUFA supplements, were pregnant or breast feeding, had 
sunbathed or used a tanning bed in the three months prior to the study, were 
taking photoactive medication, or had a history of photosensitivity, skin cancer 
or atopy. Ethical approval was granted by North Manchester Local Research 
Ethics Committee (08/H1006/30) and the study was performed in accordance 
with the Declaration of Helsinki principles. Written informed consent was 
provided by all volunteers before their inclusion in the study. Baseline 
characteristics of the women recruited for this study are presented in Table2.1. 
2.1.2.2. Study Design and Supplements 
          The subjects were computer-randomised by the study,s biostatistician into 
the two treatment groups: Group A (active group, n= 40 subjects) was 
supplemented with n-3 PUFA. The n-3 PUFA supplements were 1g gelatine 
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capsules containing Incromega E7010 SR ethyl ester which comprised ~72% 
EPA, 10% DHA. Meanwhile, Group B (placebo group, n=39 subjects) was 
supplemented with placebo supplements. The placebo supplements comprised 
1g gelatine capsules of identical appearance containing glyceryl tricoprylate 
coprate (GTCC). Volunteers were given five capsules of either n-3 PUFA or 
placebo supplements per day with breakfast for 12 weeks. The studies were 
performed at the end of the 12-week period.  Seven ml of blood was taken (pre- 
and post-supplementation) from each volunteer for assessment of red blood cell 
(RBC) fatty acids content. The samples were collected in 3.4ml ethylenediamin-
etetraacetic acid (EDTA) monovette tubes. Samples were then centrifuged for 
15 minutes at 1500rpm and the RBC fractions were collected and stored at -
70ºC. Five mm diameter skin punch biopsies were taken from an unexposed 
site of upper buttock skin under local anaesthesia and placed into 1.8mL 
cyrotubes before being snap froze in liquid nitrogen and stored at -70ºC. The 
red blood cells and skin punch biopsies were pre- and post-supplementation. 
The samples transported in dry ice and were stored at -80ºC until analysis. 
 
Table 2.1. Baseline characteristics of women recruited in the clinical study 
Demographic Range Mean ± SD 
Age (Years) 21-60 42.8±10 
Body mass index (kg/m2) 19.4-44.2 26.7±5 
Smoking status* 
Number of 
volunteers 
% of total volunteers 
Never smoked 30 39 
Ex smoker 18 27 
Current smoker 13 17 
 
* Missing data n=17 (22%) 
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2.2. Cell culture  
 2.2.1. Materials 
          Hank’s Balanced Salt Solution (HBSS) was purchased from Promo Cell 
Gimbh, Heidelberg, Germany. Dulbecco’s Modified Eagle Medium (DMEM) was 
purchased from Invitrogen, UK. RPMI 1640 media, Minimum Essential Medium 
Eagle (MEME) media, fetal calf serum heat inactive (FCS), fetal bovine serum 
(FBS), non-essential amino acid solution, dimethyl sulfoxide (DMSO), 
phosphate buffered saline (PBS), sodium pyruvate, oleic acid (OA; 99% purity), 
cis-5,8,11,14,17-eicosa-pentaenoic acid (EPA; 99% purity), cis-4,7,10,13,16,19-
docosahexaenoic acid (DHA; 98% purity), penicillin (10,000U/ml) streptomycin 
(10mg/ml),  amphotericin B (2.5ng/ml), 0.4% trypan blue solution and 0.25% 
trypsin-EDTA (1mM) solution were all purchased from Sigma, UK. 15ml 
centrifugation plastic tubes, 50 ml self standing centrifugation plastic tubes, T-
25, and T-75 culture flasks, 6, 12, and 24 well cell culture cluster and 96-well 
microplates were all purchased from Corning, Amsterdam, Netherlands. 25ml 
plastic tubes, tissue culture dishes (100/20mm) and serological plastic pipettes 
10ml were purchased from Sarstedt, Leicester, UK. Ethylenediaminetetraacetic 
acid (EDTA) monovette tubes were purchased from Sarstedt, Newton, UK. 
APOPercentage kit was purchased from Biocolor Life Science Assay, Northern 
Ireland, UK. 
2.2.2. Equipment  
          Microscope: CK40-F200, Olympus, Japan. UV lamp: UV 236 B, 
Waldmann, Germany. Light meter; Waldmann, Germany. Centrifuge: Rolofix 32 
Ilettich entrifugen, Scientific Laboratory Supplies, Germany. Shaker: MS1 
Minishaker, IKA-Labortachnik, Brasil. Incubator: Heraeus CO2 incubator BBD 
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622, Thermo Scientific, UK. Microplate reader: ELx800, BioTek Instruments, 
USA. Aspirator: Vacumsafe confort, IBS Integra Biosciences, Switzerland. 
Thermocouple, UK and Improved Neubauer haemocytometer, Gallencamp, UK.  
2.2.3. Methods   
2.2.3.1. Cell culture and passaging 
          HaCaT cells were grown in complete RPMI 1640 media (Appendix1.1) or 
complete DMEM media (Appendix 1.1) depending on the experiment. 46BR.1N 
cells were grown in complete MEME media (Appendix 1.1). All cells were grown 
in T-75 culture flasks at 37°C, 5% CO2 in an incubator. The cells were observed 
every day under the microscope to ensure that they were continuing to grow. 
When the cells reached about 90% confluences they were passaged. All cells 
were cultured up to a 10th passage per experiment. All equipment was sprayed 
with 70 % ethanol before being placed in the flow hood. The media that covered 
the cells were removed and discarded into a waste beaker containing 
disinfectant. Then, 5ml of pre-warmed (37°C) HBSS solution was added to each 
T-75 flask. In order to wash the cells, the HBSS solution was gently swirled 
inside the flasks and then discarded. 8 ml of warm (37°C) 0.25% trypsin-EDTA 
solution was then added to each T-75 flask to detach the cells. The flasks were 
placed back in the incubator for 15 min. Then, the flasks were held up to the 
light to check that all cells were detached. The cells were also checked under 
the microscope to ensure that they were completely detached. When it was 
confirmed that all cells were floating, trypsin was neutralised by adding 4ml of 
the appropriate complete cell culture medium to the T-75 flask and the contents 
of the flask were transferred to a 15 ml centrifuge tube. The tube was spun 
down (2,000 rpm, for 5 min), and the supernatant was removed and replaced by 
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4 ml of fresh complete media. The cells were then resuspended by gently 
pipetting the media up and down. Then, the cells were counted and an 
appropriate volume of cell suspension was transferred into new cell culture 
flasks or cell culture plates, as needed. Fresh medium was added to cover the 
surface of the flasks (8 ml toT-75 and 10 ml to100/20 mm Petri dishes). All 
flasks and/or plates were then placed in the incubator and used for further work.  
2.2.3.2. Cell counting 
          In order for the cells to be counted, 100µl of the original cell suspension 
was transferred to an Eppendorf tube. A dilution of 1:1 was conducted when the 
cell suspension was mixed with 100µl of 0.4% trypan blue solution. A Neubauer 
haemocytometric slide with coverslip was prepared and 10µl of this cell 
suspension was transferred to the chamber. The cells were counted in 4 grids 
per chamber under the microscope, using the 10x focus. The average number 
of cells of 4 grids was calculated and this number was used to count the total 
number of cells by using the following calculations:-      
        Number of cells/ml = [average cell number] x [104] x [dilution factor (2)] 
        Total number of cells = [Cells/ml] x [volume of original cell suspension (ml)] 
2.2.3.3. Cell treatment with Ultraviolet Radiation 
2.2.3.3.1. Effect of UVR exposure on temperature in the UV box 
          Prior to exposing the cells to UV light, it was necessary to measure the 
temperature inside the UV box to ensure that it was stable and did not increase 
during the UV exposure and affect cell viability. A thermocouple was used to 
measure the temperature in the UV box. The thermocouple was put in a Petri 
dish containing 5ml of PBS. The temperature was tested before and after the 
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UV lamp was turned on for various lengths of time corresponding to 40, 80, 120, 
160, 180 and 220 mJ/cm2. 
2.2.3.3.2 Exposure of cells to UV radiation 
          When cells reached about 80% confluence (12-well cell culture plates or 
cell culture dishes, depending on the experiment) the medium was removed 
and the cells were washed with 0.5 ml/well or 5 ml/dish pre-warmed (37°C) PBS 
to remove any remaining media and floating cells. Cells were then covered with 
a small volume (500µl/well or 5ml/dish) of pre-warmed PBS and exposed to 
UVR. The UV lamp was switched on and left for 10 min to stabilise. A light 
meter was used to measure the irradiance (mW/cm2) of the lamp to ensure that 
the lamp had stabilised. Typically, this value was 0.33 mW/cm2.  The cells were 
then placed at the base of the UV box, 30 cm under the UV lamp and irradiated 
for the required amount of time. The exposure time was calculated as follows: 
Exposure time (Sec) = Dose (mJ/cm2)/UVR intensity (mW/cm2). This 
corresponded approximately to 45 sec for 15mJ/cm2. After that, the PBS was 
removed from the wells or dishes and replaced with the appropriate amount of 
fresh media depending on the experiment. The plates or dishes were then 
incubated for the required amount of time.  
2.2.3.4. Treatment of cells with fatty acids 
          All fatty acids (EPA, DHA and OA) were dissolved in DMSO to prepare 
stock solutions (50 mM), (Appendix 1.1). DMSO is a widely used solvent, it is 
protects the cell from damage during freezing. DMSO is a good solvent of fatty 
acid and they are high solubility in it. These stock solutions were further diluted 
with culture media to give a final concentration of 10 or 50 µM. When the cells 
reached about 70% confluence, the medium was removed and the cells were 
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washed with pre-warmed HBSS. The HBSS was replaced by the required 
amount of fresh complete medium containing the fatty acid treatment: 10 µM 
fatty acid was prepared by adding 2µl of fatty acid stock solutions (50 mM) and 
8µl of DMSO into 10ml of complete medium; 50 µM fatty acid was prepared by 
adding 10µl of fatty acid stock solutions (50 mM) into 10ml of complete medium 
or vehicle control DMSO (10 µl) into 10ml of medium.  Cell cultures were then 
incubated for 72-h before being exposed to UV irradiation as described above. 
2.2.3.5. Collection of cells and media for various analyses 
          In order to investigate eicosanoid production, protein expression and 
cellular fatty acid content, the cells were grown in cell culture dishes diameter 
100 and were treated with fatty acids for 72h. After that, the media were 
removed and the dishes washed with pre-warmed PBS. 5ml of PBS was then 
added to each dish. The cells were then exposed to UVR as in section 2.2.3.3.2. 
The control experiments were placed in the UV box for the corresponding time 
but were not irradiated. PBS was then removed from all dishes and replaced 
with 10 ml of pre-warmed fresh free serum medium (see Appendix1.1). The 
plates were then incubated for a further 24h. The medium was collected 24h 
post UVR by a serological pipette and transferred into a pre-labelled 25ml tube. 
The medium was stored at -80°C to be used for the analysis of eicosanoids. In 
order for the cells to be collected 5ml of warm HBSS solution was added to 
each dish, gently swirled inside the dish and discarded. 8ml of warm (37°C) 
0.25% trypsin-EDTA solution was then added to each dish to detach the cells. 
The dish was placed back into the incubator for 15 min. Then, the cells were 
checked under the microscope to ensure that they were completely detached. 
Trypsin was neutralised by adding 3 ml of medium, and the contents of the dish 
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were transferred to a pre-labelled 15 ml centrifuge tube. The tube was spun 
down using 2,000 rpm, for 5 min. The supernatant was removed and replaced 
by 5ml of PBS. The cells were then re-suspended by gently pipetting the PBS 
up and down, and counted as described in section 2.2.3.2. In order for the cells 
to be collected and stored, the cell suspension was spun down using 2,000 rpm, 
for 5 min. Then the supernatant was removed and the cell pellet was stored at -
80°C to be used for western plot analyses and fatty acid analysis. 
2.2.3.6. Isolation of the epidermal layer from the human skin    
          Skin was provided by the Ethical Tissue Bank at the University of 
Bradford. In order to separate the epidermis, the fat was removed from the skin, 
the skin was washed with PBS and put into a clean 50 ml tube. The tube was 
then filled with 1M sodium bromide (NaBr; 5.1g in 50ml water) and incubated in 
a water bath at 37 oC for 1 hr. After this incubation, the epidermal layer was 
separated from the dermis using fine forceps. The epidermis was placed in a 
clean dish topped up by PBS and stored at 4oC until required for use. 
2.2.3.7. Effect of placing a skin epidermis layer in the path of UV light  
          In order to assess the effect of placing a skin epidermis layer in the path 
of UV light, the irradiance (mW/cm2) of the UV lamp was measured by a light 
meter for 10 min. Then, a quartz glass was placed on the light meter and the 
irradiance was measured for another 10min. Finally, the wet epidermis was 
placed on the quartz slide this was placed on the light meter and the intensity 
was measured for 10 min. 
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2.2.3.8. MTT assay  
          The MTT assay is a colorimetric method used to determine cell viability. 
The dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (yellow) 
was used in this assay. To assess cell viability post UVR and fatty acid 
treatments, the cells were cultured in 12-well cell culture plates, treated with 
vehicle (DMSO) and/or fatty acids and exposed to UVR. After the required 
amount of time post UVR (4h or 24h) the PBS was removed. Then, 1 ml of MTT 
solution (prepared by mixing 1ml of MTT (5mg/ml) with 9 ml of HBSS) was 
added to each well. Next, the plate was incubated for 4 h at 37°C. During the 
incubation, the yellow colour was reduced by enzymes in living cells to give a 
water-insoluble, purple formazan salt. At the end of the incubation time, the 
MTT reagent was aspirated and replaced by DMSO (1ml/well) to solubilise the 
formazan salt. The plate was then put on the shaker for 10 to 15 mins. 200µl 
solution from each well was transferred into a 96 well microplate, in triplicate. 
Absorbance of the purple solution was measured at 595 nm using a microplate 
reader. This is indicative of cell viability, which can be calculated as follows:  
             Cell viability (%) = (Absorbance of sample/Absorbance of control) x 100 
2.2.3.9. Apoptosis assay  
          In order to assess the effect of n-3 PUFA on cell apoptosis, the cells were 
cultured in T-75 flasks and treated with DMSO and n-3 PUFA for 48h as 
described in section 2.2.3.4. Then the cells were seeded in a 24-well cell culture 
plate as10x104 cells/well 500µl media and treated with n-3 PUFA for 24h. At 
24h post UVR the apoptosis was measured using APOPercentage™ kit. As a 
result of apoptosis, the DNA in the cells becomes fragmented and phosphatidyl 
serine is transferred to the outside of the cell membrane. The dye bands to the 
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phosphatidyl serine and inter in the cell. By the action of Dye release reagent 
the dye in labelled cells is released into purple-red solution which can measured 
using a microplate colorimeter.  
         As per the APOPercentage™ assay protocol, 10mM H2O2 (see Appendix 
1.1) was added to the positive control samples 4h before the incubation time 
ended. Nothing was added to the reagent blank sample. The medium was 
removed 30 min before the incubation time end and replaced with reagent A 
(see Appendix 1.1). After 30 min the medium was removed and replaced with 
reagent B (see Appendix 1.1). Plates were incubated for 30 min at 37°C/under 
5%CO2. The medium was removed from the wells and gently washed twice with 
500µl/well PBS. 50µl of trypsin was added to each well and the plates were 
incubated for 10 min at 37°C/5%CO2. 200 µl of dye release reagent was added 
to each well. The plates were put on the shaker for 10 min. The contents of 
each well (200 µl) were transferred into 96-well microplates and the absorbance 
of the purple-red solution was measured at 550nm. This is indicative of cell 
apoptosis, which can be calculated as follows:  Cell apoptosis (%) = 
(absorbance of sample - absorbance of reagent blank sample) / absorbance of 
control x 100   
2. 3. Fatty acid analysis  
2.3.1. Materials 
          Potassium carbonate (ACS reagent), 2,6-di-tert-butyl-4-methylphenol 
(BHT) (ACS reagent), sodium sulphate (anhydrous) (ACS reagent), 14% boron 
trifloride in methanol (BF3) and potassium chloride (ACS reagent) were 
purchased from Sigma Aldrich, UK. Trimethylpentane and toluene were 
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purchased from ACROS organics, Loughborough, UK. Methanol (HPLC grade), 
chloroform (HPLC grade) and dichloromethane (HPLC grade) were all 
purchased from Fisher Scientific, Loughborough, UK. FAME mixed standard, 
vaccenic (C18:1 n-7) methyl ester and docosapentaenoic acid methyl ester 
(C22:5n-6) were purchased from Sigma Aldrich, UK. 50 and 250 µl glass 
syringes were purchased from SGE, Australia. Glass tubes and glass Pasteur 
pipettes were purchased from Fisher, Loughborough, UK. Amber glass vial, 100 
µl insert vials, screw caps, and septa were all purchased from Kinesis, 
Bedfordshire, UK.  
2.3.2. Equipment 
        GC-FID: 6850 Series and autosampler: 6850 gas chromatography systems 
and GC operated system: Chemstation Revision B2.01software, Agilent 
Technologies UK.  Hydrogen gas generator: Parker Balston, Parker Hannifin, 
England. Column: BPX-70, 0.25mm ID 0.25m film 60mL; Phenomenex, UK. 
Vortex: Whirlmixer, Flsons Scientific Apparatus, England. Centrifuge: Sorvall 
RT6000B refrigerated centrifuge, Dupont, LTD (UK), Stevenage, Herts. Heating 
block: Reacti-Therm heating module, Pierce, UK. 
2.3.3. Methods 
2.3.3.1. Preparation of samples 
          A) The red blood cell  samples were defrosted on ice and brought to room 
temperature. RBC (1 ml) was transferred by Pasteur pipette to a clean pre-
labelled extraction tube (T1) which was placed in ice. To ensure that all the 
blood was transferred, the original vial was washed by 1 ml of water and also 
transferred to T1. Five ml of ice cold 0.01% (w/v) BHT in 2:1 chloroform: 
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methanol (see Appendix 1.2) was added to T1. The sample was extracted 
immediately as described in section 2.3.3.2   
          B) Frozen dermal skin section: the vials containing the samples were 
placed on ice to gently defrost. Once thawed, excess blood was removed from 
the tissue by handling it with tweezers and washed it in a vial containing fresh 
ice cold PBS. The vial was gently shaken for 30 sec; the biopsy was weighed 
and transferred to an extraction tube T1 containing 4 ml of ice cold 0.01% (w/v) 
BHT in 2:1 chloroform: methanol. The tube was sealed with parafilm and was 
incubated overnight at 4°C. The sample was extracted as described in section 
2.3.3.2   
          C) Frozen cell pellets: the tube containing the cell pellet was placed on 
ice to gently defrost. Then, 1ml of PBS was added to the cell pellet; the pellet 
was gently suspended and transferred to a pre-labelled extraction tube T1 
containing 4 ml of ice cold 0.01% (w/v) BHT in 2:1 chloroform: methanol. The 
sample was extracted immediately as described in section 2.3.3.2   
          D) n-3 PUFA supplements (capsule): In order to assess the purity of the 
supplement and to confirm the EPA/DHA content of the capsules in the clinical 
study, their content was analysed for fatty acid ethyl ester (n=3 active and n=3 
placebo) and total fatty acids  (n=3 active and n=3 placebo) by GC-FID. 
Specifically:  
         The capsules were opened using a scalpel and 25µl of the oil was 
aspirated using a glass syringe. The oil was transferred to aclean volumetric 
flask and dissolved in 25ml of hexane (stock solution). Then, 140 µl of the stock 
solution was transferred to a clean glass tube T1. 60 µl of C21:0 (Internal 
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standard, 900ng/ µl) was then added and the solution thoroughly mixed. The 
resulting sample solution was then transferred to a clean 100 µl insert using a 
glass syringe and, placed in an amber glass vial. The sample was immediately 
analysed for fatty acid ethyl esters. For assessment of fatty acid methyl ester 
(FAME), another aliquot of this sample solution was derivatised prior to analysis, 
as described in section 2.3.3.5. All analyses were carried out using GC-FID in 
split mode as described in section 2.3.3.6. 
2.3.3.2. Lipid extraction 
          The extraction tube T1 was then vortexed for 5 x 1 min. Between 
vortexing steps, T1 was kept cool on ice for at least 30 sec (1 ml of water was 
added to the skin extraction tube T1). The samples were centrifuged at 4oC, 
5000 rpm for 5 min. The lower layer (organic) of extract was transferred to pre-
labelled, clean extraction tube T2 and kept on ice. To the first tube T1, 4ml of 
0.01% (w/v) BHT in 2:1 chloroform: methanol was added. T1 was vortexed for 5 
x 1 min and centrifuged as above. The lower layer was then transferred and 
combined with the extract in T2. This procedure was repeated once more. 2 ml 
of 0.5M KCL in methanol (50:50, v/v) (see Appendix 1.2) was added to the 
combined lipid extract in T2. As before, the combined lipid extract T2 was 
vortexed and centrifuged. The top layer (aqueous) was removed and discarded, 
and another aliquot of 2 ml of 0.5M KCL in methanol (50:50,v/v) was added. T2 
was then vortexed and centrifuged, and the bottom layer was transferred into a 
pre-labelled, clean extraction tube T3. Approximately four spatula tips of dry 
sodium sulphate were added to T3, gently mixed. The lipid extract was passed 
and filtered through cotton wool filters (the filters were prepared  with packed 
cotton wool in Pasteur pipettes, and were previously washed with 3 ml of 0.01% 
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(w/v) BHT in 2:1 chloroform: methanol, and flashed and dried  with air). The 
filtrate was then collected and transferred to an esterification tube E1. In order 
to collect any remaining lipid extract, 2 ml of 0.01% (w/v) BHT in 2:1 chloroform: 
methanol was also passed through the filters. The filter washes were collected 
and added to E1. The lipids extract in E1 was dried under a fine stream of 
nitrogen (each sample had a needle of the nitrogen drying apparatus directly 
above it) and reconstituted in 1ml of 0.01% (w/v) BHT in 2:1 chloroform: 
methanol. The samples were stored at -20ºC for up to a week. 
2.3.3.3. Preparation of internal standard methyl ester 
          In order to prepare internal standard stock solution (1mg/ml), 0.025mg of 
heneicosanoic acid (C21:0) was dissolved in 25ml of 0.01% (w/v) BHT in 2:1 
chloroform: methanol and stored at -20ºC. In order to prepare the internal 
standard methyl ester, 300 µl or 900 µl of stock solution (1mg/ml) was 
transferred into a clean tube to esterify as described in section 2.3.3.5. The 
resulting internal standard methyl ester was reconstituted in 1ml DCM to give a 
final concentration of 300ng/µl or 900ng/µl. 100µl of internal standard methyl 
ester was then transferred to an injecting vial and the rest was stored at 20ºC for 
a week. 
2.3.3.4. Preparation of FAME cocktail for GC analysis 
2.3.3.4.1. Preparation of 1µg/µl (w/v) docosapentaenoic acid stock solution 
(C22:5 n-3)  
         Stock standard: commercially available DPA methylester as 1mg/m1 
solution in ethanol. The stock standard was dried under nitrogen and then 
reconstituted in 1ml DMC and stored at -20°C.  
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2.3.3.4.2. Preparation of 200 ng/µl docosapentaenoic acid working solution 
(C22:5 n-3)  
         In order to prepare a 200ng/µl working standard, 200µl of stock standard 
was transferred to an amber glass vial, diluted with 800µl DCM and stored at -
20°C. 
2.3.3.4.3. Preparation of 1µg/µl(w/v) vaccenic acid stock solution(C18:1n-7)  
         Stock standard: commercially available vaccenic acid methyl ester as 
1mg/m1 solution in ethanol. The stock standard was dried under nitrogen and 
then reconstituted in 1ml DMC and stored at -20°C.  
2.3.3.4.4. Preparation of 200ng/µl vaccenic acid working solution (C18:1n-
7)  
     In order to prepare a 200ng/µl working standard, 200µl of stock standard 
was transferred to an amber glass vial, diluted with 800µl DCM and stored at -
20°C. 
2.3.3.4.5. Preparation of FAME cocktail standard for a split method 
          In order to prepare the FAME cocktail standard for a split method, 20µl of 
each of the following was transferred to a glass insert: Commercially available 
FAME standard, docosapentaenoic acid methyl ester (C22:5 n-3; 200ng/l) and 
vaccenic acid methyl ester (C 18:1 n-7; 200ng/l). A final volume was made up 
to 200µl of DCM. The solution was mixed and stored at -20°C. 
2.3.3.4.6. Preparation of FAME cocktail standard for a splitless method 
          FAME cocktail standard for a splitless method was made by diluting the 
FAME cocktail standard for a split method using 1:3 dilution. For this, 20µl of 
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FAME cocktail standard for a split method was transferred to a round bottomed, 
glass insert, a 40µl DCM were added and the new solution stored at -20°C. 
2.3.3.5. Preparation of fatty acid methyl esters 
         The samples were prepared for analysis by a splitless method (RBC) or 
split method (skin and cell pellets). The lipid extracts which were in E1 and 
stored at -20oC, were defrosted. 15l or 45l of internal standard (C21) was 
added to the lipid extract. The lipid extract was dried to remove the solvent. 
250l of toluene: methanol (50/50 v/v) (see Appendix 1.2) and 250 l of 14% 
BF3-methanol solution were added to the dried lipid extract. The esterification 
tube E1 was flashed under nitrogen, closed with a Teflon cap and gently 
vortexed. The heater block set was pre-heated to 100 oC and the fatty acid 
esterification tubes were transferred onto it and left for 90 min. After 90 min had 
elapsed the tubes were transferred to an ice bath. After 10 min on ice, 1.5 ml of 
10% K2CO3 solution (w/v) (see Appendix 1.2) and 2 ml of trimethylpentane were 
added to each fatty acid esterification tube. The tubes were vortexed and 
centrifuged at 4ºC, 5000 rpm for 5 min. The upper layer, which contains the 
FAME, was carefully transferred to a clean tube E2 using a glass Pasteur 
pipette. The FAME solution was gently dried under nitrogen, reconstituted in 
60l dichloromethane, vortexed and centrifuged for 10 s at 3000rpm to help 
collect all the drops from the glass walls. The resulting solution was transferred 
to a clean 100 µl insert vial using a glass syringe, placed in an amber glass vial, 
and analysed immediately.  
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2.3.3.6. Gas chromatographic analysis  
        Fatty acid methyl esters were analysed by GC-FlD. A mixture of hydrogen 
and air were used as the detector gas, and helium as the carrier gas. The 
injection temperature was set at 220 oC and the flame ionisation detector (FID) 
was at 250 oC. The injection volume was 1l and the GC run time was as 
follows: The oven temperature was set at 70 oC for 2 min and was then 
increased to 150 oC at the rate of 20 oC /min for 5 min; it was then elevated to 
218 oC at the rate of 2.50 oC /min. The rate of increase was 0.60 oC from 218 oC 
to 225 oC. The temperature was set at 225 oC for 10 min followed by a rise to    
230 oC at the rate of 2.50 oC /min; this was then maintained for 3 min. The 
overall run time was 75 min. Dichloromethane (blank) was injected followed by 
FAME cocktail standard and internal standard methyl ester to establish the 
retention times. Blanks were injected between the standard and first sample 
injection and then this every 4 sample injections. 
2.3.3.7. Identification and quantitation of fatty acid methyl esters  
         In order to establish the retention times of each analyte, and allow 
identification and quantitation of the fatty acid methyl esters, the internal 
standard methyl ester and a mixed FAME standard cocktail were injected 
before the samples. All samples were injected in duplicate. To identify the fatty 
acids, retention times of FAME in the sample were compared to mixed FAME 
standard cocktail retention times. In order to give relative amounts of each fatty 
acid, the FAME peak area in each sample was integrated and normalised using 
the peak area of the internal standard of the run. Data are expressed as % 
weight of total fatty acid in the sample.   
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2. 4. Eicosanoid analysis  
2.4.1. Materials 
          Solid phase extraction (SPE) cartridges (C18-E 500mg, 6ml) were 
purchased from Phenomenex, Macclesfield, UK. Narrow range (2.5-4.5) pH 
indicator paper strips were purchased from Merck, UK. Methanol (HPLC grade), 
ethanol (HPLC grade), and hexane (HPLC grade) hydrochloric acid were all 
purchased from, Fisher scientific, UK.  Methyl formate was purchased from 
Sigma, UK. 50 and 250 µl glass syringes were purchased from SGE, Australia. 
Glass tubes and glass Pasteur pipettes were purchased from Fisher, 
Loughborough, UK. Amber glass vials, 100 µl insert vials, crew caps, and septa 
were all purchased from Kinesis, Bedfordshire, UK. 
2.4.2. Equipment 
         A Waters Alliance 2695 HPLC pump with a Waters 2690 autosampler 
coupled to an electrospray ionisation (ESI) triple quadruple Quattro Ultimo mass 
spectrometer and The Mass LynxTM V 4.0 operating software were purchased 
from Waters, Elstree, UK. SPE vacuum Manifold was obtained from 
Phenomenex, Macclesfield, UK. Whirlmixer was purchased from Flsons 
Scientific Apparatus, England. Sorvall RT6000B refrigerated centrifuge was 
obtained from Dupont, LTD (UK). 
2.4.3. Sample preparation 
         In order to analyse the eicosanoids in cell culture media, the cell culture 
media (10ml) from different treatment were defrosted by transferring the 
samples from -80C storage to the fridge for 2h. After that, the samples were 
placed on ice. The 50 and 250 glass syringes were washed with ethanol and 
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the internal standards PGB2-d4 (1ng/µl) and 12 HETE-d8 (1ng/µl) were mixed 5 
times. 40 µl from each internal standard was added to each sample before it 
became fully defrosted. 1.77 ml methanol was added to each 10ml sample to 
make 15% methanol. The samples were incubated for 15 min in ice. Then 
samples were centrifuged at 3000 rpm for 8 min to remove the precipitated 
protein. The SPE cartridges were labelled and attached to a vacuum manifold. 
The SPE cartridges were preconditioned with 20ml 100% methanol and washed 
with 20 ml MQ water. The pressure was adjusted so that the solvent was eluted 
from the ESP cartridges drop-wise. The samples were acidified with 1M HCl 
(see Appendix 1.3) of approximately 12-15 drops to adjust to pH 3.0. The pH of 
the samples was measured by a narrow range pH indicator paper.  The sample 
was immediately transferred to the preconditioned SPE cartridges using a glass 
Pasteur pipette. Pressure was not used in this step to elute the sample. The 
SPE cartridges were then washed with 20ml 15% methanol (see Appendix 1.3), 
20ml water (glassware were washed with hexane) and 10 ml of hexane. The 
glassware was washed with methyl formate and finally, 12 ml of methyl formate 
was added to each SPE cartridge to collect the lipid extraction. The organic 
solvent was evaporated under nitrogen; the residue was dissolved in 100 µl 
ethanol/MQ water (70/30 v/v). The samples were mixed, vortexed and 
centrifuged for 1min.  The samples were transferred to clean 100 µl insert vials, 
placed in amber glass vials and stored at -20C for up to one week for analysis. 
2.4.4. LC/ESI-MS/MS Analysis  
          LC/ESI-MS/MS analysis was performed on a Waters Alliance 2695 HPLC 
pump with a Waters 2690 autosampler coupled to an electrospray ionisation 
(ESI) triple quadruple Quattro Ultimo mass spectrometer. The Mass LynxTM V 
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4.0 was used as operating software to control the instrument and data 
acquisition. The instrument was operated in the negative ionisation mode. The 
sample chamber was a Waters 2690 autosampler and the column temperature 
was set up at 8°C. The source temperature was 120°C and the desolation 
temperature was 360°C. The capillary voltage was set at 3500V and the cone 
voltage at 35V. Collision energy settings and multiple reaction monitoring (MRM) 
transitions for each detectable compound were set up as described by Masoodi 
and Nicolaou (2006). Liquid chromatographic analysis was performed on a C18 
column (Gemini, 5µ, 150x2 mm). The injection volume was 10µl (each sample 
was injected twice), flow rate was 0.2 ml/min and the running time was 30 min. 
Prostaglandins and hydroxyl fatty acids were analysed separately.  
Prostaglandins analysis was performed using an acetonitrile-based gradient 
system of two solvents, A and B. Solvent A was: acetonitrile /water/glacial 
acetic acid, 45: 55: 0.02 (v/v/v); solvent B was: acetonitrile /water/glacial acetic 
acid, 90: 10: 0.02 (v/v/v). Hydroxy fatty acids analysis was performed using an 
isocratic system of two solvents, C and D. Solvent C was: methanol: water: 
glacial acetic acid, 80: 20: 0.02 (v/v/v); solvent D was: acetonitrile: water: glacial 
acetic acid, 45: 55: 0.02 (v/v/v). In order to calculate the concentration of each 
analyte the peak area ratio to relevant internal standard (PGB2-d4 - 12 HETE-d8) 
was calculated and read off the corresponding calibration line. The calibration 
lines were constructed using commercially available standards. Tables 2.1 and 
2.2 show the MRM transitions and retention time for commercially available 
standards that are used to detect eicosanoids and hydroxy fatty acid. This 
analysis was performed according to the protocols published by Masoodi et al. 
(2006), and Nicolaou et al (2009).  
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Table 2.2. MRM transitions and retention times for the LC-MS/MS assay of 
eicosanoids 
 
compound MRM transitions Retention time 
PGE1 353>317 4.47 
PGD1 353>317 4.79 
PGF1α 355>311 3.69 
PGB2 333>175 9.96 
PGE2 351>271 4.47 
PGD2 351>271 5.18 
PGF2α 353>193 3.77 
PGJ2 333>271 9.17 
Δ12-PGJ2 333>271 9.80 
15-deoxy-Δ12,14 PGJ2 315>271 18.10 
PGE3 349>269 3.85 
PGD3 349>269 4.08 
PGF3α 351>193 3.30 
TXB2 369>169 3.46 
13,14-dihydro-15-keto PGE1 353>335 7.42 
13,14-dihydro-15-keto PGF1α 355>193 6.67 
15-keto PGE2 349>113 6.68 
13,14-dihydro-15-keto PGE2 351>333 6.89 
13,14-dihydro PGF2α 355>311 4.79 
13,14-dihydro-15-keto PGF2α 353>113 6.12 
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Table 2.3. MRM transitions and retention times for the LC-MS/MS assay of hydroxy 
fatty acids 
 
compound MRM transitions(m/z) Retention time(min) 
9-HODE 295>171 13.98 
13-HODE 295>195 13.75 
5-HEPE 317>115 13.18 
18-HEPE 317>133 11.22 
9-HEPE 317>149 12.03 
8-HEPE 317>155 12.14 
11-HEPE 317>167 12.03 
15-HEPE 317>175 11.8 
12-HEPE 317>179 12.37 
5-OXOETE 317>203 18.35 
14(15)EET 319>113 17.2 
5-HETE 319>115 17.66 
9-HETE 319>123 16.74 
8-HETE 319>155 15.94 
11-HETE 319>167 15.36 
15-HETE 319>175 14.44 
12-HETE 319>179 15.82 
15-HETrE 321>221 17.55 
14,15-DHET 337>207 9.97 
10-HDHA 343>153 15.82 
14-HDHA 343>161 15.82 
13-HDHA 343>193 15.36 
17-HDHA 343>201 15.02 
20-HDHA 343>241 14.21 
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2. 5. Statistical analysis  
          Statistical analysis was performed with SPSS 16.0. The normality of the 
data was determined using the Kolmogorov-Smirnov test. One-way-ANOVA 
analyses were performed to compare differences in HaCaT keratinocytes and 
46BR.1N fibroblasts between control groups and treated groups. The Kruskal-
Wallis test was performed to compare differences in RBC and dermal PUFA 
content between n-3 PUFA and control groups postsupplementation. 
Spearman’s test was used to determine correlations between RBC and dermal 
PUFA content. A p value of < 0.05 was considered statistically significant. 
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Chapter 3. Effect of n-3 PUFA on the fatty acid profile of 
red blood cells and dermal tissue 
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3.1. Introduction 
          Skin has a number of internal mechanisms to defend and protect it from 
UVR damage, including melanin production, anti-oxidant defences and 
enzymatic repair pathways (Sies and Stahl, 2004). Simple methods of 
protecting against skin damage include avoiding the midday sun, seeking shade 
and wearing protective clothing. However increased protection might affect 
vitamin D synthesis in the skin and cause vitamin D deficiency (Holick, 1996, 
Moloney et al., 2002).  Application of sunscreens is another way to protect the 
skin from harmful UVR effects. These sun blocks work by scattering, reflecting 
or absorbing radiation but their effect is local and temporary, and the majority of 
UVR exposure occurs when many individuals forego sunscreen (Bech-
Thomsen and Wulf, 1992) .      
          Dietary intervention is a safe method of protecting the skin.  Omega-3 
PUFAs have a beneficial role in skin health and disease prevention (Sies and 
Stahl, 2004). They are anti-inflammatory, and have been shown to help prevent 
various skin diseases such as atopic dermatitis (AD), a skin disorder common in 
early childhood (Kay et al., 1994). Hoppu et al (2005) found that the risk of AD 
was associated with high saturated fatty acid and low n-3 PUFA concentration 
in breast milk (Hoppu et al., 2005). A double-blind study confirmed the 
beneficial role of n-3 PUFA in AD. The severity of AD was found to be lower in 
the active group, whose members received 10 g of fish oil daily (1.8 g was EPA), 
compared to control subjects, who received olive oil (Bjorneboe et al., 1987). 
Psoriasis is an inflammatory skin disorder that can be improved by n-3 PUFA 
supplementation, and studies have reported a decrease in psoriasis severity 
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and clinical improvement following n-3PUFA supplementation (Soyland et al., 
1993, Mayser et al., 2002).   
        The photoprotective effect of n-3 PUFA in skin disease has been 
supported by many studies. Rhodes et al. (2003) found, in a double-blind 
randomised study, that the minimal erythema dose (MED) was increased by 36% 
after 4g  of EPA ethyl ester daily supplement was administered for three months 
to healthy volunteers compared to a control group supplemented with 4g oleic 
acid (Rhodes et al., 2003). In a second clinical trial, 20 healthy volunteers were 
divided into placebo and fish oil (1.2g EPA and 2.8g DHA)  groups; after four 
weeks the results showed that, the MED was significantly increased in the fish 
oil supplement group compared to the placebo group (Orengo et al., 1992). A 
third randomised controlled trial was performed with 10 subjects: they were 
supplemented with 10g of fish oil daily (containing 18% EPA and 12% DHA) for 
three or six months and it was found that the fish oil supplement also increased 
the MED (Rhodes et al., 1994).  
          The topical effect of n-3 PUFA was studied in ten healthy human 
volunteers aged 25-35 years. Six sites on the surface of the forearm received 
200g of fish oil extract and were exposed to 2 MED. The sites treated with fish 
oil extract were found to have reduced UVB-induced erythema compared to the 
control sites (Puglia et al., 2005). The relation between diet intake and 
squamous cell carcinoma (SCC) was studied, and it was found that a higher 
intake of n-3 PUFA reduced the risk of SCC; Moreover, the risk was decreased 
by increasing the ratio of n-3 PUFA to n-6 PUFA in the diet (Hakim et al., 2000). 
Finally, it has been reported that consumption of fish (rich in EPA and DHA) and 
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n-3 PUFA is related to decreased incidence of malignant melanoma (MM) (Bain 
et al., 1993, Veierod et al., 1997).  
          Human cells cannot produce the essential fatty acids LA and ALA. It has 
been reported that LA is the most abundant fatty acid in the human epidermis 
followed by arachidonic acid (Chapkin et al., 1986). Essential fatty acids are 
metabolised by the action of desaturation and elongation enzymes. The 
pathway of desaturation and elongation may function differently in various cell 
types. Arachidonic acid is normally found in small amounts in the human 
epidermis, considered to be  about 3% of total epidermal fatty acids (Ziboh and 
Chapkin, 1988). DGLA is directly generated from dietary arachidonic acid. GLA 
is converted to DGLA in the human epidermis by the action of elongase enzyme 
(Huang and Ziboh, 2001). EPA and DHA are the two major n-3 PUFAs present 
in the skin, where they comprise less than 1% of total epidermal fatty acids 
(Ziboh and Chapkin, 1988).    
          The dermal skin layer is involved in homeostasis in the skin. It provides 
good support to the epidermis. One of the functions of essential fatty acids in 
the dermal layer is the production of mediators of inflammation (Ziboh and 
Chapkin, 1988).  It has been reported that the major AA metabolite in the 
dermis is the anti-inflammatory 15-HETE, which can decrease the production of 
pro-inflammatory 12-HETE, also found in the epidermis, by inhibition of 12 
lipoxygenase (Kragballe et al., 1986). 
          Randomised controlled trials (RCT) are the best choice for clinical studies. 
An RCT is a good way of assessing the effect and interference of factors such 
as drugs in populations or groups, and of determining whether there is a 
relationship between treatment and outcome.  RCTs have important features 
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such as random selection of subjects and allocation to groups (placebo and 
active). The subjects participating in the study do not know which treatment they 
are receiving until the end of the study, and the analysis focuses on the 
difference in outcomes between the two groups (Sibbald and Roland, 1998).   
                All human studies that aim to assess the effect of dietary 
supplementation on peripheral tissues need circulating biomarkers. Red blood 
cell fatty acid content is a commonly used biomarker and is considered an index 
of tissue fatty acid status because the fatty acids they contain are associated 
with structural membrane lipids (Farquhar, 1962, Poppitt et al., 2005). Normally, 
RBCs contain very low amounts of EPA and DHA and their fatty acid profile is 
affected by diet (Arterburn et al., 2006). Moreover RBC lipids are less sensitive 
to dietary fluctuations than plasma lipids (Acar et al., 2012, Dougherty et al., 
1987). This is because serum fatty acids reflect the composition of the last few 
meals, while RBCs reflect the intake for weeks or months (Glatz et al., 1989).  
          The fatty acid composition of RBCs has been used as a marker for many 
diseases. The relation of MUFA and ratio of membrane stearic to oleic acid on 
RBC membrane to breast cancer was studied by Pala et al. (2001), and they 
found that the risk of breast cancer was increased by low MUFA. A clinical 
study has shown that the concentration of DPA and DHA in red blood cells was 
low in an ischemic brain infarction patient group compared to a control group 
(Ricci et al., 1987). The relation between n-3 PUFA in RBCs and depression 
was studied by Edwards et al. (1998), who found that the severity of depression 
correlated negatively with n-3 PUFA in RBCs (Edwards et al., 1998). Harris’s 
group reported that, the risk of skin squamous cell carcinoma is associated with 
an increase in RBC arachidonic acid (Harris et al., 2005). The risk was found to 
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decrease with an increase in n-3PUFA and increased ratios of n-3 PUFA to n- 6 
PUFA (Hakim et al., 2000).  
          The clinical work described in this section was part of the study 
performed by our collaborators at the University of Manchester under the 
supervision of Prof L.E Rhodes. The study was based on the hypothesis that, 
diets rich in n-3 PUFA may be important to protect and keep the skin in good 
health. Also, epidemiological evidence indicates that n-3 PUFA could present 
such an opportunity, as high dietary levels are associated with reduced skin 
cancer risk. The study aimed to investigate the following: a) The protective role 
of n-3 PUFA against UVR on skin; b) the value of RBC measurements as 
indicator of skin content of EPA (Wallingford et al., 2012); c) the effect of oral n-
3 PUFA supplementation on photoimmunosuppression in human skin 
(Pilkington et al., 2013). The study aims were investigated in a double-blind 
randomised controlled trial. Section 2.1.2.1 describes the participation in this 
study and 2.1.2.2 describes the study design and supplements. 
          The specific purposes of the present study were as follow: a) to assess 
the compliance of the subjects taking part in the study using RBC fatty acids as 
a marker; b) to analyse the fatty acid content of the dermis in the same subjects;       
c) to investigate the relationship between RBCs and dermal fatty acids and 
explore any correlation.  
3.2. Methods 
           All relevant information is shown in section 2.3. RBC and skin sample 
preparation was described in section 2.3.3.1a and b. Lipid extraction in section 
2.3.3.2 and section 2.3.3.5 show the preparation of fatty acid methyl esters. 
Statistical analysis was performed in SPSS 16.0. The normality of the data was 
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determined using the Kolmogorov-Smirnov test. Spearman correlation was 
used to assess the linear relationship between RBC and dermis. 
3.3 Results 
3.3.1. Analysis of the supplements (capsules) 
          The content of capsules containing the active (~72% EPA, 10% DHA) 
and placebo (glyceryl tricoprylate coprate, GTCC) supplementation were 
analysed by GC-FID.  
         N-3 supplementation was presented as EPA ethyl ester (EPAEE) and 
DHA ethyl ester (DHAEE). So, Active and Placebo capsules was analysed as 
FAEE. Figure 3.1 shows total fatty acid ethyl ester (FAEE) profile in the active 
and placebo capsules. It is clear that the EPA and DHA were in the active 
capsules and the EPA: DHA ratio was 6.3:1. Also, the results confirmed that 
there was no n-3 PUFA in the placebo supplement. 
          Placebo supplementation was presented as glyceryl tricoprylate coprate. 
So, Placebo and Active capsules were also analysed as FAME. This was done 
in order to identify the present of any other fatty acids in Active that may not 
have been detected as ethyl ester. The results shown in Figure 3.2 confirm that 
EPA and DHA were in the active capsules and EPA: DHA ratio also was 6.3:1. 
FAEE and FAME results confirm that EPA and DHA were present in the active 
capsules only and that the ratio of EPA to DHA was 6.3:1, nearly to what the 
manufactures specified to be 7:1. But there were some other fatty acids found 
by FAME analysis. These were C16:0, C18:0, C20:1n9 and C20:3n-3. The 
composition of EPA and DHA in the supplement was ~80% and the fatty acids 
C16:0, C18:0, C20:1n9 and C20:3n-3) made up the rest. 
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Figure 3.1. Fatty acid ethyl aster profile in ACTIVE (n-3 PUFA supplement) and 
placebo (glyceryl tricoprylate coprate) capsules. Results are expressed as % weight of 
total fatty acids (mean ± standard deviation) of 3 capsules per group, each analysed in 
duplicate. 
 
Figure 3.2. Fatty acid methyl aster profile in ACTIVE (n-3 PUFA supplement) and 
placebo (glyceryl tricoprylate coprate) capsules. Results are expressed as % weight of 
total fatty acids (mean ± standard deviation) of 3 capsules per group, each analysed in 
duplicate. 
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3.3.2. Analysis of fatty acid content of red blood cells   
          There were four groups in this study: pre-supplementation placebo,    
post-supplementation placebo, pre-supplementation active and Post 
supplementation active. This data is shown in Appendix 2.1. Statistically, there 
were no differences between pre-supplementation placebo and pre-
supplementation active, therefore there two groups were combined to get the 
baseline reading for this study. The three groups used for data analysis were 
Baseline, Placebo and Active as shown in Table 3.1.  
 3.3.2.1 Fatty acid profile in red blood cells at baseline  
          The fatty acid composition of RBC is shown in Table (3.1). In detail: The 
saturated fatty acid group (SFA) comprised 44.27 ± 7.43% of all fatty acids. 
There were 10 SFA detected: C12:0, C14:0, C15:0, C16:0, C17:0, C18:0, C20:0, 
C23:0 and C24:0, with the main ones being C16:0 at 25.53±4.39% and C18:0 at 
14.89 ± 3.08%. Monounsaturated fatty acids (MUFA) were about 20.94 ± 3.29% 
of total RBC fatty acids. 10 MUFA were detected in this group: C14:1 C15:1, 
C16:1, C17:1, C18:1n-9t, C18:1n-9c, C18:1n-7, C20:1n-9, C22:1n-9 and C24:1. 
The main fatty acid was C18:1n.9c at 16.63 ± 2.98%. About 30% of RBC fatty 
acids were n-6 PUFA. This group comprised five n-6 PUFA: C18:2n.6t, 
C18:2n.6c, C18:3n-6, C20:3n-6 and C20:4n-6. The main PUFA was C18.2n.6c 
at 14.62 ± 3.28% followed by C20:4n-6 at 12.85 ± 0.53%. Five n-3 PUFA were 
also found and they comprised 6.82 ± 1.55% of total RBC fatty acid. These 
were C18:3n-3, C20:3n-3, C20:5n-3, C22:5n-3 and C22:6n-3. C22:6n-3 was 
found in high amount 3.57 ± 0.69% followed by C22:5n-3 and C20:5n-3 which 
were 1.91 ± 0.45%, 0.91 ± 0.42%, respectively.  
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Table 3.1 Fatty acid profile of RBC at baseline, (n=69) and post 
supplementation with Placebo (n=33) and n-3 supplement (Active; n=35). 
Results are expressed as % weight of total fatty acid (mean ± SD). a,b =p≤0.05, 
aa, bb =p≤0.01, aaa, bbb =p≤0.001 . (a) comparing baseline to active group and 
(b) comparing placebo to active group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FATTY ACID Baseline(n=69) Placebo (n=33) Active (n=35)  
C12:0 0.09 ± 0.12 0.10 ± 0.02 0.10 ±0.02 
C14:0 0.66 ± 0.23 0.63 ±0.11 0.63 ± 0.11 
C15:0 0.16 ± 0.05 0.15 ±0.03 0.15 ± 0.03 
C16:0 25.53 ± 4.39 25.18 ± 4.38 24.44 ± 4.13 
C17:0 0.31 ± 0.14 0.28 ± 0.05 0.31± 0.05 
C18:0 14.89 ± 4.39 14.81± 2.58 14.41± 2.44 
C20:0 0.27 ± 0.12 0.25 ± 0.04 0.23± 0.04 
C22:0 0.59 ± 0.32 0.48 ± 0.08 0.54 ± 0.09 
C23:0 0.09 ± 0.07 0.07 ± 0.01 0.08 ± 0.01 
C24:0 1.69 ± 0.88 1.46 ± 0.25 1.36 ± 0.23 
ΣSFA 44.27 ± 7.43 43.41 ± 7.56 42.26 ± 7.14 
C14:1 0.06 ± 0.03 0.01 ± 0.01 0.01 ± 0.01 
C15:1 0.01 ± 0.01 0.01 ±0.01 0.01 ± 0.01 
C16:1 0.84 ± 0.63 1.05 ±0.18 0.71 ±0.12 
C17:1 0.01 ±0.02 0.01 ± 0.01 0.03 ±0.01 
C18:1n-9t 0.13 ±0.26 0.09 ± 0.02 0.06 ±0.01 
C18:1n-9c 16.63 ±2.98 16.57 ±2.88 16.67 ± 2.82 
C18:1n-7 1.15 ±0.33 1.13 ±0.20 1.44 ± 0.24 
C20:1n-9 0.46 ±0.93 0.45 ±0.08 0.31 ± 0.05 
C22:1n-9 0.09 ± 0.05 0.09 ±.0.02 0.11±0.02 
C24:1 1.61 ±0.91 1.40 ±.0.24 1.49 ± 0.25 
ΣMUFA 20.94 ± 3.29 20.79 ± 3.62 20.84 ± 3.52 
C18:2n-6t 0.06 ± 0.01 0.06±0.01 0.03 ± 0.01 
C18:2n-6c 14.62 ± 3.28 15.51± 2.70 13.73 ± 2.32a,bb 
C18:3n-6 0.19 ± 0.18 0.16 ±.0.03 0.11 ± 0.02aaa,bb 
C20:3n-6 1.88 ± 0.53 1.97 ± 0.34 1.56 ± 0.26aaa,bbb 
C20:4n-6 12.85 ± 0.53 12.77 ± 2.22 11.84 ± 2.00a,b 
ΣN-6PUFA 29.61 ± 5.53 30.46 ± 5.30 27.28 ± 4.61aaa,bbb 
C18:3n-3 0.40 ±.0.32 0.37 ±.0.07 0.31 ± 0.05 
C20:3n-3 0.02 ± 0.05 0.03±.0.01 0.02 ± 0.001 
C20:5n-3 0.91 ± 0.42 0.92 ±0.16 3.61 ± 0.61aaa,bbb 
C22:5n-3 1.91 ± 0.45 1.93 ±.0.34 3.19 ± 0.54aaa,bbb 
C22:6n-3 3.57 ±.0.69 3.53 ±0.61 4.20 ± 0.71aa,bb 
ΣN-3PUFA 6.82 ± 1.55 6.79 ± 1.18 11.34 ±1.92 aaa,bbb 
C20:2 0.19 ± 0.23 0.26 ± 0.05 0.20 ±0.03 
C22:2 0.07 ±0.01 0.04 ± 0.01 0.06 ±0.01 
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3.3.2.2. Effect of placebo on red blood cell fatty acid profile 
There was no statistically significant difference in the levels of fatty acids in the 
Placebo group compared to the Baseline group (Table 3.1).  
3.3.2.3. Effect of n-3PUFA supplementation on red blood cell fatty acids  
          Statistical analysis has shown that there was not any effect of the n-3 
PUFA supplement on the saturated and monounsaturated fatty acids in red 
blood cells, but there was an effect on the n-6 and n-3 PUFA. Specifically:  
          A decrease in n-6 PUFA was observed in the Active group compared to 
the Baseline and Placebo groups. A significant decreased from 29.6% ± 5.5 at 
baseline to 27.3 ± 3.0% in active group (p≤0.001). Also a significant decreased 
from 30.5% ± 5.0 at placebo to 27.3 ± 3.0% in active group (p≤0.001). These 
changes are due to changes in the level of individual fatty acids. Specifically: 
The concentration of C18:2 n-6c and C18:3 n-6 were significantly decreased in 
the Active group compared to Baseline (p≤0.05, and p≤0.001, respectively). 
Also they were significantly decreased in the Active group compared to Placebo 
(p≤0.006, and p≤0.005, respectively) (Table 3.1). The amount of C20:3n-6 was 
significantly decreased in the Active group compared to Baseline (p≤0.001) and 
Placebo groups (p≤0.001). Also a significantly decreased in the concentration of 
C20:4 n-6 in the Active group compared to Baseline (p≤0.05) and Placebo 
groups (p≤0.05). Results shown in Table 3.1. 
          Finally the results show that the amount of n-3 PUFA increased in the 
Active group. It was significantly increase from 6.80 ± 1.6% at the Baseline and 
Placebo group to 11.34 ± 1.92% in Active group (p≤0.001). Table 3.1 shows the 
effect of n-3 PUFA supplementation on C20:5n-3. There was a significant 
increase in the Active group when compared to Baseline (p≤0.001) and Placebo 
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groups (p≤0.001). Also, a significant increase was observed in the amount of 
C22:5n-3 after n-3 PUFA supplementation (Active) compared to Baseline 
(p≤0.001) and Placebo group (P≤0.001). Finally, An increase of C22:6n-3 
concentration was observed in the Active group after n-3 PUFA 
supplementation. This was significantly increased compared to Baseline and 
Placebo groups (p≤0.001 and p≤0.01, respectively). 
3.3.3. Analysis of fatty acid content of dermis 
          There were four groups in this study: pre-supplementation placebo, post-
supplementation placebo, pre-supplementation active and post-
supplementation active. This data is shown in Appendix 2.2. Statistically, there 
were no differences between pre-supplementation placebo and pre- 
supplementation active; therefore the two groups were combined to get the 
baseline reading for this study. The three groups used for data analysis were 
baseline, placebo and active as shown in Table 3.2.  
3.3.3.1. Fatty acid profile of dermis  
        The fatty acid composition of human dermis is shown in Table 3.2. In detail: 
Saturated fatty acids were 27.06 ± 9.54% of total fatty acids and it was less than 
it was in RBC (Figure 3.3). Ten SFA were detected : C12:0, C14:0, C15:0, 
C16:0, C17:0, C18:0, C20:0, C23:0 and C24:0, with the main fatty acid being 
C16:0.  
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Table 3.2 Fatty acid profile of human dermis at baseline, (n=33), placebo (n=14) and 
post n-3 supplement (active)(n=19). Results are expressed as % weight of total fatty 
acid (mean ± SD). a,b = p≤0.05  aaa,bbb = p≤0.001 . (a) comparing baseline to active 
group and (b) comparing placebo to active group. 
 
 
Fatty acid Baseline(n=33) Placebo(n=14)  Active(n=19)  
C12:0 0.18 ± 0.37 0.21 ± 0.05 0.17 ± 0.04 
C14:0 1.83 ± 0.57 1.82 ± 0.49 1.76 ± 0.40 
C15:0 0.23 ± 0.09 0.24 ± 0.06 0.21 ±  0.05 
C16:0 21.05 ± 7.65 20.52 ± 5.48 19.06 ± 4.37 
C17:0 0.20 ± 0.17 0.23 ± 0.06 0.13 ± 0.03 
C18:0 3.27 ± 2.4 3.72 ± 0.99 2.57 ± 0.59 
C20:0 0.18 ± 0.14 0.13 ± 0.03 0.16 ± 0.04 
C22:0 0.03 ± 0.01 0.04 ± 0.01 0.01 ±0.01 
C23:0 0.02 ± 0.01 0.01 ± 0.01 0.00 ±0.00 
C24:0 0.06 ± 0.06 0.07 ± 0.02 0.05 ± 0.01 
ΣSFA 27.06 ± 6.78 26.97 ± 7.71 24.13 ± 5.54 
C14:1 0.52 ±0.35 0.49 ± 0.13 0.57 ± 0.13 
C15:1 0.03 ± 0.05 0.02 ± 0.01 0.01 ± 0.01 
C16:1 10.0 ± 4.23 8.21 ± 2.19 10.38 ± 2.38 
C17:1 0.18 ± 0.05 0.17 ± 0.04 0.21 ± 0.05 
C18:1n-9t 0.85 ±0.25 0.72 ± 0.19 0.34 ± 0.08 
C18:1n-9c 43.78 ± 9.42 46.01 ±12.30 46.82 ± 10.74 
C18:1n-7 3.08± 1.50 3.28 ± 0.88 2.75 ± 0.63 
C20:1n-9 0.40 ± 0.12 0.44 ±0.12 0.39 ± 0.09 
C22:1n-9 0.05 ± 0.01 0.06 ± 0.02 0.03 ± 0.01 
C24:1 0.03 ± 0.01 0.04 ± 0.01 0.02 ± 0.01 
ΣMUFA 58.90 ± 9.80 59.43 ± 15.88 61.52 ± 14.11 
C18:2n-6t 0.14 ± 0.11 0.14 ± 0.04 0.10 ± 0.02 
C18:2n-6c 10.96 ± 2.81 10.99 ± 2.94 11.63 ± 2.67 
C18:3n-6 0.06 ± 0.02 0.08 ± 0.02 0.07 ± 0.02 
C20:3n-6 0.21 ± 0.09 0.22 ± 0.06 0.19 ± 0.04 
C20:4n-6 0.66 ± 0.32 0.66 ± 0.18 0.61 ± 0.14 
ΣN-6PUFA 12.47 ± 3.33 12.08 ± 3.23 12.60 ± 2.89 
C18:3n-3 0.75 ± 0.26 0.69 ± 0.19 0.81 ± 0.19 
C20:3n-3 0.04 ± 0.01 0.04 ± 0.01 0.04 ± 0.01 
C20:5n-3 0.06 ± 0.32 0.06 ± 0.02 0.12 ± 0.03 aaa,bbb 
C22:5n-3 0.20 ± 0.74 0.19 ±0.05 0.24 ± 0.05a,b 
C22:6n-3 0.18 ± 0.09 0.16 ± 0.04 0.21 ± 0.05 
ΣN-3PUFA 1.32± 0.37 1.14 ±0.31 1.42 ±0.33 
C20:2 0.37 ± 0.08 0.36 ± 0.10 0.32 ± 0.07 
C22:2 0.02 ± 0.01 0.02 ± 0.01 0.01 ± 0.01 
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          The monounsaturated fatty acids group was found at higher levels 
(58.90±9.80%) and it is higher than in RBC (Figure 3.3). Ten MUFA were 
detected in this group; C14:1 C15:1, C16:1, C17:1, C18:1n-9t, C18:1n-9c, 
C18:1n-7, C20:1n-9, C22:1n-9 and C24:1. C18:1n.9c was the main fatty acid.  
         N-6 PUFA comprised about 12.47±3.33% of total dermal fatty acids with 5 
PUFA present: C18:2n.6t, C18:2n.6c, C18:3n-6, C20:3n-6 and C20:4n-6. 
C18.2n.6c was the main n-6 PUFA with 10.96±2.81%. The n-6 PUFA levels 
were lower than in RBC (Figure 3.3)   
         Five n-3 PUFA, C18:3n-3, C20:3n-3, C20:5n-3, C22:5n-3, C22:6n-3 were 
detected in n-3 PUFA group and comprised 1.23±0.37% of total dermal fatty 
acid. The levels of n-3 PUFA were less than in RBC (Figure 3.3).  
 3.3.3.2. Effect of supplementation on dermal fatty acids 
         There was no statistically significant difference in the levels of fatty acids 
in the placebo group comparing to the baseline group.  
          Also, there was no effect of n-3PUFA supplementation on SFA, MUFA 
and n-6 PUFA. However, n-3 PUFA was affected by n-3PUFA supplementation. 
Specifically:  C20:5n-3 and C22:5n-3 increased after 3 months of n-3PUFA 
supplementation. C20:5n-3 was significantly increased from 0.06 ± 0.02% at the 
baseline and Placebo group to 1.12 ± 0.03% at Active group, and this was 
statistically significant (p=0.001 and p≤0.001, respectively) (Table 3.2). Also, 
C22:5n-3 was significantly increase in active group compared to baseline 
(p≤0.05) and placebo (p≤0.05). (Table 3.2)   
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Figure 3.3. Fatty acid groups of red blood cell (RBC, n=69) and dermis (n=33) at 
baseline. Results are expressed as % weight of total fatty acids (mean ± SD). SFA= 
saturated fatty acids. MUFA= monounsaturated fatty acids, N-6 PUFA= n-6 
polyunsaturated fatty acids. N-3 PUFA= n-3 polyunsaturated fatty acids. 
 
3.3.4. Correlation of fatty acids in dermis and RBC  
         Correlation test (Spearman correlation test for non parametric data) was 
run between the main PUFA of the samples in the Placebo and Active groups 
before and after supplementation. Results in Figure 3.4 suggest that AA, EPA 
DPA and DHA showed no significant correlation between dermis and RBC 
before and after supplementation at Placebo group.  
          Among all PUFA in the Active group, AA shown a significant correlation at 
post (r=0.581, p≤0.011) supplementation. Although, the results show that the 
correlation of EPA was not statistically significant, it is clear that the EPA data 
were in the lower left of the scatter plot at pre-active supplementation group. In 
contrast the n-3PUFA supplement takes the data in the upper right of the 
scatter plot (Figure 3.5).    
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                     PLACEBO: BEFORE                                  PLACEBO: AFTER 
 
 
 
 
 
Figure 3.4. Correlation of dermal and red blood cells (RBC) level of arachidonic acid 
(AA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA) and docosahexa-
enoic acid (DHA) before and after placebo supplementation (n=14 subjects). 
DER=dermal. RBC=, PL.PRE= Placebo pre supplement. PL.PST= Placebo post 
supplement. 
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R= 0.158 
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                      ACTIVE: BEFORE                                       ACTIVE: AFTER 
 
 
 
 
 
Figure 3.5. Correlation of dermal and red blood cells (RBC) level of arachidonic acid 
(AA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA) and docosahexa-
enoic acid (DHA) before and after active supplementation (n=19 subjects). 
DER=dermal. ACTV.PRE= Active pre supplement. ACTV.PST= Active post 
supplement. 
p=0.173 
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3.3.5. Fatty acid profile of epidermis  
          Five samples of epidermis were available for fatty acid analysis. The 
detailed fatty acid profile for epidermis, dermis and RBC is shown in       
Appendix 2.3. 
          Figure 3.6 shows that SFA were higher in RBC (42%) followed by 
epidermis (37%) and dermis (25%). The main SFA C16:0 was at the same level 
in epidermis and dermis (20%) and at RBC(24%). C18:0 was lower in dermis 
(3%), then in epidermis (10%) and RBC (14%).  
         High amounts of MUFA were found in dermis (61%) followed by epidermis 
(46%) and RBC (22%). C18:1n-9c was found to be the main FA in this group 
with a high level in dermis (45%) followed by epidermis (35%) and lower RBC 
(17%) (Figure 3.7). 
          N-6 PUFA was higher in RBC (30%) followed by epidermis (14%) and 
dermis with (12%). The amount of C18:2n-6c was at the same concentration at 
epidermis and dermis with (11%) and RBC (15%). C20:4n-6 was found at low 
level in dermis with (0.7%) and epidermis (2.3%) and higher in RBC (14%) 
(Figure 3.8). 
          N-3 PUFA was higher in RBC (6.8%) and lower in epidermis (2.3%) and 
dermis (1.2%). The amount of C20:5n-3 was also at low concentration in the 
dermis (0.07%), epidermis (0.61%) and RBC (0.77%). C22:5n-3 level were also 
low in dermis was also low (0.18%), epidermis (0.41%) and at RBC (1.78%). 
C22:6n-3 was found at a high level in RBC (3.83%) but low in epidermis (0.38%) 
and at dermis (0.19%) (Figure 3.9).  
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Figure 3.6.Level of saturated fatty acids (SFA), palmitic acid (C16:0) and stearic acid 
(C18:0) on epidermis, dermis and red blood cells (RBC). Results are expressed as % 
weight of total fatty acids (mean ± SD of 5 volunteers, each analysed in duplicate).  
 
 
 
Figure 3.7.Level of monounsaturated fatty acid (MUFA), oleic acid (C18:1n-9c) on 
epidermis, dermis and red blood cells (RBC). Results are expressed as % weight of 
total fatty acids (mean ± SD of 5 volunteers each analysed in duplicate).  
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Figure 3.8.Level of n-6 polyunsaturated fatty acid (n-6 PUFA), linoleic acid (LA, 
C18:2n-6c) and arachidonic acid (AA, C20:4n-6) on epidermis, dermis and red blood 
cell (RBC). Results are expressed as % weight of total fatty acid (mean ± SD) of 5 
volunteers each analysed in duplicate.  
 
 
Figure 3.9. Level of n-3 polyunsaturated fatty acid (n-3 PUFA), eicosapentaenoic acid 
(EPA, C20:5n-3), docosapentaenic acid (DPA, C22:5n-3) and docosahexaenoic acid 
(DHA, C22:6n-3) on epidermis, dermis and red blood cell (RBC). Results are 
expressed as % weight of total fatty acids (mean ± SD) of 5 volunteers each analysed 
in duplicate.  
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3.4. Discussion 
          In clinical studies testing drugs or nutritional supplementation, it is 
important to have some measure of compliance or relevant biomarkers. It has 
been confirmed by many studies that the fatty acid composition of RBCs, white 
blood cells and plasma can change in response to n-3PUFA supplementation 
(Poppitt et al., 2005, Harris et al., 2007, Morlion et al., 1996) Furthermore, it has 
been reported that the fatty acid profile of RBCs is less changeable, and it has 
been a better biomarker than white blood cells (Witte et al., 2010) and plasma 
(Harris and Thomas, 2010). 
           The baseline results in this study shown that 32 fatty acids were detected 
in RBCs. The SFA group was the higher concentration; palmitic acid (C16:0) 
and stearic acid (C18:0) were the main SFAs. Harris et al (2005) also reported 
that palmitic acid (27%) and stearic acid (17%) were the main SFAs in RBCs 
(Harris et al., 2005); these concentration were higher than in our study, were 
they were 25% and 14.8%, respectively (Table 3.1). A higher amount of palmitic 
acid (44%) and a lower amount of stearic acid (11%) than those recorded in our 
results were found by Ricci et al. (1987). Moreover, in the control group (women 
(n=18) and men (n=2)) it was found that C16:0 (20.62%) and C18:0 (15.6%) 
were the main SFAs ( Miranda et al., 2011). Palmitic acid was lower and stearic 
acid was higher compared to our results (Table 3.1) It has also been reported 
that, among the Shanghai women, the amount of palmitic acid (18%) was lower 
than that found in the present study (Manchester women) while the amount of 
stearic acid (13%) was mostly the same (Table 3.3) (Shannon et al., 2007). In 
contrast, among Swedish women the amount of palmitic acid (27%) was higher 
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and the amount of stearic acid (11%) was lower than in the current study 
(Table3.5) (Wirfalt et al., 2004).   
          In this study, oleic acid has been found to be the main MUFA in RBCs at 
17%.  Certain studies reported OA as the main MUFA; higher amounts than 
found in this study were reported by Harris et al. (2005), Ricci et al. (1987) and 
Wirfalt et al. (2004), while lower amounts than found in this study were reported 
by  Shannon et al. (2007), Gemma Miranda et al. (2011).  
 
Table 3.3. Composition of RBC fatty acids in Manchester, Shanghai and Swedish 
women  
Fatty 
acids 
Manchester 
(present study) 
Shanghai 
(Shannon et al., 2007) 
Sweden 
(Wirfalt et al., 2004) 
C16:0 25.53 ± 4.39 18.73 ± 1.04 27.8 ± 1.03 
C18:0 14.89 ± 4.39 13.93 ± 0.95 11.4 ± 0.81 
ΣMUFA 20.94 ± 3.29 19.18 ± 2.27  
C18:1n-9c 16.63 ± 2.89 10.38 ± 1.22 18.0 ± 1.01 
ΣN-6PUFA 29.61 ± 5.53 28.13 ± 2.42 28.13 ± 2.42 
C18:2n-6c 14.62 ± 3.28 12.17 ± 2.84 13.4 ± 1.39 
C20:4n-6 12.85 ± 0.53 12.08 ± 1.19 12.4 ± 1.12 
ΣN-3PUFA 6.82 ± 1.55 7.69 ± 1.07  
C22:6n-3 3.57 ± 0.69 4.92 ± 0.85 6.47 ± 1.06 
C22:5n-3 1.91 ± 0.45 1.86 ± 0.34 2.62 ± 0.29 
C20:5n-3 0.91 ± 0.42 0.60 ± 0.22 1.71 ± 0.58 
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The results presented in Table 3.1, show that LA (15%) is the main n-6 PUFA in 
RBCs followed by AA (13%). The amount of LA in this study was higher than 
reported in other studies (Wirfalt et al., 2004, Shannon et al., 2007) but the 
amount of AA was similar to that found in these studies (Table 3.1). Low 
amounts of LA (12%) and AA (3.8%) were reported by Ricci et al. (1987). In 
contrast to our result AA was found to be the main n-6PUFA (13.3%) followed 
by LA (10%) and both were lower than in our study (Gemma Miranda et al., 
2011). Furthermore, the amount of AA (14.6%) was higher and that of LA 
(13.0%) was lower compared to our results (Harris et al., 2005).  
          In the current study the main n-3 PUFA in RBCs was DHA (3.57%) 
followed by DPA (1.91%) and EPA (0.91%). A similar result was reported by 
other groups (Harris et al., 2005, Wirfalt et al., 2004, Barcelo-Coblijn et al., 
2008). Another group reported a lower value of DPA (1.19%; main n-3 PUFA) 
followed by DHA (0.39%), and a smaller amount of EPA (0.15%) than was 
observed in this study (Ricci et al., 1987). In a higher amount than found in our 
study, DHA (3.71%) was the main n-3 PUFA, while EPA (0.42%) was lower 
than in our result ( Miranda et al., 2011). 
        The profile of dermal fatty acids shows that the SFA comprised about 27% 
of total fatty acids; this was not as high as in RBC cells and C16:0 was the main 
SFA in the dermis (21%). MUFA were found in higher amounts in the dermis 
where they comprised about 59% of total fatty acids. However this was not the 
same in RBCs where they comprised only 21% of total fatty acids. C18:1n-9c is 
the main MUFA in the dermis at 74.20% of MUFA. The concentration of n-6 
PUFA in RBC was 29.6%, and was higher than the level found in the dermis 
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where it was only 12%. C18:2n-6c was the main fatty acid in the dermis, 
comprising 91.3% of the total  n-6 PUFA.  
       The fatty acid profile of the epidermis was studied in only five samples that 
were available for this study. The composition of fatty acids in the epidermis is 
shown in Appendix 2.3. The results suggest that C18:1n-9c was the most 
abundant (35%) of total fatty acids in the epidermis, followed by C16:0 (21%), 
C18:2n-6c (10.77%) and C18:0 (10.65%).The amount of n-3 PUFA was higher 
in the epidermis (2.29%) than in the dermis (1.20%). In the epidermis, the 
concentration of EPA (0.61%) was higher than DPA (0.41%) and DHA (0.38%). 
In contrast, dermis DHA (0.19%) was higher than DPA (0.18%) and EPA 
(0.07%). Ni Raghallaigh et al (2012) reported that C16:0 (22%) is the main SFA 
in the skin surface lipid layer and C16:1(21%) is the main MUFA, rather than 
C18:1 as shown in this study. They also show that the concentration of DHA 
(0.30%) was higher than EPA (0.21%) (Ni Raghallaigh et al., 2012). C16:0 and 
C18:0 were found in high amounts in both living and stratum corneum of human 
sole skin epidermis (Ansari et al., 1970). A study of human epidermis observed 
that C16:0 (14%) was the main SFA, followed by C18:0 (11.06%), both of which 
were lower than in our study. OA (15.12%) was the main MUFA, in a low 
amount compared to our result. LA (21.52%) was the main n-6 PUFA followed 
by AA (6.22%) both of which were higher than found in the current study 
(Appendix 2.3) (Chapkin et al., 1986).   
         A variety of scientific associations and regulatory bodies have 
recommended a greater intake of n-3 PUFA (EPA and DHA) to help reduce the 
risk of disease in population. Determining the effect of n-3 PUFA supplement on 
fatty acid composition in RBCs and skin dermis was one target of this study. 
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The profile of the RBC fatty acids of the Active group was compared to that of 
the Baseline group to investigate whether there was any alteration to the fatty 
acid profile after three months of n-3 supplementation.  
          The result shows that PUFA composition of RBC changed after n-3 PUFA 
supplementation. Among n-6 PUFA, only C18:2n-6t was not significantly 
affected. C18:2 n-6c, GLA, DGLA and AA significantly decreased after three 
months of mainly EPA supplementation. By contrast, EPA, DPA and DHA were 
significant increased after 3 months of EPA and DHA supplementation.  This 
result was in agreement with the literatures where it was reported that the n-3 
PUFA content of RBCs increased linearly in relation to n-3 PUFA 
supplementation (Witte et al., 2010). Prisco et al reported that EPA, DPA and 
DHA significantly increased after four months of EPA (2.04g) and DHA (1.4g) 
ethyl ester (4g/d) supplementation (Prisco et al., 1996). Palozza et al found that 
after 30 and 180 days of n-3 supplementation, the PUFA pattern of the RBCs 
changed and the concentration of both EPA and DHA increased (Palozza et al., 
1996). Barcelo Coblijn also reported that the supplementation of fish oil (0.6 and 
1.2 g/d) led to an increase in n–3 PUFA content in RBCs compared with the 
placebo group (Barcelo-Coblijn et al., 2008). A significant increase in n–3 PUFA 
concentration in RBCs after consumption of 6g fish oil/d compared with a 
placebo group receiving microcrystalline cellulose was reported by (Oostenbrug 
et al., 1997). Cao et al (2006) have also reported that after 8 weeks of fish oil 
supplement (EPA 1296 mg, DHA 864 mg) at 6 capsules per day plus one 
capsule of vitamin E (400 IU), EPA, DHA and DPA increased significantly in 
RBC membranes (Cao et al., 2006). 
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        The fatty acid profile in skin dermis did not change in a way similar to 
RBCs. Among all fatty acids in the dermis only EPA and DPA significantly 
increased after three months of n-3 PUFA supplementation (Table 3.2).  Few 
studies have reported the effect of n-3 PUFA supplementation in skin fatty acids.  
Rhodes et al (1994) reported that in skin shave biopsies (predominantly 
epidermis with some dermal tissue) the EPA content increased after three 
months, supplementation with 10g of Max EPA (18% EPA, 12% DHA) daily. The 
total n-3 PUFA increased from 1.8% of total fatty acid in the epidermis to 24.2% 
after three months of n-3 PUFA supplementation (Rhodes et al., 1994).  Rhodes 
et al. (2003) also reported an eightfold increase in skin (epidermis and dermis) 
EPA concentration after supplementation with 4g/day 95% EPA ethyl for three 
months (Rhodes et al., 2003).  
          The RBC and dermal PUFA data produced another finding: RBC EPA 
has been elongated and desaturated to DPA and DHA (Table 3.1) but this was 
not observed in the skin samples, where we only see an increase in EPA which 
had been elongated to and increased to DPA but not DHA. This may be 
because the amount of DHA in the supplement (1/7th of the supplement) was 
not sufficient to alter skin DHA content. The inability of skin to desaturate DPA 
to DHA is an indication of the lack of desaturase activity in the human epidermis.  
It has been suggested that the absence of epidermal desaturase activity may be 
result of the freezing of tissue specimens or contamination of the microsomal 
preparations (Chapkin et al., 1986). Another observation from this study is the 
lack of effect on arachidonic acid levels in both RBCs and skin, suggesting that 
the supplement did not reduce arachidonic acid availability for PGE2 (and other 
eicosanoids) and may not have anti-inflammatory activity.  
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           In summary, after three months of n-3 PUFA supplementation the 
volunteers who participated in this study were regularly taking the supplement. 
This was confirmed by an increase in the levels of EPA, DPA and DHA in RBCs 
and also by an increase in EPA and DPA in skin.  No significant correlations 
between n-3 PUFA in RBCs and skin were found.  Moreover, the n-3 PUFA in 
circulation is not a good measure of skin bioavailability of these long-chain n-3 
PUFA. 
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Chapter 4. The effect of PUFA and UVR on skin cell 
viability  
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4.1. Introduction  
          The effect of UVR on humans, animals and bacteria has been widely 
studied. Data from experimental as well as epidemiological studies have 
provided strong evidence that UVR is involved in the pathogenesis of many 
diseases. Depending on the wavelength and dose of UVR, the effect of UVR on 
human health can be useful or harmful (Ohnaka, 1993). Small doses of UVR 
are functionally useful for humans, essentially in vitamin D synthesis (MacKie, 
2000). UVR is also used in the medical field to treat many diseases such as 
psoriasis, eczema, rickets and jaundice (EUROSKIN, 2000).  
          The harmful effects of UVR depend on the wavelength of the radiation. In 
general, harmful effects result in photocarcinogenesis, photodamage, damage 
to the eyes, DNA damage, modification of the skin’s immune system, and 
chemical hypersensitivity (Ohnaka, 1993, Nataraj et al., 1995). In skin, all main 
types of skin cancer, (basal cell carcinoma, squamous cell carcinoma and 
melanoma) are linked to UVR in sunlight (IARC, 1992). Overall, toxic effects of 
UVR from natural sources, artificial lamps and sun beds are major risk factors 
for human skin cancer.        
          The sun is the main source of natural UVR. The UVB component of 
sunlight is about 5%-10% of total UVR (280 and 320 nm) and 90%-95% of UVR 
is UVA (320-400nm). Although the sun is the main source of terrestrial UVR, 
artificial sources such as welding arcs, germicidal lamps and tanning lamps all 
emit UVR. A Philips TL12 UV lamp, with an emission range of 270 – 400 nm 
and a peak of 311nm was used in this study. The same source of UVR was 
used to irradiate HaCaT cells in other similar studies (Storey et al., 2007).     
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Yoo et al (2008) used an FS20 Lamp that emits light at a continuous spectrum 
from 270 to 390 nm, with peak emission at 313 nm. UVB accounts for 65% of 
the light emitted by this lamp (Yoo et al., 2008).  
          N-3 PUFAs play an important role in the growth and development of 
human cells. Diet supplementation with EPA and DHA is known to have various 
useful effects such as prevention of cardiovascular diseases (Kris-Etherton et 
al., 2002), and reduction in blood triglycerol levels (Weber and Raederstorff, 
2000), reduction in platelet aggregation and blood pressure (Holub, 2002). 
Studies in humans have reported that n-3 PUFAs have anti-inﬂammatory 
properties and may protect UVB-exposed skin (Rhodes et al., 2003, Rhodes et 
al., 1994, Orengo et al., 1992).  
         Programmed cell death is an active process that controls cell numbers in 
several tissues and is involved in morphogenesis during embryonic 
development and throughout adult life (Thompson, 1995). Cell death can occur 
by either of two main mechanisms: apoptosis or necrosis (Raff et al., 1993, 
Schwartzman and Cidlowski, 1993, Williams, 1991). UVR can induce apoptosis 
by various pathways including DNA damage, mitochondrial damage and direct 
activation of membrane bound cell death receptors (Pustisek and Situm, 2011, 
Kulms and Schwarz, 2000).  
         Studies have shown that PUFAs can regulate cellular proliferation and 
apoptosis through different mechanisms in vitro and ex vivo (Diep et al., 2000, 
Sessler and Ntambi, 1998). These include chromatin condensation, phospha-
tidylserine externalisation, processing and activation of caspases and cleavage 
of endogenous caspase substrates (Arita et al., 2001, Finstad et al., 1994). 
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However, the mechanisms used by PUFAs to mediate apoptosis are not fully 
understood. Some of these apoptotic effects include gene expression, 
eicosanoid formation, signal transduction and lipid peroxidation (Field et al., 
2002). Lipid peroxidation has been found to be associated with increased 
oxidative stress (Avula and Fernandes, 1999), which is a significant mediator of 
apoptosis (Buttke and Sandstrom, 1994). 
           In an animal study, the apoptosis of VSMC cells (vascular smooth 
muscle cells) was increased when they were treated with DHA. Maximum effect 
(57%) was shown 24h post (40 μmol/L) DHA treatment. Stimulation of VSMCs 
with DHA (40 μmol/L) increased both caspase 3 activity and protein expression 
of active forms of caspase 3 (Diep et al., 2000). Another study using HL-60 cells 
reported that DNA fragmentation and activation of various caspases were 
increased when cells were treated with AA and EPA (60µM) and exposed to 
UVR (Arita et al., 2003).  
          The effect of n-3 PUFAs on monocytes apoptosis in a human neonatal 
model was also studied (Sweeney et al., 2007). Here, it was reported that EPA 
and DHA had dose-dependent effects on monocyte apoptosis. Moreover, AA 
increased apoptosis in monocytes cells. PUFA concentration ranged from 25 to 
100 µmol/L (Sweeney et al., 2007). 
       Therefore, before we study the protective effect on n-3 PUFA EPA and 
DHA we must study their possible toxicity and apoptotic effects. The purpose of 
this study was to evaluate this in the in vitro model system of HaCaT 
keratinocytes and 46BR.1N fibroblastic cells. The objectives were as follows: 
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A) Identify an effective UVR dose that does not reduce cell viability by more 
than 80%. 
B) Identify the range of toxic UVR doses that reduce cell viability by more than 
50%. 
C) Assess the toxicity of various doses of n-3 PUFA. 
D) Assess the toxicity of UVR and n-3 PUFA in combination. 
E) Investigate the degree of apoptosis induced by n-3 PUFA. 
4.2. Materials and Methods 
          All information relevant to the experiments reported in this study is 
presented in section 2.2. Cell culture and passaging in section 2.2.3.2 and cell 
counting in section 2.2.3.2. The effect of UVR exposure on the temperature of 
the UV box is reported in section 2.2.3.3.1 and exposure of cells to UV radiation 
in section 2.2.3.3.2. Section 2.2.3.4 describes the treatment of cells with fatty 
acids and section 2.2.3.5 shows the collection of cells and media. Fatty acid 
analysis is reported in section 2.2.4. 
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4.3. Results  
4.3.1. Effect of UV exposure on temperature at UV box  
        This experiment was performed in order to measure the temperature inside 
the UV box and ensure that it was stable and did not increase during the UV 
exposure and affect the cell viability. Pre-warmed (37°C) PBS (5ml) and a 
Thermocouple were used for this measurement. The results show that the PBS 
temperature did not increase during the UVR exposure.  This means that 
temperature inside the UV box was stable and did not change during the 
experiment. The results are shown in Table 4.1 
Table 4.1. Temperature inside the UV box before (0mJ/cm2) and during UV 
irradiation (20-200mJ/cm2) (n=2 readings of 1 experiment). 
 
4.3.2. Effect of skin epidermis layer on UVR intensity 
          The effect of placing a layer of human skin epidermis in the UV light path 
was tested using a light meter to measure the intensity (mW/cm2) of UVR.         
The results are shown in Table 4.2. The intensity of UVR was 0.33 mW/cm2 
when it was measured without anything placed above the light meter. A similar 
result was found when clean quartz glass slide was placed above the light 
meter. However, the intensity decreased to 0.13 mW/cm2 when a layer of 
human skin epidermis was placed on the quartz glass slide and both of them 
placed above the light meter. 
 
UVR (mJ/cm2) 0 20 40 60 80 100 120 140 160 180 200 
Temperature °C 37 37 37 37 36 36 35 35 34 34 34 
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Table 4.2. Effect of placing a layer of skin epidermis in the UV light path 
 
 
4.3.3. Analysis of fatty acid stock solution  
          The fatty acids were prepared as stock solutions of 50 mM in DMSO, 
aliquoted and stored at –20°C. In order to assess the purity of each stock 
solution, they were analysed by GC. Results in Figure 4.1 confirmed the identity 
of these fatty acids and they were not pure. The purity of OA was~ 96%, EPA 
95% and 91% was DHA. C16:0 and C18:0 were impurities found in stock 
solutions and not any other n-3 PUFA. 
Exposure 
Time(min) 
UVR Intensity (mW/cm2) 
(-) Quartz 
(-) Epidermis 
(+) Quartz 
(-) Epidermis 
(+) Quartz 
(+) Epidermis 
1 0.32 0.31 0.13 
2 0.31 0.30 0.13 
3 0.33 0.30 0.13 
4 0.33 0.30 0.13 
5 0.33 0.30 0.13 
6 0.33 0.30 0.13 
7 0.33 0.32 0.13 
8 0.33 0.33 0.13 
9 0.33 0.33 0.13 
10 0.33 0.33 0.13 
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Figure.4.1. GC-FID analysis of oleic acid (OA), eicosapentaenoic acid (EPA), and 
docosahexaenoic acid (DHA) stock solutions (50mM) used in this study to treat the 
cells. Results are expressed as % weight of total fatty acids of 2 capsules per fatty acid, 
each analysed in duplicate. 
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4.3.4. The effect of UVR and fatty acids treatment on HaCaT cell viability 
and apoptosis 
4.3.4.1. Determination of UVR dose  
          These experiments were performed in order to determine the dose of 
UVR that results in a) cell viability greater than 80% (effective dose) and b) cell 
viability of about 50% (toxic dose). The viability was measured using the MTT 
assay. 
4.3.4.1.1. Cell viability at 4h post UVR 
          Confluent cells were exposed to 20, 60, 90, 100, 200, 300 and 400        
mJ /cm2 and cell viability was measured at 4h post UVR. No significant changes 
occurred in cell viability between the control and groups which were exposed to 
UVR doses of 20, 60 and 90 mJ/cm2 (Figure 4.2). Here, cell viability decreased 
no more than 95%. However, significant decreases in cell viability occurred 
when cells were exposed to 100, 200 and 300 mJ /cm2: viability decreased 
significantly at the UV dose increased (Figure 4.2). A decrease in cell viability to 
80% (effective dose) was noted at 200 mJ /cm2. Cell viability was reduced to 45% 
(toxic dose) when cells were treated with 300 mJ /cm2 (Figure 4.2). 
4.3.4.1.2. Cell viability at 24h post UVR 
          When confluent HaCaT cells were exposed to 15, 30, 70, 100, 130 and 
160 mJ/cm2, the number of viable cells at 24h post UVR decreased compared 
to the non-irradiated cells (Figure 4.3). The viability of the cells decreased to 
around 80% when cells were treated with15 mJ/cm2, so this dose was selected 
for further studies. Also the toxic dose at 50 mJ/cm2 (cell viability 50%) selected 
using the dose study shown in Figure 4.3. 
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Figure 4.2. Effect of UVR dose on HaCaT keratinocyte viability, assessed 4h post UVR. 
Results are shown as mean ± SD for 3 independent experiments (each one performed 
in triplicate). ***p≤0.001, comparing data to untreated control.(0). 
 
 
 
Figure 4.3.  Effect of UVR dose on HaCaT keratinocyte viability, assessed 24h post 
UVR. Results are shown as mean ± SD for 3 independent experiments (each one 
performed in triplicate). *p≤0.05, ***p≤0.001, comparing data to untreated control. 
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4.3.4.2. The effect of fatty acid and UVR treatment on HaCaT cell viability 
         HaCaT cells were treated with OA, EPA and DHA at two doses: 10 and 50 
µM. The fatty acids were dissolved in DMSO to prepare stock solutions of 50 
mM. The fatty acid solutions were further diluted with culture media to get the 
desired final concentration. The cells that were not treated with any fatty acids 
were treated to an equal amount of DMSO during the incubation to serve as 
controls. After 72h of treatment with fatty acid in complete media, the cells were 
transferred to PBS and exposed to 15 and 50 mJ/cm2 of UVR. Free fatty acid 
complete media was added to the cells and incubated at 37°C. Cell viability was 
assessed by the MTT assay 24 h post UVR.  
4.3.4.2.1. Effect of fatty acid treatment on HaCaT cell viability  
       Figure 4.4A shows the effect of OA treatment on HaCaT cell viability. There 
was no significant decrease in cell viability when treated with 10 µM of OA. Cell 
viability did not decrease significantly when HaCaT cells were treated with 50 
µM of OA either (Figure 4.4A). 
    There was no significant decrease on cell viability when HaCaT were treated 
with 10 µM of EPA.  Cell viability did not significant decrease when HaCaT cells 
were treated with 50 µM either (Figure 4.4B). 
            Finally, when cells were treated with 50 µM DHA their viability 
decreased to 82% (p≤0.01). However, a low dose of DHA (10 µM) did not affect 
cell viability (Figure 4.4C). 
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Figure 4.4. The effect of fatty acid treatment, (A) oleic acid (OA), (B) eicosapentaenoic 
acid (EPA) and (C) docosahexaenoic acid (DHA) on HaCaT keratinocyte cell viability. 
Cells were treated with two concentrations of each fatty acid (10µM and 50 µM) for 72h. 
Cell viability was assessed as percent of untreated cells (control). Results are shown 
as mean ± SD for 3 independent experiments (each one performed in triplicate). 
**p≤0.01 comparing treatment to control.  
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4.3.4.2.2. Effect of fatty acid treatment on HaCaT cell viability at 24 h post 
15mJ/cm2 UVR 
       A decrease in cell viability (p ≤ 0.05) was observed when HaCaT cells were 
exposed to 15mJ/cm2 UVR; this fell to 85% compared to the non- irradiated 
(FA(-)/UVR(-)) controls (Figure 4.5).  
          A significant decrease in cell viability was observed when cells treated 
with 10 µM OA, were exposed to 15 mJ/cm2 (p ≤0.01). Moreover, the viability of 
HaCaT cells treated with 50 µM OA showed a further significant decrease to 83% 
when irradiated with 15 mJ/cm2 (p ≤0.01) (Figure 4.5A). 
       EPA-treated cells showed decreased cell viability after UV exposure as 
shown in Figure 4.5B. Viability of HaCaT cells treated with EPA (10 and 50µM) 
was significantly decreased to 80% (p ≤0.01) and 77% (p ≤ 0.01) respectively, 
when cells were exposed to 15 mJ/cm2 of UVR and compared to the non- 
irradiated (FA(-)/UVR(-)) control (Figure 4.5B). 
       Following exposure to 15 mJ/cm2, HaCaT cells treated with 10 µM DHA 
showed a statistically significant decreased cell viability to 80%, when 
compared with the non- irradiated (FA(-)/UVR(-)) control (p ≤0.001) (Figure 
4.5C). Further decrease in cell viability was observed when cells were treated 
with 50 µM DHA; cell viability was significantly decreased to 67% (p ≤ 0.001) 
compared to the non- irradiated (FA(-)/UVR(-)) controls. 
         Significant decreased on cell viability was observed when HaCaT cell 
treated with 50µM EPA (p ≤ 0.05) and DHA (p≤0.001) and exposed to 15mJ/cm2 
UVR compared to the irradiated cells (FA(-)/UVR(+)) controls (Figure 4.5.B,C). 
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Figure 4.5. The effect of fatty acid treatment, (A) oleic acid (OA), (B) eicosapentaenoic 
acid (EPA) and (C) docosahexaenoic acid (DHA) on HaCaT keratinocyte cells viability 
at 24 h post UVR (15 mJ/cm2). Cells were treated with two concentrations of each fatty 
acid (10µM and 50 µM) for 72h. Cell viability was assessed as percent of untreated 
cells (control). Results are shown as mean ± SD for 3 independent experiments (each 
one performed in triplicate). *p≤0.05**,∆∆p≤0.01, ***,∆∆∆p≤0.001, *=compared to non 
irradiated control (FA(-)/UVR(-)). ∆=compared to irradiated control (FA (-)/UVR(+)) 
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4.3.4.2.3. The affect of fatty acid treatment on HaCaT cell viability at 24 h 
post 50mJ/cm2 UVR 
          A significant decrease in cell viability to approximately 68% occurred 
when HaCaT cells were exposed to 50mJ/cm2 UVR (p ≤ 0.01) (Figure 4.6). 
           The viability of HaCaT cells treated with 10 and 50 µM of OA was 
reduced at 64% and 61% respectively, when irradiated with 50 mJ/cm2, (p ≤ 
0.01, p ≤ 0.01, respectively)  (Figure 4.6A). 
          The viability of HaCaT cells treated with EPA was also at the same levels 
as the UVR treated cells, 67% (10µM) and 66% (50µM). This was significantly 
reduced compared to the untreated control (p≤0.001, p≤0.001, respectively) 
(Figure 4.6B). 
         When HaCaT cells were treated with DHA and exposed to 50 mJ/cm2 
UVR, their viability was further decreased. This further decreased was 
statistically significant and reached 55% when cell treated with 10 µM (p≤0.001) 
and 46% when cell treated with 50 µM (p≤0.001) (Figure 4.6C). 
          Statistically, OA and EPA did not have any effects and there was no 
difference when compared to irradiated cell (FA(-)/UVR (+)).  Viability of HaCaT 
cells treated with DHA 50µM was significantly decreased (p≤0.05) when cells 
were exposed to 50 mJ/cm2 UVR and compared to the irradiated control (FA(-) / 
UVR (+)) (Figure 4.6.C). 
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Figure 4.6. Effect of fatty acid treatment, (A) oleic acid (OA), (B) eicosapentaenoic acid 
(EPA) and (C) docosahexaenoic acid (DHA) on HaCaT keratinocyte cells viability at 24 
h post UVR (50 mJ/cm2). Cells were treated with two concentrations of each fatty acid 
(10µM and 50 µM) for 72h. Cell viability was assessed as percent of untreated cells. 
Results are shown as mean ± SD for 3 independent experiments (each one performed 
in triplicate). *,∆p≤0.05,**p≤0.01, ***p≤0.001, *=compared to non irradiated control 
(FA(-)/UVR(-)). ∆=compared to irradiated control (FA (-)/UVR(+)). 
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4.3.4.3. The affect of fatty acid and UVR treatment on HaCaT cell apoptosis 
          The apoptosis experiments were performed in order to further explore the 
previous results that n-3 PUFA reduced viability of the HaCaT cells after 
exposure to 15 and 50 mJ/cm2 UVR.   
          In order to assess the effect of n-3 PUFA in cell apoptosis, HaCaT cells 
were treated with EPA and DHA (10 and 50 µM) and irradiated with a low and 
high dose of UVR. Apoptosis was measured using APOPercentage™ kit. 
During apoptosis, phosphatidyl serine is transferred to the outside of the cell 
membrane. The Apopercentage dye binds to phosphatidyl serine and the dye is 
taken up into the cell. The dye in the labelled cells is then released into a lysis 
solution. Measuring the concentration of dye reflects degree of cell apoptosis. 
The result was assessed as % of a positive control (H2O2). H2O2 was prepared 
to a final concentration of 10mM and cells treated for 4h (100% apoptosis) 
4.3.4.3.1. Effect of fatty acid treatment on HaCaT cell apoptosis  
         Figure 4.7A shows the effect of EPA treatment on HaCaT cell apoptosis. 
Although there was an increase in the % apoptotic cells when were treated with 
10 and 50 µM of EPA, this was not statistically significant.  
          A low dose of DHA (10 µM) showed no significant increase on cell 
apoptosis. In contrast when cells were treated with 50 µM DHA for 72 h, cell 
apoptosis was significantly increased compared to the corresponding controls 
(p≤0.01) (Figure 4.7B).  
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Figure 4.7. The effect of n-3 polyunsaturated fatty acid treatment, (A) eicosa-
pentaenoic acid (EPA) and (B) docosahexaenoic acid (DHA) on HaCaT keratinocyte 
cells apoptosis. Cells were treated with two concentrations of eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA) (10µM and 50 µM) for 72h. Cell apoptosis was 
assessed as percent of H2O2 (10mM) treated cells (positive control). Results are shown 
as mean ± SD of 3 independent experiments (each one performed in triplicate). 
**P≤0.01 compared treatment to control.  
* 
 
10 
20 
30 
40 
50 
60 
A
p
o
p
to
s
is
  
a
s
 %
 H
2
O
2
 c
o
n
tr
o
l 
EPA            control                         10µM                          50µM 
 
 
10 
20 
30 
40 
50 
60 
70 
80 
A
p
o
p
to
s
is
 a
s
 %
 H
2
O
2
 c
o
n
tr
o
l 
DHA           control                       10µM                          50µM 
 
** 
B 
 
A 
 
118 
 
4.3.4.3.2. Effect of fatty acid treatment on HaCaT cell apoptosis at 24 h 
post 15mJ/cm2 UVR 
         An increase in cell apoptosis was observed when the cells were exposed 
to 15mJ/cm2 UVR, but this did not reach statistical significance (Figure 4.8) 
          Figure 4.8A shows that a significant increase in cell apoptosis was 
observed when cells treated with 10 µM EPA and then exposed to 15 mJ/cm2  
(p ≤ 0.05). Moreover, the apoptosis of HaCaT cells treated with 50 µM EPA 
appeared to be further increased when irradiated with 15 mJ/cm2, in 
comparison to the non-irradiated corresponding control (p ≤ 0.05) (Figure 4.8A)    
      The same effect was observed in DHA-treated cells. There was a significant 
increase on cell apoptosis following exposure to 15mJ/cm2 UVR and after was 
treated with 10 µM of DHA (p ≤0.05) or 50 µM of DHA (p ≤ 0.001) (Figure 4.8B).  
        In order to see if PUFA have an addition effects on cell apoptosis after 
UVR, treated and irradiated cell were compared to irradiated cell (FA(-)/UVR 
(+)). Results in Figure 4.8 shown that low dose (10µm) of EPA and DHA have 
no significantly effect on cell apoptosis when compared to irradiated cells. 
HaCaT cell apoptosis was only significantly different when cells treated with 
50µM EPA (p≤0.01) and DHA (p≤0.001) were exposed to 15mJ/cm2 UVR 
comparing to the irradiated corresponding control (FA(-) / UVR (+)).  
4.3.4.3.3. Effect of fatty acid treatment on HaCaT cell apoptosis at 24 h 
post 50 mJ/cm2 UVR 
          There was no significant increase of cell apoptosis when un-treated 
HaCaT cells were exposed to 50mJ/cm2 UVR (Figure 4.9).The results shown in 
Figure 4.9A suggest that cell apoptosis was significantly increased (p ≤ 0.05) 
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when cells were treated with 10 µM EPA were expose to 50 mJ/cm2. A further 
increase in HaCaT cell apoptosis was observed when cells treated with 50 µM 
EPA were exposed to 50 mJ/cm2     (p ≤ 0.001) (Figure 4.9A).  
          HaCaT cell apoptosis increased when cells treated with DHA were 
exposed to 50mJ/cm2 UVR. Specifically, apoptosis significantly increased to 64% 
(p ≤ 0.01) when the cells were treated with 10 µM of DHA, and this was even 
higher when cells were treated with 50µM DHA (95%) (p ≤ 0.001) (Figure 4.9B).  
          A significant increase on HaCaT cell apoptosis was observed when cells 
were treated with EPA 50µM (p ≤ 0.05), and DHA (p ≤ 0.01) and exposed to 50 
mJ/cm2 UVR were compared to the irradiated controls (FA (-)/UVR (+)) 
Overall the apoptosis experiments showed that: 
a) UVR increased cell apoptosis but this was not statistically significant. 
b) EPA and DHA treatment increased apoptosis in the HaCaT cells and a 
further statistically significant increase was observed when the treated cells 
were exposed to 15 or 50 mJ/cm2. Furthermore, the apoptosis appeared to be 
fatty acid dose dependent. 
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Figure 4.8. The effect of n-3 polyunsaturated fatty acid treatment, (A)eicosapentaenoic 
acid (EPA) and (B) docosahexaenoic acid (DHA) on HaCaT keratinocyte cells 
apoptosis at 24 h post UVR (15 mJ/cm2). Cells were treated with two concentrations of 
each fatty acid (10µM and 50 µM) for 72h. Cell apoptosis was assessed as percent of 
H2O2 (10mM) treated cells (positive control). Results are shown as mean ± SD of 3 
independent experiments (each one performed in triplicate). *p≤0.05, ∆∆p≤0.01, 
***,∆∆∆p≤0.001, *= comparing to non irradiated control (FA(-)/UVR(-)). ∆=comparing to 
irradiated control (FA (-)/UVR(+)).  
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Figure 4.9. The effect of n-3 polyunsaturated fatty acid treatment, (A) eicosa-
pentaenoic acid (EPA) and (B) docosahexaenoic acid (DHA) on HaCaT keratinocyte 
cells apoptosis at 24 h post UVR (50 mJ/cm2). Cells were treated with two 
concentrations of each fatty acid (10µM and 50 µM) for 72h. Cell apoptosis was 
assessed as percent of H2O2 (10mM) treated cells (positive control). Results are shown 
as mean ± SD of 3 independent experiments (each one performed in triplicate). 
*,∆p≤0.05, ***,∆∆∆p≤0.001, *= compared to non irradiated control (FA(-)/UVR(-)). 
∆=compared to irradiated control (FA (-)/UVR(+)).  
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4.3.4.4. Effect of skin epidermis layer on HaCaT ell viability 
          In ordered to observe the effect of the epidermal skin layer in protecting 
cells from UV radiation, HaCaT cells were cultured in two 24 well culture plates.    
3 wells for each plate were covered with epidermis and other 3 were not. The 
plates were placed under UV lamp and exposed for 5 and 10 min. During 
irradiation the cells were covered with PBS. The HaCaT cells viability was 
tested directly after UV exposed by MTT assay. 
        There was a 80% decrease in cell viability when the cells were not covered 
with the epidermis compared to non irradiated control (Figure 4.10). However, 
when the cells were covered with the epidermal layer, cell viability was only 
decreased to approximately 20% of the non irradiated control (Figure 4.10). 
 
 
Figure 4.10. HaCaT keratinocyte cell viability with and without the epidermal layer 
placed directly the UVR. Each condition was performed in triplicate wells. The cell 
viability was assessed by MTT assay.  Results shown as mean of 3 readings, n=1 
experiment.  
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4.3.5. The effect of fatty acid and UVR treatment on 46 BR.1N cell viability 
and apoptosis 
4.3.5.1. Determination of UVR dose  
          These experiments were performed in order to determine the dose of UV 
that results in a) cell viability greater than 80% (effective dose) and b) cell 
viability of about 50% (toxic dose). The viability was measured using the MTT 
assay. 
4.3.5.1.1. Cell viability at 4h post UVR 
          Confluent cells were exposed to 15, 50 and 100 mJ /cm2. Cell viability 
measured at 4h post UVR was not statistically different between the control 
(untreated cells) and cells treated with 15 and 50 mJ/cm2 (Figure 4.11). Cell 
viability decreased from 100% for the control group to approximately 82% when 
cells were exposed to 100 mJ /cm2. This decrease was statistically significant 
(p≤ 0.001) (Figure 4.11). 
4.3.5.1.2. Cell viability at 24h post UVR 
          In order to assess the effect of UVR on 46BR.1N on cell viability, cells 
were exposed to different UVR doses: 0, 15, 30, 50, 70,100,130 and 160 
mJ/cm2. The results shown that the effect of UVR in cell viability was dose-
dependent. The viability was decreased following increased UVR. Cell viability 
was significantly decreased to 85% (p ≤ 0.01) at 15mJ/cm2 compared to un-
irradiated control (Figure 4.12). 
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Figure 4.11 Effect of UVR dose on 46BR.1N fibroblast cell viability, assessed 4h post 
UVR. Results are shown as mean ± SD for 3 independent experiments (each one 
performed in triplicate). ***p≤0.001, comparing data to untreated control. 
 
 
Figure 4.12.  Effect of UVR dose on 46BR.1N fibroblast cell viability, assessed 24h 
post UVR. Results are shown as mean ± SD for 3 independent experiments (each one 
performed in triplicate). **p≤0.01, ***p≤0.001 comparing data to untreated control. 
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4.3.5.2. The effect of fatty acid and UVR treatment on 46BR.1N cell viability 
          Stock solutions of 50 mM of OA, EPA and DHA were prepared in DMSO. 
The fatty acid solutions were further diluted with culture media to get the desired 
final concentration (10 and 50 µM). 46BR.1N cells were incubated 72h with 
different fatty acid treatments in complete media. The cells that were not treated 
with any fatty acids were treated to an equal amount of DMSO during the 
incubation to serve as vehicle controls. Cell viability was assessed by the MTT 
assay 24 h post 15 and 50 mJ/cm2 UVR.  
4.3.4.4.1. Effect of fatty acid treatment on 46BR.1N cell viability 
           The results in Figure 4.13A show that 46BR.1N viability decreased to 93% 
and 89% when OA treatment was increased from 10 µM to 50µM respectively. 
However this was not statistically significant.       
         Also there was no significant decrease in cell viability when 46BR.1N cells 
were treated with EPA 10 and 50 µM. Results are shown in Figure 4.13B.  
          Cell viability did not reach statistical difference when cells were treated 
with 10 µM DHA. In contrast, a decrease in 46BR.1N cell viability to 73% was 
observed when the cells were treated with 50 µM DHA; this was statistically 
significant compared to untreated cells (p ≤ 0.01). Results shown in Figure 
4.13C. 
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Figure 4.13. The effect of fatty acid treatment, (A) oleic acid (OA), (B) eicosa-
pentaenoic acid (EPA) and (C) docosahexaenoic acid (DHA) on 46BR.1N fibroblast 
cells viability. Cells were treated with two concentrations of each fatty acid (10µM and 
50 µM) for 72h. Cell viability was assessed as percent of untreated cells (control). 
Results are shown as mean ± SD for 3 independent experiments (each one performed 
in triplicate). *p≤0.05 comparing treatment to control.  
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4.3.5.3. The effect of fatty acid treatment on 46BR.1N cell viability at 24 h 
post 15mJ/cm2 UVR 
          Exposure of untreated 46BR.1N cells to 15mJ/cm2 showed significant 
decrease in cell viability (86%, p ≤ 0.05) when compared to the corresponding 
controls. The dose 15mJ/cm2 was considered as the active dose and was used 
in this study (Figure 4.14).   
          When OA treated cells (10 and 50µM) were exposed to 15mJ/cm2, Cell 
viability significant decreased to 82% (p≤0.01) and 77% (p≤0.01), respectively. 
The results are shown in Figure 4.14A. 
          The same result was observed when cells were treated with EPA; the 
viability decreased to 83% (p≤0.05) and 79% (p≤0.01) when the EPA dose 
increased from 10 to 50 µM, Figure 4.14B. 
          As shown in Figure 4.14C, DHA induced a dose-dependent reduction in 
46BR.1N cell viability. DHA (10 µM) significantly reduced the viability to 76% 
(p≤ 0.01) compared to control cells. The 50 µM of DHA treatment reduced cell 
viability even more and this was significantly decreased to 58% (p≤0.001) 
compared to control cells. 
          There was no statistical difference in cell viability between 46BR.1N cells 
treated with OA and EPA 10 or 50µM, and 10 µM DHA when exposed to 
15mJ/cm2 and compared to the corresponding irradiated controls (FA(-
)/UVR(+)). In contrast, when cells were treated with DHA 50µM, DHA showed 
an additive effect and the cell viability was significantly decreased (P≤ 0.001) 
compared to corresponding irradiated controls (FA (-)/UVR(+)) (Figure 4.14C). 
 
128 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14. Effect of fatty acid treatment, (A) oleic acid (OA), (B) eicosapentaenoic 
acid (EPA) and (C) docosahexaenoic acid (DHA) on 46BR.1N fibroblast cells viability at 
24 h post UVR (15 mJ/cm2). Cells were treated with two concentrations of each fatty 
acid (10µM and 50 µM) for 72h. Cell viability was assessed as percent of untreated 
cells. Results are shown as mean ± SD for 3 independent experiments (each one 
performed in triplicate). *p≤0.05,**=p≤0.01, ***,∆∆∆p≤0.001, *=comparing to non 
irradiated control (FA(-)/UVR(-)). ∆=comparing to irradiated control (FA (-)/UVR(+)). 
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4.3.5.4. The effect of fatty acid treatment on 46BR.1N cell viability at 24 h 
post 50mJ/cm2 UVR 
          In order to assess the effect of UVR in 46BR.1N cell viability, the cells 
were exposed to 50mJ/cm2 UVR. This was considered to be a toxic dose. The 
results shown in Figure 4.15 suggest that the viability of 46BR.1N cells was 
significantly decreased to 65% (p≤0.01) compare to the corresponding 
untreated controls. 
          The effect of OA on 46BR.1N cell viability is shown in Figure 4.15A. It is 
clear that post 50mJ/cm2 UVR treatment, cell viability significantly decreased 
when the dose of fatty acid increased.  Cell viability in cells treated with OA (10 
and 50µM) was significantly decreased to 61% and 58%, respectively (p≤ 
0.001and p≤0.001, respectively), when compared to non treated cells.  
          The viability of 46BR.1N which were treated with EPA (10 and 50µM) and 
exposed to 50mJ/cm2, was significantly decreased to 64% and 60%, 
respectively (p≤ 0.001and p≤0.001, respectively), when compared to non 
treated cells as shown in Figure 4.15B. 
           Cell viability was even lower when cells that were treated with DHA were 
exposed to 50mJ/cm2 UVR. Viability was significantly decreased to 64% 
(P≤0.001), following 10 µM DHA and 47% (P≤0.001) following treatment with 50 
µM DHA (Figure 4.15C).  
         OA and EPA did not have any additive effect and when compared to 
irradiated cells there was no statistically difference. However, 50 µM DHA 
showed an additive effect to UVR and was significantly different (P≤0.001) 
compared to corresponding controls (Control:-/+ fatty acid/UVR) (Figure 4.15C). 
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Figure 4.15. Effect of fatty acid treatment, (A) oleic acid (OA), (B) eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA) on 46BR.1N fibroblast cells viability at 24 
h post UVR (50 mJ/cm2). Cells were treated with two concentrations of each fatty acid 
(10µM and 50 µM) for 72h. Cell viability was assessed as percent of untreated cells. 
Results are shown as mean ± SD for 3 independent experiments (each one performed 
in triplicate). *p≤0.05,**p≤0.01, ***,∆∆∆p≤0.001, *=comparing to non irradiated control 
(FA(-)/UVR(-)). ∆=comparing to irradiated control (FA (-)/UVR(+)). 
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4.3.5.5. The effect of fatty acid and UVR treatment on 46BR.1N cell 
apoptosis. 
          In order to assess the effect of n-3 PUFA and UVR in 46BR.1N apoptosis, 
the cells were treated for 72h with and without EPA and DHA 10 and 50µM. 
After that, cells were exposed to 15 or 50mJ/cm2 UVR, and cells apoptosis was 
measured at 24h post UVR by using the APOPercentage kit. 
4.3.5.5.1. Effect of fatty acid treatment on HaCaT cell apoptosis  
          Cell apoptosis increased but was not statistically significant when cells 
were treated with 10 µM EPA. However, a statistically significant increased was 
observed when the cells were treated with 50 µM EPA (p≤0.01) compared to 
untreated cells (FA(-)/UVR(-)) (Figure 4.16A). 
           Result in figure 4.16B shown that DHA treatment induced apoptosis at 
10 µM (p ≤ 0.05) and 50 µM (p≤0.001) compared to untreated cells (FA (-
)/UVR(-)). 
4.3.5.5.2. The affect of fatty acid treatment on 46BR.1N cell apoptosis at 24 
h post 15mJ/cm2 UVR 
          An increase in cell apoptosis was observed when untreated cells were 
exposed to 15mJ/cm2 UVR, but this increase was not statistically significant 
when compared to non-irradiated group (Figure 4.17).  
          The apoptosis of 46BR.1N cells treated with 10 and 50µM EPA was 
significant increase after 15mJ/cm2 UVR (p≤0.01 and p≤0.01) compared to the 
corresponding non-irradiated controls (Figure 4.17A). 
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Figure 4.16. The effect of n-3 polyunsaturated fatty acid treatment, (A) eicosa-
pentaenoic acid (EPA) and (B) docosahexaenoic acid (DHA) on 46BR.1N fibroblast 
cells apoptosis. Cells were treated with two concentrations of EPA and DHA (10µM and 
50 µM) for 72h. Cell apoptosis was assessed as percent of H2O2 treated cells (positive 
control) Results are shown as mean ± SD of 3 independent experiments (each one 
performed in triplicate). *p≤0.05, ***p≤0.001compared treatment to control. 
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          Following exposure to 15 mJ/cm2, 46BR.1N cells treated with 10 µM DHA 
showed increase in cell apoptosis, this was statistical significant when 
compared with the corresponding non-irradiated controls (p ≤ 0.01) (Figure 
4.14.B). Further increase in cell apoptosis was observed when cells were 
treated with 50 µM DHA. This increase was significant compared to the non-
irradiated (FA(-)/UVR(-)) corresponding controls (p ≤ 0.001) (Figure 4.16B).                
Also, 50 µM DHA showed an additive effect (p ≤ 0.001) compared to the 
irradiated corresponding controls (Figure 4.17B) 
4.3.5.5.3. The effect of fatty acid treatment on 46BR.1N cell apoptosis at 24 
h post 50 mJ/cm2 UVR 
          The apoptosis of 46BR.1N cells was significantly increased (50%) when 
cells exposed to 50mJ/cm2 UVR compared to the corresponding non-irradiated 
controls (p≤0.05) (Figure 4.18). EPA-treated cells showed an increase on cell 
apoptosis after UV exposure as shown in Figure 4.18A. Apoptosis of 46BR.1N 
cells treated with 10 and 50µM EPA was significantly increased to 62% 
(p≤0.001) and 72% (p≤0.001), respectively, when cells were exposed to 50 
mJ/cm2 of UVR and compared to the corresponding non-irradiated control 
          The results shown in figure 4.18B suggest that, cell apoptosis was 
significantly increase to 63% when cells were treated with 10 µM DHA and 
exposed to 50 mJ/cm2 (p≤0.001). The apoptosis of 46BR.1N treated with 50 µM 
DHA and exposed to 50 mJ/cm2 was further increased to 113% compared to the 
non-irradiated control (FA(-)/UVR(+) (p ≤ 0.001) (Figure 4.17.B). Also, 50 µM 
DHA showed additive effect (p≤0.001) compared to the irradiated corresponding 
controls (Figure 4.18B) 
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Figure 4.17. Effect of n-3 polyunsaturated fatty acid treatment, (A) eicosapentaenoic 
acid (EPA) and (B) docosahexaenoic acid (DHA) on 46BR.1N fibroblast cells apoptosis 
at 24 h post UVR (15 mJ/cm2). Cells were treated with two concentrations of each fatty 
acid (10µM and 50 µM) for 72h. Cell apoptosis was assessed as percent of H2O2 
(10mM) treated cells (positive control). Results are shown as mean ± SD for 3 
independent experiments (each one performed in triplicate). **p≤0.01, ***,∆∆∆p≤0.001, 
*=comparing to non irradiated control (FA(-)/UVR(-)). ∆=compared to irradiated control 
(FA (-)/UVR(+)). 
 
 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
A
p
o
p
to
s
is
 a
s
 %
 H
2
O
2
 c
o
n
tr
o
l 
EPA                 -                        -                    10µM                50µM 
UVR                 -                       +                        +                     + 
 
** 
** 
 
20 
40 
60 
80 
100 
120 
A
p
o
p
to
s
is
 a
s
 %
 H
2
O
2
  
c
o
n
tr
o
l 
∆∆∆ 
DHA                 -                        -                    10µM                50µM 
UVR                 -                       +                        +                     + 
 
** 
*** 
A 
B 
135 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18. Effect of n-3 polyunsaturated fatty acid treatment, (A) eicosapentaenoic 
acid (EPA) and (B) docosahexaenoic acid (DHA) on 46BR.1N fibroblast cells apoptosis 
at 24 h post UVR (50 mJ/cm2). Cells were treated with two concentrations of each fatty 
acid (10µM and 50 µM) for 72h. Cell apoptosis was assessed as percent of H2O2 
(10mM) treated cells (positive control). Results are shown as mean ± SD of 3 
independent experiments (each one performed in triplicate). *=p≤0.05, ***,∆∆∆p≤0.001, 
*=compared to non irradiated control (FA(-)/UVR(-)). ∆=compared to irradiated control 
(FA (-)/UVR(+)). 
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4.4. Discussion  
          Ultraviolet radiation is an important pathogenic component of solar light. It 
is one of the most important acute and chronic skin stressors, and has been 
implicated in inflammation, skin aging and cancer. However, it also has 
beneficial health effects such as vitamin D3 synthesis. 
          To assess the effect of UVR on human skin cells, two cell lines one as 
epidermal keratinocytes (HaCaT) and one as dermal fibroblasts (46BR.1N) 
were used as models. First, the temperature inside the UV box was measured, 
because any increase could impact on cell viability. The temperature inside the 
UV box was measured for a period of time corresponding to exposure of 0 to 
200 mJ/cm2. The temperature was stable during the exposure time (Table 4.1), 
suggesting that the experiments were not affected by temperature-related 
factors. The cytotoxic effect of temperature has been  investigated with various 
cutaneous cell lines, such as the human melanoma cell line A375, HaCaT 
keratinocytes, the epidermoid carcinoma A431, the primary human melanoma 
cell line WM35, and a metastatic melanoma cell line, HS294T (Shellman et al., 
2008). It has been found that various cytotoxic effects appear above 37°C. In 
another study it was reported that four human cell lines, the human colon 
carcinoma cell line WiDr, human glioblastoma-astrocytoma U-87MG, human 
lung carcinoma A-549, and normal human lung fibroblasts CCD-lSLu were 
relatively resistant to temperatures up to 43°C or 45°C (Armour et al., 1993). 
Temperatures of more than 43°C were beneficial in patients with superficial 
tumours receiving radiation therapy (Jones et al., 2005). Human WiDr cells 
treated with 5-aminolevulinic acid (0.5 mM) and exposed to different 
temperatures before or after light exposure were found to have decreased 
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survival chances when exposed to 41 °C for 1 h before light exposure 
(Juzeniene et al., 2006). 
          To find a UVR dose that keeps the cell viability greater than 80%, the 
effect of various doses of UVR were investigated on HaCaT and 46BR.1N cell 
viability, at 4h and 24h after exposure. After 4h of irradiation HaCaT cells 
showed a decrease in viability when exposed to doses of 100 mJ/cm2 and 
above compared to the non-irradiated cells. However, different results were 
found when cell viability was measured at 24 h after exposure. Cell viability 
decreased in HaCaT and 46BR.1N cells exposed to 15, 30, 70, 100, 130 and 
160 mJ/cm2 compared to the non-irradiated cells and at 24 h after exposure. 
The UVB doses used in our study were 15 and 50 mJ/cm2. 24h post UVR was 
chosen as a period after exposure to UVR, as covered all phases of the cell 
cycle. Relevant to that, one MED is the level of UVR that causes skin erythema 
(sunburn) which appears as reddening on the skin after 24h. However, in 
human skin the epidermal layer reduced the level of irradiation reaching the 
epidermis as shown by our data and reported in the literature (Table 4.2).  
         In the resent study, the data clearly showed that HaCaT cell viability 
decreased with increased UV radiation (Figure 4.3). This result was consistent 
with evidence from the literature. It has been reported that there was no 
significant decrease in the viability of normal human keratinocytes following UV 
doses ranging from 4.5 to 36 mJ/cm2 and at 1h after exposure, but there was a 
significant decrease at 24h  after exposure to 9 mJ/cm2 (Wong et al., 2000). A 
decrease in the proliferation of HaCaT cells by 50% was reported following UV 
exposure to 200 mJ/cm2 (Park and Lee, 2008). Another study using HaCaT 
cells reported that there was no effect on cell viability at 48h post UVB doses of 
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25, 50 or 75 mJ/cm2, but there was a significant decrease to 86.7% after an 
exposure to 100 mJ/cm2  (Storey et al., 2007). HaCaT cell viability was also 
found to have decreased from  80% to 60% when UVB irradiation increased 
from 30 to 60mJ/cm2, respectively; whilst viability was less than 30% when the 
UVB was 120mJ/cm2 (Lee et al., 2003).  
          The effect of UVB on primary human keratinocytes was examined in 
another study where cell viability measured at 24 h post 5, 10 and 25mJ/cm2 
broadband UVB (BBUVB) significantly decreased (Cho et al., 2008). Lawley et 
al. (2000) reported that the viability of primary human keratinocytes exposed to 
40 and 80mJ/cm2 UVB was slightly decreased after 3h of UV treatment. A 
significant decrease in viability was observed at 20h post UV treatment (Lawley 
et al., 2000). Finally, the viability of a cell line of normal human epidermal 
keratinocytes was decreased to 95%, 83% and 77% when the cells were 
exposed to 10, 30 and 60 mJ/cm2, respectively. Viability was assessed 24h post 
UVR (Izykowska et al., 2009). 
          A similar effect was found with fibroblasts 46BR.1N. The cell viability was 
decreased to less than 80% when cells were exposed to more than 15mJ/cm2 
(Figure 4.11). This was consistent with reports showing that viability of cultured 
dermal fibroblasts was decreased to 91%, 81%and 56% when exposed to 35, 
70, and 140 mJ/cm2 at 24h post UVR respectively (Ryoo et al., 2001). 
100mJ/cm2 was found to be a toxic dose for cultured normal human dermal 
fibroblasts extracted from breast skin (Yan et al., 2010). Meanwhil, Storey et al. 
reported that the viability of dermal fibroblast cells CCD922SK was unchanged 
after 25 mJ/cm2 but was reduced to 50% or less when exposed to 50mJ/cm2 
UVB or more (Storey et al., 2007). Viability of normal human dermal cells was 
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also found to be reduced after exposure to different UVR doses (Xu et al., 2010). 
D'Errico (2005) reported that viability of both primary fibroblasts and 
keratinocytes was decreased post 500 and 1000mJ/cm2.  The viability of normal 
human dermal fibroblasts was significantly decreased to 95%, 83% and 77% 
when cells were exposed to 10, 30 and 60 mJ/cm2, respectively; viability was 
assessed 24h post UVR (Izykowska et al., 2009). Finally, human primary 
fibroblast viability was decreased to 80% after 30min of UVR and 30% after 
60min of UVR (Silvana Gaiba et al., 2012). 
          Epidermal and dermal cells are target to UVA. Depending on their 
location in the body, function and metabolic characteristics keratinocytes and 
fibroblast may respond differently to UVR (Tyrrell and Keyse, 1990). Our results 
clearly show that viability of both HaCaT and 46BR.1N cells were decreased by 
increased UVR. A comparison was made between HaCaT and 46BR.1N cells 
and revealed that there was no difference when cells were exposed to low 
doses, e.g.15 and 30mJ/cm2. However, 46BR.1N were more resistant to UVR 
when exposed to doses greater than 70mJ/cm2. HaCaT cells were less 
resistant and their viability was reduced to a greater extent at high UVR doses. 
The differential sensitivity to UVB of keratinocytes and fibroblasts may be a 
result of differences in the level or repair of DNA damage in the two cell types 
(D'Errico et al., 2003). 
               In order to investigate the effect of EPA, DHA and OA on the viability 
of HaCaT and 46BR.1N cells, cells were treated with 10 and 50 μM of each fatty 
acid and viability was assessed by MTT. OA was chosen as a control fatty acid 
in this study because it is not an essential monounsaturated FA abundant in cell 
membranes (Grammatikos et al., 1994). It does not metabolise to n-3 or n-6 
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PUFA, EPA and DHA. .The data in this study showed that cell viability was not 
significantly decreased when cells were treated with OA and EPA. However, a 
significant decrease in cell viability was observed with an increased DHA dose. 
Many studies have examined the effect of fatty acids on cell viability. A 
decrease in the viability of pro-monocytic U937 cells treated with DHA for 24h 
was found to be dose-dependent (5-20 μmol/L), as reported by Yano et al. 
(2000). Ramos cell (Human Burkitt's lymphoma cell line) viability was decreased 
when it was treated with EPA (Finstad et al., 2000). The effect of AA, EPA, DHA, 
OA and stearic acid (SA) on viability of 14 different leukaemia cell lines was 
studied by Finstad et al. (1998) and they found that cell viability decreased in 10 
of these cell lines when treated with AA, EPA and DHA at 30, 60 and/or 120 µM 
and for 3 days. However, there was no effect when the cells were treated with 
OA and SA. A variation in the toxic effect of fatty acids on murine and human 
melanoma cell viability, when treated with AA, LA, palmitic, and palmitoleic 
acids (Andrade et al., 2005) was also observed. Several studies on fatty acids 
have reported that µM of n-3PUFA concentrations are toxic to cancer cells both 
in vitro and in vivo. EPA at 40µM was cytotoxic to the human leukemic cells K-
562 and HL-60 (Chiu and Wan, 1999). 
         However, other studies have claimed that EPA and DHA do not affect cell 
viability. DHA was not toxic to the human melanoma cell line SK-Mel 23 
(Andrade et al., 2005).There was no significant effect on keratinocyte and 
fibroblast viability when treated with EPA and DHA 50µM for 4.5 days (Storey et 
al., 2005). Moreover, no signiﬁcant difference in HaCaT cell viability was 
observed after supplementation of CLA, CLA isomers and OA (50 µM) for 4 or 5 
days (Storey et al., 2007).  
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         To assess the potential protective role of n-3 PUFA on skin cell against 
UVR, HaCaT and 46BR.1N were treated with OA, EPA and DHA at 10 and 
50µM and viability was measured with and without 15 and 50 mJ/cm2 24h post 
UVR. The results show that viability of both cell types was significantly 
decreased when they were treated with the fatty acid. Moreover, 50 µM of EPA 
and DHA produced a significant decrease in HaCaT viability following exposure 
to 15 and 50mJ/cm2 UVR. Only a high concentration of DHA (50µM) produced a 
significant decrease in 46BR.1N viability following exposure to15 and 50mJ/cm2 
compared to the irradiated control cells (FA(-)/UVR(+)) 
        Apoptosis is one of the pathways of cell death (Kerr et al., 1972).  
Henseleit et al (1996) reported that UVB can change the morphology of DNA 
fragmentation. APOPercentage™ kit was used to assess the DNA damage. The 
results in the current study show that, UVR, EPA and DHA were able to induce 
apoptosis in HaCaT and 46BR.1N cells. Apoptosis was significantly increased 
when higher doses of UVR or concentrations of PUFA were used. Takasawa et 
al (2005) reported that 80% of HaCaT cells underwent apoptosis post 500J/m2 
UVB or 100UVA J/m2 at 24h (Takasawa et al., 2005). Reagan-Shaw reported 
that HaCaT viability was significantly decreased by UVB and apoptosis was 
significantly increased to 50% of un-treated cells at 24h after being treated with 
15mJ/cm2 and 50 mJ/cm2 increased apoptosis to 66% (Reagan-Shaw et al., 
2006). This was also confirmed in other studies including a time dependent 
experiment where apoptosis increased from 50.5% at 2h to 70% at 4h and 93% 
at 8h post 50mJ/cm2 UVR (Fischer et al., 2006). Furthermore, a dose study 
showed an increase from 0.21% to 71.18% at 0mJ/cm2 and 90mJ/cm2 UVB, 
respectively (Reagan-Shaw et al., 2006). The apoptotic level was not significant 
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in primary human keratinocytes when exposed to physiological doses of UVB 
between 10 and 40mJ/cm2 (Sesto et al., 2002). Serini et al (2011) reported that 
HaCaT apoptosis increased 3.8 fold post 60mJ/cm2 compared to the untreated 
control, while, nr-HaCaT treated with DHA 30 and 50µM for 24h showed 
increased cell apoptosis. A further increase was observed when nr-HaCaT cells 
treated with DHA (50µM) were exposed to 60mJ/cm2 UVR. EPA reduced the nr-
HaCaT apoptosis in a dose-dependent manner and it did not change after 
exposure to UVR. A similar effect was observed with OA and LA (Serini et al., 
2011). The number of human primary fibroblasts apoptosis cells was 
significantly increased to 21% post 30min and to 50% post 60min following 
exposure to UVR (Silvana Gaiba et al., 2012). 
          The results suggest that both UVR and the n-3 PUFA EPA and DHA 
decrease cell viability and increase apoptosis in a dose-dependent manner in 
HaCaT and 46BR.1N cells. Moreover, further decreases in viability and 
increased apoptosis were observed when cells were treated with n-3 PUFA and 
exposed to UVR. 
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Chapter 5. Effect of n-3 PUFA on the fatty acid 
composition of HaCaT keratinocytes and 46BR.1N 
fibroblasts 
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5.1. Introduction 
          The skin is an organ that plays important roles in protection, biosynthesis, 
storage, excretion, absorption and heat regulation of the body (Madison, 2003). 
The skin is composed of many layers and has several types of cells. 
Understanding how these cells are acting and regulate signalling pathways has 
great potential for the treatment of skin disorders such as inflammation, skin 
cancer and genetic abnormalities (Deyrieux and Wilson, 2007). In vitro models 
are needed to study this. These models should mimic the real physiological 
pathways in the skin. HaCaT keratinocytes and 64BR.1N fibroblasts were used 
in this project in order to study the response of skin cells under UVR and fatty 
acid treatments. 
          Primary keratinocytes can be used as an in vitro model; unfortunately, 
they provide only a short time in which to investigate and they rapidly die. 
Moreover, these cells require specific supplementation with growth factors in 
order to survive. In contrast, the immortalised human HaCaT keratinocytes can 
grow in normal cell culture media without any specific supplementation. HaCaT 
can survive in cultures for a long time and are considered immortal cells (more 
than 140 passages) (Boukamp et al., 1988). After multiple passages HaCaT 
cells are still able to retain their capacity for differentiation similar to normal 
keratinocytes (Boukamp et al., 1988). This offers a stable model for the study of 
keratinocytes (Boukamp et al., 1988). HaCaT cells have been used to study the 
differentiation of keratinocytes (Deyrieux and Wilson, 2007). HaCaT has also 
been used as a model to study the effect of UVR and assess the protective 
effect of inositol hexaphosphate (IP6) (Williams et al., 2011) , silibinin 
(Dhanalakshmi et al., 2004) and ketoprofen (Liu et al., 2007) on skin epidermal 
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cells against UVB and skin cancer. The composition and synthesis of lipids in 
normal human adult keratinocytes and HaCaT cells were studied, and the 
results suggest that, there was no difference between the cells in the total lipid 
content and distribution of major lipid classes (Schurer et al., 1993). No 
significant differences were observed between the lipid profile of normal 
keratinocytes grown in normal or low Ca2+ concentration in a submerged culture 
(Ponec et al., 1988).  
          The human fibroblastic cell line 46BR.1N was derived from 46BR. The 
parent cell line was derived from a young female with immunodeficiency 
(hypogammaglobulinaemia) (Teo et al., 1983).  The cells were transformed with 
the plasmid pSV3neo expressing SV40 T-antigen and is now immortal. They are 
hypersensitive to DNA-damaging agents (Somia et al., 1993). 46BR.1N has been 
used to represent human dermal fibroblasts. 46BR.1N was used to study the 
effects of enoxaparin and onion extract on cytokine production in skin 
fibroblasts (Michał Pikuła et al., 2009). Both cells, HaCaT keratinocyte and 
46BR.1N, are used in this study because they are human skin cells, immortal as 
opposed to normal cells, and they are not cancer cells. 
          Skin epidermis is an active site of lipid synthesis. The intercellular lipids of 
human stratum corneum are unique in composition and quite different from the 
lipids found in most biological membranes (Lampe et al., 1983). The three major 
lipids in the human stratum corneum are free fatty acids, cholesterol and 
ceramides (Grubauer et al., 1987). Fatty acids can be synthesised by 
keratinocytes de novo; in addition, they need to be taken up from circulation. It 
has been reported that an increase in fatty acid synthesis on the epidermal 
layer was marked during the disruption of the permeability barrier (Ottey et al., 
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1995). Moreover, barrier disruption increases the activity and mRNA levels of 
both acetyl CoA carboxylase and fatty acid synthase, which are  the key 
enzymes required for de novo fatty acid synthesis (Harris et al., 1997). 
          In this study, HaCaT and 46BR.1N cell lines were used to represent the 
epidermis and dermis layers, respectively. They were cultured and treated with 
n-3 PUFA to achieve and answering the following:- 
1- Is there any difference between HaCaT and 46BR.1N with regard to their 
fatty acid composition? 
2- Do both HaCaT and 46BR.1N up take the n-3 PUFA treatment? 
3-  How does the n-3 PUFA treatment affect the fatty acid profile of both cell 
lines? 
5.2. Materials and methods  
            All information relevant to the experiments reported in this study is 
presented in section 2.2. Cell culture and passaging in section 2.2.3.2 and cell 
counting in section 2.2.3.2. Section 2.2.3.4 describes the treatment of cells with 
fatty acids and section 2.2.3.5 shows the collection of cells and media. Fatty 
acid analysis is reported in section 2.4. Preparation of sample was described in 
section 2.3.3.1, lipid extraction in section 2.3.3.2 and section 2.3.3.5 shows the 
preparation of fatty acid methyl esters for GC analysis. 
5.3. Results 
5.3.1. Fatty acid profile of HaCaT and 46BR.1N cells  
          The fatty acid profiles of HaCaT and 46BR.1N cells are shown in Table 
5.1. Thirty one fatty acids were detected by GC analysis: The SFA group 
comprised 37.11 ± 9.16% of total fatty acids in HaCaT keratinocytes but it was  
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Table 5.1. Fatty acid profile of HaCaT keratinocytes and 46BR.1N fibroblasts. Results 
are expressed as % weight of total fatty acid (mean ± SD) of n=3 independent 
experiments  
FATTY ACID HaCaT keratinocytes   46BR.1N fibroblasts 
C12:0 0.05 ± 0.04 0.16 ± 0.11 
C14:0 1.52 ± 0.32 1.00 ± 0.93 
C15:0 0.11 ± 0.07 0.41 ± 0.05 
C16:0 18.96 ± 2.48 00.68 ± 2.36 
C17:0 0.26 ± 0.12 1.17 ± 0.13 
C18:0 15.32 ± 8.09 26.83 ± 5.30 
C20:0 0.23 ± 0.08 0.42 ± 0.05 
C23:0 0.03 ± 0.01 0.05 ± 0.02 
C24:0 0.64 ± 0.53 0.72 ± 0.26 
ΣSFA 37.11 ± 9.16 51.94 ± 8.68 
C14:1 0.03 ± 0.10 0.04 ± 0.03 
C16:1 9.85 ± 4.90 1.79 ± 0.33 
C17:1 0.53 ± 0.08 0.46 ± 0.31 
C18:1n-9t 0.09 ± 0.03 0.23 ± 0.10 
C18:1n-9c 26.47 ± 1.77 18.23 ± 2.98 
C18:1n-7 14.85 ± 5.17 5.24 ±0.73 
C20:1n-9 1.51 ± 0.39 0.34 ± 0.08 
C22:1n-9 0.48 ± 0.32 0.35 ± 0.03 
C24:1 0.35 ± 0.24 0.39 ± 0.21 
ΣMUFA 54.22 ± 8.82 27.07 ± 4.79 
C18:2n-6t 0.10 ± 0.09 0.23 ± 0.04 
C18:2n-6c 2.19 ± 1.00 4.25 ±1.10 
C18:3n-6 0.13 ± 0.25 0.08 ± 0.08 
C20:3n-6 0.43 ± 0.15 0.65 ± 0.08 
C20:4n-6 3.04 ± 1.69 9.40 ± 3.61 
ΣN-6PUFA 5.88 ± 2.64 14.62 ± 5.10 
C18:3n-3 0.03 ± 0.01 0.19 ± 0.04 
C20:3n-3 0.33 ± 0.08 0.49 ± 0.10 
C20:5n-3 0.25 ± 0.09 0.94 ± 0.34 
C22:5n-3 1.0±0.26 1.82 ± 0.45 
C22:6n-3 1.13 ± 0.23 2.68 ± 0.47 
ΣN-3PUFA 2.72 ± 0.49 6.11 ± 1.40 
C20:2 0.18 ± 0.09 0.19 ± 0.04 
C22:2 0.04 ± 0.02 0.04 ± 0.01 
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higher in 46BR.1N fibroblasts at 51.94 ± 8.68%. A total of 9 SFAs were 
detected : C12:0, C14:0, C15:0, C16:0, C17:0, C18:0, C20:0, C23:0 and C24:0, 
with the main ones being C16:0 and C18:0. The amounts of these fatty acids in 
46BR.1N were more than in HaCaT (Table 5.1)   
          MUFA were 54.22 ± 8.82% of total fatty acids in HaCaT cell and less 
were found (27.07±4.79%) in 46BR.1N. Nine fatty acids were detected in this 
group; C14:1, C16:1, C17:1, C18:1n-9t, C18:1n-9c, C18:1n-7, C20:1n-9, 
C22:1n-9 and C24:1. The main fatty acid was C18:1n.9c (26.47 ± 1.77%and 
18.23 ± 2.98%) followed by C18:1n-7 (14.85% ± 5.17 and 5.24±0.73%) on 
HaCaT and 46BR.1N, respectively. 
          N-6 PUFAs were 5.88 ± 2.64% and 14.62 ± 5.10% of total HaCaT and 
46BR.1N fatty acids, respectively. This group comprised five PUFA; C18:2n.6t, 
C18:2n.6c, C18:3n-6, C20:3n-6 and C20:4n-6. C20:4n-6 was the main n-6 
PUFA in both HaCaT and 46BR.1N cells with 3.04 ± 1.69% and 9.40 ± 3.61%, 
respectively. Followed by C18:2n-6c at 2.19 ± 1.0% in HaCaT cell and at 4.8 ± 
1.1% on 46BR.1N.  
         Finally, 5 n-3 PUFAs were found in both cell lines. These were C18:3n-3, 
C20:3n-3, C20:5n-3, C22:5n-3 and C22:6n-3. In HaCaT n-3 PUFA were 2.72 ± 
0.49% of total while in 46BR.1N the total % was higher (6.11 ± 1.40%). In 
HaCaT C22:6n-3 was found 1.13 ± 0.23% followed by C22:5n-3 at 1.0 ± 0.26%. 
The same fatty acids were detected in 46BR.1N and C22:6n-3 was 2.68 ± 0.47% 
followed by C22:5n-3 at 1.82± 0.45% and C20:5n-3 at 0.94± 0.34%. 
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5.3.2. Effect of n-3 PUFA treatment on HaCaT fatty acid profile 
       These experiments were performed in order to assess the effect of EPA 
and DHA on the fatty acid profile of the HaCaT cell line. The cells were cultured 
in Petri dishes and treated with n-3 PUFA (10 and 50µM) for 72h. Oleic acid 
was chosen as a control treatment for the experiments.  After that the cells were 
collected and lipid extracts were analyzed by GC for fatty acid methyl ester. 
          There was no statistically significant difference on the levels of SFA, 
MUFA and n-6 PUFA after 72h of treatment with OA, EPA and DHA (10 or 50 
µM) compared to non-treated control cells. Detailed data are shown in 
Appendices 3.1, 3.2 and 3.3. However, the UVR and fatty acid treatments 
affected the n-3 PUFA specificities;  
           The OA treatment did not affect the level of n-3 PUFA group comparing 
to control cells. These results are shown in Figure 5.1.  
       Statistical analysis showed no a significant increase on total n-3 PUFA 
when HaCaT treated with 10µM EPA. However, further increase was shown 
when the cells were treated with EPA 50µM (11.02 ± 1.98 %, p≤0.001) these 
results are shown in Figure 5.1.  
          When the HaCaT cells were treated with DHA 10µM there was no 
statistically significant increase on the total n-3 PUFA level. However, the 
amount of n-3 PUFA group was significant increased from 2.72±0.49% in 
untreated HaCaT cells to 10.63 ± 4.96% (P≤0.01) follows treatment with 50µM 
DHA. The results are shown in Figure 5.1. 
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          When we looked of individual n-3 PUFA we found that the EPA and DHA 
treatment had affected the levels of EPA, DPA and DHA specifically:  
          There was no effect on C20:5 n-3 when HaCaT cells were treated with 
OA 10 and 50µM (Figure 5.2.). When HaCaT were treated with EPA 10µM 
there was no significant increase on C20:5 n-3 concentration. Significantly 
increased on C20:5 n-3 (p≤0.001) was observed when cells were treated with 
EPA 50µM compared to non-treated cells (Figure 5.2). Similar, no significantly 
increase on C20:5n-3 was observed when HaCaT cells were treated with 10µM 
DHA. But significant increases on C20:5 n-3 (p≤0.05) were observed when the 
cells were treated with 50µM DHA (Figure 5.2). 
         The levels of C22:5 n-3 were not significantly increased when HaCaT cells 
were treated with OA or DHA (10 and 50µM) (Figure 5.3). They were significant 
increased when the cells were treated with EPA 10µM (p≤0.01) and 50µM 
(p≤0.001). Results are shown in Figure 5.3 
          Finally, statistical analysis showed that there was no effect of OA and 
EPA (10 and 50 µM) on the level of C22:6 n-3 as shown in Figure 5.4. DHA 
treated HaCaT cells showed increased levels of C22:6 n-3. This was not 
statistically significant when cells were treated with 10µM DHA but when treated 
with DHA 50µM this became significant (P≤0.01). Results are shown in Figure 
5.4. 
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Figure.5.1. Effect of fatty acid treatment, oleic acid (OA), eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA) on the level of total n-3 PUFA in HaCaT cells. 
Results are shown as mean ± SD of 3 independent experiments, each analysed in 
duplicate. **=p≤0.01, ***=p≤0.001, comparing data to non-treated group.  
 
Figure 5.2. Effect of fatty acid treatment, oleic acid (OA), eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA) on the level of eicosapentaenoic acid (EPA,C20:5 n-
3) on HaCaT cells. Results are shown as mean ± SD of 3 independent experiments, 
each analysed in duplicate. *=p≤0.05, ***=p≤0.001, comparing data to non-treated 
group.  
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Figure.5.3. Effect of fatty acid treatment, oleic acid (OA), eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA) on docosapentaenoic acid (DPA, C22:5 n-3) in 
HaCaT cells. Results are shown as mean ± SD of 3 independent experiments, each 
analysed in duplicate. **=p≤0.01, ***=p≤0.001, comparing data to non-treated group.  
 
 
 
 
 
 
 
 
 
 
Figure.5.4. Effect of fatty acid treatment, oleic acid (OA), eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA) on the level of docosahexaenoic acid (DHA, C22:6 
n-3) in HaCaT cells. Results are shown as mean ± SD of 3 independent experiments, 
each analysed in duplicate. **=p≤0.01, comparing data to non-treated group.  
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5.3.3. Effect of n-3 PUFA treatment on 46BR.1N fatty acid profile 
        These experiments were performed in order to assess the effect of fatty 
acid treatment (OA, EPA and DHA) on the fatty acid profile of the 46BR.1N cell 
line. The cells were cultured in Petri dishes and treated with the fatty acids     
(10 and 50µM) for 72h. Statistical analysis shown that there were no effects on 
the saturated, monounsaturated or n-6 PUFA levels in 46BR.1N cells, but there 
were changes in some n-3 PUFA. Specifically:  
         There were no statistically significant differences in the n-3 PUFA group 
after 72h treatment with OA (10 and 50 µM) compared to non-treated control 
(Figure 5.5). Also no statistically significant increases in the levels of n-3 PUFA 
post treatment with a low dose of EPA and DHA (10µM). Significant increases 
on n-3 PUFA were observed when cells were treated with EPA 50µM (p≤0.01) 
and DHA 50µM (p≤0.01) compared to non-treated cells (Figure 5.5). Detailed 
data are shown in Appendixes 3.4, 3.5 and 3.6. 
            Furthermore, the fatty acid treatment changed the levels of some fatty 
acids in 46BR.1N specificities: 
         The concentration of C18:1n-9c was significantly increased to 31.74 ± 
3.09% when the cells were treated with OA 50µM compared to non-treated cell 
(P≤0.05); but there was no significant different when treated with EPA and DHA 
as shown in Figure 5.6. The amount of C20:3n-6 was significantly increased 
when the cells were treated with DHA 10µM (p≤0.05) and 50 µM (p≤0.05) and 
compared to control groups. Results are shown in Figure (5.7). The 
concentration of C18:3n-3 was not affected by OA and DHA. However, EPA 50 
µM increased it significantly (p≤0.05) (Figure 5.8). 
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Figure 5.9 shows the effect of fatty acid treatment on C20:5n-3 levels in 
46BR.1N cells. The level of C20:5n-3 did not change with OA and DHA 
treatment. However, there was a significant increase when the cells were 
treated with EPA 10µM (p≤0.001) and 50µM (P≤0.001). Also, a significant 
increase was observed in the amount of C22:5n-3 after treating the cells with 
EPA 10µM (p≤0.05) and 50µM (P≤0.001) and compared to control group. 
(Figure 5.10) 
          Finally, an increase in the concentration of C22:6n-3 was observed in 
46BR.1N cells treated with DHA (50µM). This was significantly increased 
compared to the control group (P≤0.001) (Figure 5.11) 
 
 
 
 
Figure.5.5. Effect of fatty acid treatment, oleic acid (OA), eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA) on the level of total n-3 PUFA in 46MR.1N fibroblasts 
cells. Results are shown as mean ± SD of 3 independent experiments, each analysed 
in duplicate. **=p≤0.01, comparing data to non-treated group.  
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Figure 5.6. Effect of fatty acid treatment, oleic acid (OA), eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA) on the level of oleic acid (OA, C18:1n-9c) in 
46BR.1N fibroblast cells. Results are shown as mean ± SD of 3 independent experi-
ments, each analysed in duplicate. **=p≤0.01, comparing data to non-treated group 
 
 
 
Figure 5.7. Effect of fatty acid treatment, oleic acid (OA), eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA) on the level of Dihomo-γ-linolenic (DG LA,C20:3 n-6) 
on 46BR.1N fibroblast cells. Results are shown as mean ± SD of 3 independent 
experiments, each analysed in duplicate. *=p≤0.05, comparing data to non-treated 
group.  
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Figure.5.8. Effect of fatty acid treatment, oleic acid (OA), eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA) on the level of α-linolenic acid (ALA, C18:3 n-3) on 
46BR.1N fibroblast cells. Results are shown as mean ± SD of 3 independent 
experiments, each analysed in duplicate. *=p≤0.05, comparing data to non-treated 
group. 
 
 
 
Figure 5.9. Effect of fatty acid treatment, oleic acid (OA), eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA) on the level of eicosapentaenoic acid (EPA, C20:5 n-
3) on 46BR.1N fibroblast cells. Results are shown as mean ± SD for 3 independent 
experiments, each analysed in duplicate. ***=p≤0.001, comparing data to non-treated 
group.  
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Figure 5.10. Effect of fatty acid treatment, oleic acid (OA), eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA)on the level of docosapentaenoic acid (DPA, C22:5 
n-3) in 46BR.1N fibroblast cells. Results are shown as mean ± SD of 3 independent 
experiments, each analysed in duplicate. *=p≤0.05, ***=p≤0.001, comparing data to 
non-treated group.  
 
 
 
Figure 5.11. Effect of fatty acid treatment, oleic acid (OA), eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA) on the level of docosahexaenoic acid (DHA, C22:6 
n-3) in 46BR.1N fibroblast cells. Results are shown as mean ± SD of 3 independent 
experiments, each analysed in duplicate. ***=p≤0.001, comparing data to non-treated 
group.  
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5.4. Discussion 
                In order to assess the effect of EPA and DHA on the fatty acid profile 
of HaCaT cells, the baseline concentration was analysed. The results show that 
C16:0 (19%) and C18:0 (15.3%) were the main SFA. Terashi, et al (2000) 
reported that in primary human epidermal keratinocytes from the face grown in 
culture C16:0 (17.5%) was the main SFA followed by C18:0 (16%) (Terashi et 
al., 2000). Also, in human keratinocytes C16:0 (16.7%) was the predominant 
SFA, followed by C18:0 (9.3%), when cells were cultured in normal conditions 
(Ponec et al., 1988). The amount of C16:0 (23.1%) in cultured oral 
keratinocytes and normal oral mucosal keratinocytes (27.18%) was higher in 
that found in our study (Moriyama et al., 2011). C18:1n-9t (26.47%) was found 
to be the main MUFA. This level was higher than that found in C18:1n-9 (16.0%) 
in cultured oral keratinocytes and lower than that found in human keratinocyte 
(Ponec et al., 1988). In this study, the levels of C18:2 n-6 (2.2%) and C20:4n-6 
(3.0%) were lower than in cultured oral keratinocytes which were 27.4% and 6.3% 
respectively. Finally, the level of EPA and DHA was about 0.25% and 1.13% 
respectively in the HaCaT cells used in the present study and this was similar to 
the level found in cultured oral keratinocytes. Furthermore, it has been reported 
that the amount of EPA and DPA was 0% in HaCaT keratinocytes (Storey et al., 
2005).   
          The fatty acid profile of 46BR.1N dermal skin fibroblasts was analysed by 
GC. Thirty one fatty acids were detected, and C18:0 (26.8%) was the main SFA, 
followed by C16:0 (20.7%). A similar result was found in cultured human skin 
fibroblasts and the main SFA was C18:0 (22.4%), followed by C16:0 (19.9%) 
(Williard et al., 2001). In another study on human skin fibroblasts, C18:0 (29.8%) 
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was the main SFA, followed by C16:0 (27.9%) (Yu-Poth et al., 2005). Our 
results show that C18:1n-9 was the main MUFA at 18.2% of total fatty acids. 
This was lower than the level of C18:1n-9 (22.4% and 24.7%) found in cultured 
human skin fibroblasts (Williard et al., 2001, Yu-Poth et al., 2005) and C18:1n-9 
(25.52%) in Indian muntjac fibroblasts (Higgins et al., 1999).  Among the 10 
PUFAs detected in 46BR.1N, AA (9.4%), LA (4.5%), EPA (0.94%), DPA (1.82%) 
and DHA (2.68%) were the main ones. Compared to what was found in cultured 
human skin fibroblasts, AA (11.6%) and DHA (4.2%) were higher, and LA 
(2.6%), EPA (0.3%) and DPA (1.4%) were lower than in 46BR.1N (Williard et al., 
2001). Also, Indian muntjac fibroblasts showed a higher amount of DHA (3.2%) 
and a lower amount of EPA (0.3%) compared to 46BR.1N (Higgins et al., 1999).   
          The results of this study show that there were no significant changes in 
the concentration of fatty acids when HaCaT cells were treated with 10 and 50 
µM OA. Although there were trends showing increased levels of OA following 
this treatment, this failed to show any statistical significance. Furthermore, the 
result shows that the fatty acid composition in HaCaT was not affected when 
treated with OA, which was chosen as a control (Appendix 3.1). In contrast, 
HaCaT cells treated with EPA and DHA show significant increases in these fatty 
acids (Figures 5.2 and 5.4). The same results were found when HaCaT 
keratinocytes were treated with 50 µM OA, EPA and DHA (Storey et al., 
2005).They reported that the level of EPA and DHA was increased from 0% to 
3.4% and 6.3% respectively. In addition to an increase in EPA level after EPA 
supplementation, DPA was also increased in the EPA treated cells, while DHA 
treatment showed an increase in DHA and EPA but not DPA. A similar result 
was found by Storey et al (2005) who reported that the level of EPA was 0% in 
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control HaCaT cells but increased to 2.4% when cells were treated with 50 µM 
DHA. DPA concentration was increased from 1.5% (mol) to 25.5% when normal 
human keratinocytes were treated with 50 µM EPA while DHA did not increase.   
            The concentration of OA on 46BR.1N increased significantly after being 
treated with 50µM OA (Figure 5.6). This was also found in Indian muntjac 
fibroblasts when treated with 50µM OA. In this study, the concentration of OA 
increased from 25.52% to 37.99%. This was not in agreement with what was 
reported by Storey et al. (2005). Who found that when treating CCD922SK 
fibroblasts (derived from normal human breast skin) with 50 µM OA there was 
no significant effect on the concentration of OA. Treated cells with OA did not 
affect the concentration of any other fatty acid. Meanwhile, treating the cells 
with EPA significantly increased EPA and DPA, and treating the cells with DHA 
significantly increased DHA only. An increase in EPA and DHA was observed in 
Indian muntjac fibroblasts treated with 50 µM of each fatty acid.  EPA and DHA 
were increased from 0.23% and 3.2% to 9.88% and 14.35%, respectively 
(Higgins et al., 1999). Furthermore, EPA and DHA levels were increased from 
5.7% and 3.2% to 11.1% and 17.4%, respectively, when CCD922SK fibroblasts 
were treated with 50 µM EPA and DHA (Storey et al., 2005). It has also been 
reported that only trace amounts of EPA, DPA and DHA were present at basal 
levels in fibroblasts. However, they increased significantly, when human skin 
fibroblasts were treated with 0.4mmol/L of EPA or DHA (Yu-Poth et al., 2005).  
An increase in the concentration of DPA only was noted after EPA treatment, 
this could be a result of elongation of EPA or saturation of DHA. Furthermore, 
there were no significant increases in either EPA or DPA when cells were 
treated with DHA; this indicated the retro-conversion of DHA to EPA, which 
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takes place in peroxisomes by Δ4 enoyl reductase and Δ2, Δ3 enoyl CoA 
isomerise enzymes.                         
         Overall, the  aim of this study was achieved; cells were packed up the 
fatty acid treatment and the content of EPA and DHA was increased in the cells. 
The fatty acid profile in un-treated cells shows that the content of n-3 and n-6 
PUFA was higher in 46BR.1N compared with HaCaT keratinocytes, specifically 
the  levels of  LA, AA, EPA, DPA and DHA. In contrast, OA was lower in 
46BR.1N, and this may explain the significant increase inOA afterbeing treated 
with 50 µM OA. 
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Chapter 6. Effect of UVR and n-3 PUFA on prostanoid 
production in skin cells 
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 6.1. Introduction      
         Prostanoids are generated from the action of cyclooxygenase (COX-1 and 
COX-2) and prostanoid synthases on AA, EPA and DHA (Schumert et al., 1988). 
COX-2 is often implicated in inflammatory diseases that are characterised by 
oedema and tissue injury due to the release of many inflammatory cytokines 
and chemotactic factors (Tanaka et al., 1997, Arslan and Zingg, 1996). It has 
been suggested that prostanoids inhibit apoptosis (Sheng et al., 1998) and 
increase the metastatic potential of cancer cells (Kakiuchi et al., 2002).  
        There are many factors that can influence eicosanoid producing enzymes. 
UVR can induce COX-2 and increase the PG levels in the skin (Buckman et al., 
1998). It has been reported that increases in COX-2 expression in human skin 
epidermis occurred when human subjects were irradiated with up to four times 
their MED and biopsied 24 h later (Rhodes et al., 2009). Furthermore, increased 
COX-2 protein was noted when cultured human keratinocytes were exposed to 
30mJ/cm2UVB (Buckman et al., 1998). It has also been reported that UVB 
exposure up-regulated the expression of COX-2 and increased protein levels of 
COX-2 on culture HaCaT cells post 30mJ/cm2 UVB (Lee et al., 2013). UVR can 
affect the COX-2 expression via activation of multiple signal transduction 
pathways including the following: (1) extracellular molecules (such as growth 
factor receptors (GFR), (2) intracellular signaling pathways (such as the 
mitogen-activated protein kinases (MAPKs), and (3) extraceullar signal-
regulated protein kinases (ERK)  that ultimately result in enhanced production of 
effector proteins including cytokines, growth factors, and MMPs.  
          Keratinocyte growth factor (KGF) is a member of the fibroblast growth 
factor (FGF) family and appears to represent a key mediator of epithelial growth 
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and differentiation (Finch et al., 1989). Secreted from cells of mesenchymal 
origin, it elicits its activity specifically on epithelial cells through binding to the 
keratinocyte growth factor receptor (KGFR) (Miki et al., 1992).  An activation on 
GFR was observed in NIH3T3 cells when they were exposed to 25-50mJ/cm2 
UVB.  (Marchese et al., 2003). It has been shown that MAPK pathways lead to 
proto-oncogene expression, and  members of the MAPK family play a role in 
chemical carcinogen induced COX-2 gene expression (Yang et al., 2000; 
Arbabi et al., 2000). It has also been reported that extraceullar signal-regulated 
protein kinases (ERK) and p38 were significantly increased in cultured human 
keratinocytes and HaCaT cells post UVR treatment (Chen et al., 2001, Mutou et 
al., 2010).  
         Peroxisome proliferator-activated receptors (α, β and γ) (PPAR) are 
nuclear hormone receptors and ligand-activated transcription factors that 
regulate target gene expression by binding to specific peroxisome proliferator-
response elements (PPREs) (Berger and Moller, 2002). It has been suggested 
that PPARγ mediates the COX-2 expression in human synovial fibroblasts 
(Kalajdzic et al., 2002), and UVB increases COX-2 expression via PPARγ 
activation on keratinocytes (Zhang et al., 2005) and in normal primary human 
keratinocytes (Konger et al., 2010). On the other hand, UVB has been shown to   
down-regulate PPAR-α and PPAR-β (Kippenberger et al., 2001). 
         Furthermore, it has been reported that PUFAs and their oxidised products 
are able to bind and activate all three isoforms of PPARs (Wahli et al., 1995). it 
has also been reported that EPA and GLA are able to up-regulate COX-2 
expression via PPARγ in HaCaT keratinocytes (Chene et al., 2007). Moreover, 
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it has been found that EPA inhibits the expression of COX-2 in many systems 
including human skin (Kim et al., 2006). 
This part of the study aimed to explor the eicosanoid production in HaCaT 
keratinocytes and 46BR.1N fibroblasts and to answer the following:  
A) What kind of prostanoids are produced by these cells? 
B) What is the effect of UVR on the production of these prostanoids? 
C) What is the effect of n-3 PUFA on the production of these prostanoids with 
and without UVR treatment? 
 6.2. Materials and methods 
         All information relevant to the experiments reported in this study is 
presented in section 2.2. Cell culture and passaging are in section 2.2.3.2 and 
cell counting in section 2.2.3.2. Exposure of cells to UVR described in section 
2.2.3.3.2. Section 2.2.3.4 describes the treatment of cells with fatty acids and 
section 2.2.3.5 shows the collection of cells and media. Prostanoids analysis is 
reported in section 2.4 including sample preparation and LC/ESI-MS/MS 
analysis.  
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6.3. Results 
6.3.1. Profile of prostanoids produced by HaCaT and 46BR.1N 
      Cells were cultured, treated with 10 and 50µM OA, EPA and DHA, exposed 
to 15mJ/cm2 UVR and the media were analysed for prostanoids as described 
previously. 20 Prostanoids were screened for and 7 prostaglandins were 
detected: PGE1, PGD1, PGE2, PGD2, PGE3 and PGD3 (Table 6.1). PGF2α also 
was detected in low concentration which was close to the quantitation limit of 
the method, so it was difficult to accurately determine its true abundance. Also, 
a number of prostaglandin deactivation products were detected (Table 6.1). 
Results in Table 6.1 show the concentration (pg/million cell) of PG and their 
main deactivation products. It is clear that 46BR.1N produced more 
prostaglandins than HaCaT cells. PGE2 was found to be the most abundant PG 
in both cell lines.  
Table 6.1. Profile of prostanoids produced by HaCaT and 46BR.1N. Results are shown 
as mean ± SD for 3 independent experiments (each one performed in duplicate). 
Compound 
HaCaT( pg/ 
million cell) 
HaCaT (% 
total PG) 
46BR.1N (pg/ 
million cell) 
46BR.1N (% 
total PG) 
PGE1 0.84 ± 0.41 1.2 4.4 ± 0.09 2.0 
PGD1 0.63 ± 0.43 0.9 1.4 ± 0.09 0.5 
PGE2 7.96 ± 3.18 12.2 44.2 ± 23.0 17.6 
PGD2 1.48 ± 1.19 1.98 17.1 ± 9.71 4.8 
PGE3 1.39 ± 0.19 2.5 4.7 ± 1.04 2.7 
PGD3 1.18 ± 1.16 1.99 10.7 ± 7.46 7.0 
15-keto PGE2 6.28 ± 3.23 11.4 13.1 ± 7.99 11.0 
13,14dihydro-15-PGE1 1.85 ± 1.47 2.3 3.7 ± 2.46 2.9 
13,14dihydro-15-PGE2 32.3 ± 19.56 46.5 55.2 ± 37.8 42.3 
13,14dihydro-15-PGF2α 14.6 ± 12.7 19.1 20.0 ± 2.04 9.1 
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6.3.2. The effect of UVR and fatty acid treatment on prostanoids produced 
by HaCaT keratinocyte 
6.3.2.1. The effect of UVR and fatty acid treatment on series-1 prostanoids.  
          PGE1, PGD1 and 13,14-dihydro-15-keto PGE1 are all products of DGLA, 
their levels were increased in HaCaT post UVR exposure. However only PGE1 
was statistically significantly higher (p≤0.05) compared to non-irradiated control 
(FA(-)/UVR(-)) (Figure 6.1-3). HaCaT cells treated with 10 and 50µM of OA 
showed no significant changes in PGE1, PGD1 and 13,14-dihydro-15-keto PGE1.  
Similarly there were no significant effects of OA (10 and 50µM) on the levels of 
PGE1, PGD1 and 13,14-dihydro-15-keto PGE1 post UVR compared to irradiated 
control (FA (-)/UVR(+)).Figures 6.1A, 6.2A and 6.3A 
          There was no significant decrease in PGE1, PGD1 and 13,14-dihydro-15-
keto PGE1 when HaCaT cells were treated with 10 and 50µM  of EPA Figures 
(6.1B, 6.2B and 6.3B) . But PGE1 was significantly increased (p≤0.05) when the 
cells were exposed to15 mJ/cm2 compared to irradiated control (FA (-)/UVR(+)) 
(Figure 6.1B). PGE1, PGD1 and 13,14-dihydro-15-keto PGE1 were slightly 
decreased following treatment with EPA and post UVB. These changes were 
not statistically significant compared to the irradiated controls (FA (-)/UVR(+)).  
            When HaCaT keratinocytes were treated with 10 and 50 µM DHA there 
was no significant decreased on the level of PGE1, PGD1 and 13,14-dihydro-15-
keto PGE1 at baseline when compared to non irradiated control (FA(-)/UVR(-)). 
However, a significant decreased on PGE1 post UVR was noted when the cells 
were treated with 10 and 50µM of DHA (p≤0.05 and 0.01 respectively) 
compared to irradiated control (FA (-)/UVR(+))(Figure 6.1C,6.2Cand 6.3C). 
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Figure 6.1. Effect of UVR and fatty acid treatment, (A) oleic acid (OA), (B) eicosa-
pentaenoic acid (EPA) and (C) docosahexaenoic acid (DHA) on PGE1 produced by 
HaCaT keratinocyte 24 h post UVR (15 mJ/cm2). Cells were treated with two 
concentrations of each fatty acid (10µM and 50 µM) for 72h. Results are shown as 
mean ± SD for 3 independent experiments (each one performed in duplicate). 
*∆p≤0.05, ∆∆p≤0.01, *=compared to non-irradiated control (FA(-)/UVR(-)). ∆=compared 
to irradiated control (FA (-)/UVR(+)).  
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Figure 6.2. Effect of UVR and fatty acid treatment, (A) oleic acid (OA), (B) eicosa-
pentaenoic acid (EPA) and (C) docosahexaenoic acid (DHA) on PGD1 produced by 
HaCaT keratinocyte 24 h post UVR (15 mJ/cm2). Cells were treated with two 
concentrations of each fatty acid (10µM and 50 µM) for 72h. Results are shown as 
mean ± SD for 3 independent experiments (each one performed in duplicate).  
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Figure 6.3. Effect of UVR and fatty acid treatment, (A) oleic acid (OA), (C) eicosa-
pentaenoic acid (EPA) and (C) docosahexaenoic acid (DHA)on 13,14-dihydro-15-keto 
PGE1 produced by HaCaT keratinocyte 24h post UVR (15 mJ/cm
2). A) OA, B) EPA, C) 
DHA. Cells were treated with two concentrations of each fatty acid (10µM and 50 µM) 
for 72h. Results are shown as mean ± SD for 3 independent experiments (each one 
performed in duplicate).  
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6.3.2.2. The effect of UVR and fatty acid treatment on series-2 prostanoids  
           Series-2 prostanoids are products of AA. When HaCaT cells were 
exposed to 15mJ/cm2 UVR, we noticed a statistically increased increase in 
PGE2 and 13,14-dihydro-15-keto PGE2 (p≤0.001and p≤0.05, respectively) when 
compared to non irradiated control (FA(-)/UVR(-)) (Figure 6.4 and 6.7). The 
baseline level of PGE2, PGD2, 15-keto PGE2 and 13,14-dihydro-15-keto PGE2 
did not change when the cells were treated with 10 and 50 µM OA, and 
compared to non irradiated control (FA(-)/UVR(-)). Results are shown in Figure 
6.4A, 6.5A, 6.6A and 6.7A. In addition, OA shown no affect on series 2 
prostaglandin levels post UVR compared to irradiated control (FA (-
)/UVR(+)).(Figure 6.4A, 6.5A, 6.6A and 6.7A). 
         The results in Figures 6.4B, 6.5B, 6.6B and 6.7B, show the effect of EPA 
treatment (10 and 50 µM) on the level of PGE2, PGD2, 15-keto PGE2 and 13,14-
dihydro-15-keto PGE2 produced by HaCaT cells. Although there was an 
decrease in the level of these mediators when the cells were treated with 10 
and 50 µM of EPA, this was not statistically significant when compared to non 
irradiated control (FA(-)/UVR(-)) (Figures 6.4B, 6.5B, 6.6B and 6.7B). An 
increase in PGE2 and 13, 14-dihydro-15-keto PGE2 was observed when EPA 
treated HaCaT cells were exposed to 15mJ/cm2 UVR, and this was statistically 
significant (p≤0.001and p≤0.05, respectively) compared to non-irradiated control 
(FA(-)/UVR(-)) Figure 6.4B and 6.7B. The levels of PGD2 and 15-keto PGE2 
were increased when the cells were exposed to with 15m J/cm2, but this change 
was not statistically significant when compared to non-irradiated control (FA(-
)/UVR(-)) (Figure 6.5B and 6.6B). HaCaT treated with 10 and 50 µM of EPA and 
exposed to 15 mJ/cm2 UVR showed a significant decreased in PGE2 (p≤0.05 
172 
 
and p≤0.01, respectively) and 13,14-dihydro-15-keto PGE2 production (p≤0.05 
and p≤0.01, respectively), but changes in PGD2, and 15-keto PGE2  were not 
significant.(Figure 6.4B, 6.5B, 6.6B and 6.7B). 
           HaCaT treated cells DHA with (10 µM) showed no statistically significant 
changes in PGE2, PGD2, 15-keto PGE2 and 13,14-dihydro-15-keto PGE2  
productionwhen compared to non irradiated controls (FA(-)/UVR(-)). Results 
shown in Figures 6.4C, 6.5C, 6.6C and 6.7C.  However, ssignificantly reduced 
level of PGE2 (p≤0.05) and 13,14-dihydro-15-keto PGE2 (p≤0.05) was observed 
when the cells were treated with 50 µM DHA. Exposure of untreated HaCaT 
cells to 15 mJ/cm2 showed significant increase in PGE2 and 13,14-dihydro-15-
keto PGE2 (p≤0.001 and p≤0.05, respectively) when compared to the 
corresponding controls (FA(-)/UVR(-))(Figure 6.4C and 6.7C). Whilst, no 
significant increase in HaCaT cell PGD2 and 15-keto PGE2 were observed. 
(Result shown in Figure 6.5C and 6.6C). As shown in Figures 6.4C and 6.7C, 
DHA induced a dose-dependent reduction in PGE2 and 13,14-dihydro-15-keto 
PGE2 levels post exposure to 15 mJ/cm
2. DHA (10 µM) significantly reduced the 
levels of PGE2 (p≤ 0.01) and 13,14-dihydro-15-keto PGE2 (p≤0.001) compared 
to irradiated control cells (FA(-)/UVR(-)). The of DHA (50 µM) treatment further 
reduced the concentration of PGE2 (p≤0.01) and 13,14-dihydro-15-keto PGE2 
(p≤0.001) compared to irradiated control cells (FA(-)/UVR(+)). However, the 
reduction in the levels of PGD2 and 15-keto PGE2 post UVR were not 
statistically significant when compared to irradiated control (FA (-)/UVR(+)). 
(Figure 6.5C and 6.6C).   
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Figure 6.4. Effect of fatty acid and UVR treatment, (A) oleic acid (OA), (B) eicosa-
pentaenoic acid (EPA) and (C) docosahexaenoic acid (DHA) on PGE2 produced by 
HaCaT keratinocyte 24h post UVR (15 mJ/cm2). Cells were treated with two 
concentrations of each fatty acid (10µM and 50 µM) for 72h. Results are shown as 
mean ± SD for 3 independent experiments (each one performed in duplicate). 
*∆p≤0.05, **∆∆p≤0.01 ***,∆∆∆p≤0.001, *=compared to non-irradiated control (FA(-
)/UVR(-)). ∆=compared to irradiated control (FA (-)/UVR(+)). 
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Figure 6.5. Effect of UVR and fatty acid treatment, (A) oleic acid (OA), (B) eicosa-
pentaenoic acid (EPA) and (C) docosahexaenoic acid (DHA) on PGD2 produced by 
HaCaT keratinocyte 24 h post UVR (15 mJ/cm2). Cells were treated with two 
concentrations of each fatty acid (10µM and 50 µM) for 72h. Results are shown as 
mean ± SD for 3 independent experiments (each one performed in duplicate).  
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Figure 6.6. Effect of UVR and fatty acid treatment, (A) oleic acid (OA), (B) 
eicosapentaenoic acid (EPA) and (C) docosahexaenoic acid (DHA)on 15-keto PGE2 
produced by HaCaT keratinocyte 24 h post UVR (15 mJ/cm2). A) OA, B) EPA, C) DHA. 
Cells were treated with two concentrations of each fatty acid (10µM and 50 µM) for 
72h. Results are shown as mean ± SD for 3 independent experiments (each one 
performed in duplicate).  
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Figure 6.7. Effect of UVR and fatty acid treatment, oleic acid (OA), eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA)treatment on HaCaT 13,14-dihydro-15-
keto PGE2 produced by HaCaT keratinocyte 24 h post UVR (15 mJ/cm2). Cells were 
treated with two concentrations of each fatty acid (10µM and 50 µM) for 72h. Results 
are shown as mean ± SD for 3 independent experiments (each one performed in 
duplicate). *∆p≤0.05, **∆∆p≤0.01 ***,∆∆∆p≤0.001, *=compared to non-irradiated control 
(FA(-)/UVR(-)). ∆=compared to irradiated control (FA (-)/UVR(+)). 
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6.3.2.3. The effect of UVR and fatty acid treatment on series-3 prostanoids 
         Exposure of untreated HaCaT cells to 15mJ/cm2 showed no significant 
increase in the EPA products PGE3 and PGD3 when compared to the 
corresponding controls (FA(-)/UVR(-)). Figures 6.8A and 6.9A show the effect of 
OA treatment on PGE3 and PGD3. There was no a significant deference in 
PGE3 and PGD3 levels when HaCaT cells were treated with 10 and 50 µM of 
OA and compared to non-treated cells. Also, there was no significant deferent 
on PGE3 and PGD3 levels when HaCaT cells treated with 10 and 50 µM of OA, 
were exposed to 15 mJ/cm2. 
           We did not observe any statistically significant increase on PGE3 and 
PGD3 levels when HaCaT cells were treated with 10 µM of EPA, compared to 
the corresponding controls (FA(-)/UVR(-)) (Figure 6.8B and 6.9B).  But when 
the cells were treated with EPA (50 µM) a shown significant increase (p≤0.01) in 
PGE3 but not in PGD3 was noted. (Figure 6.8B and 6.9B). In order to see the 
effect of EPA on PGE3 and PGD3 post UVR, EPA treated irradiated cells were 
compared to untreated irradiated cells (FA(-)/UVR (+)). The results shown in 
Figure 6.8 C show that EPA at 10 and 50 µM has significant effect on PGE3 
(p≤0.05 and p≤0.001) not in PGD3. 
          Finally, when cells were treated with DHA (10 and 50 µM), PGE3 and 
PGD3 levels were not statistically deferent when compared to the corresponding 
controls (FA(-)/UVR(-)) (Figure 6.8C and 6.9C). Also, there was no significant 
difference on the levels of PGE3 and PGD3 produced by DHA treated with 
HaCaT cell when exposed to 15 mJ/cm2 UVR results showed in figures 6.8C 
and 6.9C). A summary of the effect of UVR and n-3 PUFA on series-1, -2 and -3 
prostanoids are shown in Table (6.2). 
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Figure 6.8. Effect of UVR and fatty acid treatment, oleic acid (OA), eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA) on PGE3 produced by HaCaT 
keratinocyte 24 h post UVR (15 mJ/cm2). Cells were treated with two concentrations of 
each fatty acid (10µM and 50 µM) for 72h. Results are shown as mean ± SD for 3 
independent experiments (each one performed in duplicate). *∆p≤0.05, **∆∆p≤0.01 
***,∆∆∆p≤0.001, *=compared to non-irradiated control (FA(-)/UVR(-)). ∆=compared to 
irradiated control (FA (-)/UVR(+)). 
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Figure 6.9. Effect of UVR and fatty acid treatment, oleic acid (OA), eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA) on PGD3 produced by HaCaT 
keratinocyte 24 h post UVR (15 mJ/cm2). Cells were treated with two concentrations of 
each fatty acid (10µM and 50 µM) for 72h. Results are shown as mean ± SD for 3 
independent experiments (each one performed in duplicate).   
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Table 6.2. Summary of the effect of UVR and n-3 PUFA treatment on the 
prostanoid mediators produced by HaCaT keratinocyte 
 
 
UVR 
(15mJ/cm2) 
No UVR UVR (15mJ/cm2) 
Compound EPA DHA EPA DHA 
PGE1 * ــــــ ــــــ ــــــ Δ 
PGD1 ــــــ ــــــ ــــــ ــــــ ــــــ 
PGE2 * ــــــ * Δ Δ 
PGD2 ــــــ ــــــ ــــــ ــــــ ــــــ 
PGE3 ــــــ * ــــــ Δ ــــــ 
PGD3 ــــــ ــــــ ــــــ ــــــ ــــــ 
15-keto PGE2 ــــــ ــــــ ــــــ ــــــ ــــــ 
13,14dihydro-
15-PGE1 
ــــــ ــــــ ــــــ ــــــ ــــــ 
13,14dihydro-
15-PGE2 
* ــــــ * Δ Δ 
 
ــــــ= No significant effect 
  = Significant decrease 
  = Significant increase 
*= compared to untreated cells (FA(-)/UVR (-)) 
Δ= compared to untreated irradiated cells (FA(-)/UVR (+)) 
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6.3.3. The effect of UVR and fatty acid treatment on prostanoids produced 
by 46BR.1N cells 
6.3.3.1. The effect of UVR and fatty acid treatment on series-1 prostanoids 
            PGE1, PGD1 and 13,14-dihydro-15-keto PGE1 levels were increased 
post UVR exposure, with the increases in PGE1 and 13,14-dihydro-15-keto 
PGE1 being statistically significant (p≤0.01 and p≤0.001, respectively) compared 
to non-irradiated control (FA(-)/UVR(-)). Figures 6.10A, 6.11A and 6.12A show 
the effect of OA treatment on 46BR.1N PGE1, PGD1 and 13,14-dihydeo-15-keto 
PGE1. There were no significant changes in the levels of these mediators when 
cells were treated with 10 and 50µM of OA or when the OA treated cells were  
exposed to UVR compared to irradiated control (FA (-)/UVR(+)). 
          There was no significant decrease on PGE1, PGD1 and 13,14-dihydeo-
15-keto PGE1 when 46BR.1N cells were treated with 10 µM of EPA. But a 
significant decrease (p≤0.05) was noted for PGE1 when 46BR.1N cells were 
treated with 50 µM EPA compared to control (Figures 6.10B, 6.11B and 6.12B). 
Furthermore, the levels of PGE1, PGD1 and 13,14-dihydeo-15-keto PGE1 in 
EPA treated cells increased post UVR. But only PGE1 was significantly lower 
post 10 (p≤0.01) and 50µM EPA (p≤0.01) (Figures 6.10B, 6.11B and 6.12B) 
              Finally, when cells were treated with 10 and 50 µM DHA the levels of 
PGE1, PGD1 and 13,14-dihydeo-15-keto PGE1 did not change compared to non 
irradiated controls. Although, the DHA treated appeared to reduce the levels of 
PGE1, PGD1 and 13,14-dihydeo-15-keto PGE1 post UVR, none of the observed 
changes was statistically significant compared to irradiated controls (FA (-
)/UVR(+))(Figure 6.10C, 6.11C and 6.12C).  
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Figure 6.10. Effect of UVR and fatty acid treatment, (A) oleic acid (OA), (B) eicosa-
pentaenoic acid (EPA) and (C) docosahexaenoic acid (DHA)on PGE1 produced by 
46BR.1N fibroblasts 24 h post UVR (15 mJ/cm2). Cells were treated with two 
concentrations of each fatty acid (10µM and 50 µM) for 72h. Results are shown as 
mean ± SD for 3 independent experiments (each one performed in duplicate). 
*∆p≤0.05, **∆∆p≤0.01, *=compared to non-irradiated control (FA(-)/UVR(-)). 
∆=compared to irradiated control (FA (-)/UVR(+)). 
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Figure 6.11. Effect of UVR and fatty acid treatment, (A) oleic acid (OA), (B) eicosa-
pentaenoic acid (EPA) and (C) docosahexaenoic acid (DHA) on PGD1 produced by 
46BR.1N fibroblasts 24 h post UVR (15 mJ/cm2). Cells were treated with two 
concentrations of each fatty acid (10µM and 50 µM) for 72h. Results are shown as 
mean ± SD for 3 independent experiments (each one performed in duplicate).  
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Figure 6.12. Effect of UVR and fatty acid treatment, (A) oleic acid (OA), (B) eicosa-
pentaenoic acid (EPA) and (C) docosahexaenoic acid (DHA)on 13,14-dihydro-15-keto 
PGE1 produced by 46BR.1N fibroblasts 24 h post UVR (15 mJ/cm
2). Cells were treated 
with two concentrations of each fatty acid (10µM and 50 µM) for 72h. Results are 
shown as mean ± SD for 3 independent experiments (each one performed in 
duplicate). *p≤0.05, *=compared to non-irradiated control (FA(-)/UVR(-)).  
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6.3.3.2. The effect of UVR and fatty acid treatment on series-2 prostanoids 
          When 46BR.1N cells were exposed to 15mJ/cm2 UVR, the levels of PGE2 
and 15-keto PGE2 were found to be statistically significantly higher (p≤0.001 
and p≤0.05; respectively) when compared to non irradiated controls (FA(-
)/UVR(-)) (Figures 6.13 and 6.15). The levels of PGE2, PGD2, 15-keto PGE2 and 
13,14-dihydro-15-keto PGE2 did not change when cells were treated with 10 
and 50 µM OA and compared to non irradiated control (FA(-)/UVR(-)). Result 
shown in Figure 6.13A, 6.14A, 6.15A and 6.16. In addition, OA treatment did not 
have any statistically significant on series 2 prostaglandins levels post UVR 
when compared to irradiated control (FA (-)/UVR(+))(Figure 6.13A, 6.14A, 
6.15A and 6.16). 
          Figures 6.13B, 6.14B, 6.15B and 6.16B show the effect of EPA treatment 
(10 and 50 µM) on PGE2, PGD2, 15-keto PGE2 and 13,14-dihydro-15-keto 
PGE2 reduced by 46BR.1N cell level. Although there was an decrease in the 
level of this mediators when the cells were treated with 10 and 50 µM of EPA, 
this was not statistically significant when compared to non irradiated control 
(FA(-)/UVR(-)). Also, the levels of PGD2, 15-keto PGE2 and 13,14-dihydro-15-
keto PGE2 were decreased when 46BR.1N cells were treated with  10 and 50 
µM of EPA and exposed to 15 mJ/cm2 UVR, these changes were not 
statistically significant when compared to irradiated control (FA (-)/UVR(+)). 
(Figure 6.14B, 6.15B and 6.16B). As shown in Figure 6.13B, EPA (50 µM) 
significantly reduced PGE2 levels (p≤0.05) after 46BR.1N cells were exposed to 
15 mJ/cm2 and compared to irradiated control (FA (-)/UVR(+)). 
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            The production of PGE2, PGD2, 15-keto PGE2 and 13,14-dihydro-15-
keto PGE2  by 10 and 50 µM DHA treated 46BR.1N cells showed no statistically 
significant change when compared to the non irradiated control (FA(-)/UVR(-)). 
(Results shown in figure 6.13C, 6.14C, 6.15C and 6.16C).   
          As shown in Figure 6.13C, DHA induced a dose-dependent reduction in 
PGE2 level in the 46BR.1N cells after they were exposed to 15 mJ/cm
2. DHA 
(10 µM) significantly reduced PGE2 levels (p≤0.01) compared to irradiated 
control cells (FA(-)/UVR(-)) and 50 µM of DHA reduced the concentration of 
PGE2 even more and this was statistically significant (p≤0.001) compared to 
irradiated control cells (FA(-)/UVR(+)). Although, the DHA treatment reduced 
the level of PGD2 and 13,14-dihydro-15-keto PGE2  post UVR, but these 
changes were not statistically significant when compared to irradiated control 
(FA (-)/UVR(+)) (Figure 6.14C and 6.16C).   
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Figure 6.13. Effect of UVR and fatty acid treatment, (A) oleic acid (OA), (B) eicosa-
pentaenoic acid (EPA) and (C) docosahexaenoic acid (DHA) on PGE2 produced by 
46BR.1N fibroblasts 24 h post UVR (15 mJ/cm2). Cells were treated with two 
concentrations of each fatty acid (10µM and 50 µM) for 72h. Results are shown as 
mean ± SD for 3 independent experiments (each one performed in duplicate). 
∆∆p≤0.01 ***,∆∆∆p≤0.001, *=compared to non-irradiated control (FA(-)/UVR(-)). 
∆=compared to irradiated control (FA (-)/UVR(+)). 
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Figure 6.14. Effect of UVR and fatty acid treatment, (A) oleic acid (OA), (B) eicosa-
pentaenoic acid (EPA) and (C) docosahexaenoic acid (DHA)on 46BR.1N PGD2 
produced by 46BR.1N fibroblasts 24 h post UVR (15 mJ/cm2). Cells were treated with 
two concentrations of each fatty acid (10µM and 50 µM) for 72h. Results are shown as 
mean ± SD for 3 independent experiments (each one performed in duplicate).   
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Figure 6.15. Effect of UVR and fatty acid treatment, (A) oleic acid (OA), (B) eicosa-
pentaenoic acid (EPA) and (C) docosahexaenoic acid (DHA) on 46BR.1N 15-keto 
PGE2 produced by 46BR.1N fibroblasts 24 h post UVR (15 mJ/cm
2). A) OA, B) EPA, C) 
DHA. Cells were treated with two concentrations of each fatty acid (10µM and 50 µM) 
for 72h. Results are shown as mean ± SD for 3 independent experiments (each one 
performed in duplicate). **p≤0.01,*=compared to non-irradiated control (FA(-)/UVR(-)). 
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Figure 6.16. Effect of UVR and fatty acid treatment, (A) oleic acid (OA), (B) eicosa-
pentaenoic acid (EPA) and (C) docosahexaenoic acid (DHA) on 13,14-dihydro-15-keto 
PGE2 produced by 46BR.1N fibroblasts 24 h post UVR (15 mJ/cm
2). Cells were treated 
with two concentrations of each fatty acid (10µM and 50 µM) for 72h. Results are 
shown as mean ± SD for 3 independent experiments (each one performed in 
duplicate).  
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6.3.3.3. The effect of UVR and fatty acid treatment on series-3 prostanoids  
          Exposure of 46BR.1N cells to 15 mJ/cm2 showed significant increases in 
PGE3 (p≤0.01) levels but the increase in PGD3 failed to reach statistical 
significances when compared to the negative controls (FA(-)/UVR(-)). Figures 
6.17A and 6.18A shows the effect of OA treatment on PGE3 and PGD3. There 
were no significant differences on PGE3 and PGD3 levels when the 46BR.1N 
cells were treated with 10 and 50 µM OA and when exposed to 15 mJ/cm2.  
       Although there was no significant increase on PGE3 and PGD3 when 
46BR.1N cells were treated with 10 µM of EPA, higher concentration of EPA (50 
µM) increased the levels of PGE3 but not PGD3 and this was significant 
(p≤0.001) compared to the corresponding controls (FA(-)/UVR(-)). (data shown 
in figure 6.17B and 6.18B). In order to see if EPA have an effects on PGE3 and 
PGD3 after UVR, fatty acid treated and irradiated cells were compared to 
irradiated cells (FA(-)/UVR (+)) and this results are shown in Figure 6.17B. We 
observed that low dose of EPA (10 µM) had no significantly effect on PGE3 and 
PGD3 when compared to irradiated cells. However, a significantly increase in 
PGE3 was observed when 46BR.1N cells were treated with 50µM EPA (p≤0.001) 
and were exposed to 15mJ/cm2 UVR comparing to the irradiated corresponding 
control (FA(-) / UVR (+)) (Figure 6.17 and 6.18). This was not noted for PGD3. 
          Finally, when cells were treated with DHA (10 and 50 µM) PGE3 and 
PGD3 appeared increased. Also there were no significant differences on PGE3 
and PGD3 levels when the 46BR.1N cells were treated with 10 and 50 µM DHA 
and exposed to 15 mJ/cm2. (Figure 6.17C and 6.18C).                       .                                             
A summary of the effect of UVR and n-3 PUFA on series-1, -2 and -3 
prostanoids are shown in Table (6.3). 
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Figure 6.17. Effect of UVR and fatty acid treatment, (A) oleic acid (OA), (B) eicosa 
pentaenoic acid (EPA) and (C) docosahexaenoic acid (DHA) on PGE3 produced by 
46BR.1N fibroblasts 24 h post UVR (15 mJ/cm2). Cells were treated with two 
concentrations of each fatty acid (10µM and 50 µM) for 72h. Results are shown as 
mean ± SD for 3 independent experiments (each one performed in duplicate). *≤0.05, 
**≤0.01 ∆∆∆p≤0.001, *=comparing to non-irradiated control (FA(-)/UVR(-)). 
∆=comparing to irradiated control (FA (-)/UVR(+)). 
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Figure 6.18. Effect of UVR and fatty acid treatment, (A) oleic acid (OA), (B) eicosa-
pentaenoic acid (EPA) and (C) docosahexaenoic acid (DHA) on PGD3 produced by 
46BR.1N fibroblasts 24 h post UVR (15 mJ/cm2). Cells were treated with two 
concentrations of each fatty acid (10µM and 50 µM) for 72h. Results are shown as 
mean ± SD for 3 independent experiments (each one performed in duplicate).  
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Table 6.3. Summary of the effect of UVR and n-3 PUFA treatment on the 
prostanoid mediators produced by 46BR.1N fibroblasts 
 
 
UVR 
(15mJ/cm2) 
No UVR UVR (15mJ/cm2) 
Compound EPA DHA EPA DHA 
PGE1 * * ــــــ Δ Δ 
PGD1 ــــــ ــــــ ــــــ ــــــ ــــــ 
PGE2 * ــــــ ــــــ Δ Δ 
PGD2 ــــــ ــــــ ــــــ ــــــ ــــــ 
PGE3 * * ــــــ Δ ــــــ 
PGD3 ــــــ ــــــ ــــــ ــــــ ــــــ 
15-keto PGE2 * ــــــ ــــــ ــــــ ــــــ 
13,14dihydro-
15-PGE1 
* ــــــ ــــــ ــــــ ــــــ 
13,14dihydro-
15-PGE2 
ــــــ ــــــ ــــــ ــــــ ــــــ 
 
ــــــ= No significant effect 
  = Significant decrease 
  = Significant increase 
*= compared to untreated  cells (FA(-)/UVR (-)) 
Δ= compared to untreated irradiated cells (FA(-)/UVR (+)) 
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6.4. Discussion  
          This study has demonstrated that prostaglandin profiles of both HaCaT 
keratinocytes and 46BR.1N fibroblasts cells were the same. Moreover, the 
results show that 46BR.1N fibroblasts produced more prostaglandins than 
HaCaT keratinocytes as shown in Table 6.1. The results also show that the 
concentration of PGE2 and its inactivation products were great than PGE1 and 
PGE3 and their inactivation products. This may be because the level of AA, 
which is the precursor of PGE2, in these cells is more than DGLA and EPA, 
which are the precursors of PGE1 and PGE3 respectively. This is supported by 
the analysis of the contents of these fatty acids in these cells, the data on which 
are shown in Table 5.1. The results of this study shown that PGE2 is the main 
PG in HaCaT at 12.17% of total lipid and at 17.6% in 46BR.1N fibroblasts. It 
has been reported that PGE2 (26%) was the major PGs product in cultured 
human skin fibroblasts (Mayer et al., 1984), and the results of this study agree 
with this.   
          It has been reported that UVR is responsible for cutaneous damage after 
acute or chronic exposure. This causes many cellular and pathological changes 
including DNA damage and release of pro-inflammatory mediators such as 
PGE2 (Filip et al., 2011). Use of photoprotective agents is one way of protecting 
skin from the harmful effects of UVR. Recently, natural compounds have been 
considered as skin protectors. In this study, we have shown that n-3 PUFA 
could be an effective therapeutic natural material for protection against UVB-
induced inflammatory mediators.  
          The results of this study show that, when HaCaT cells were exposed to 
15 mJ/cm2 UVR, the concentration of PGE1 and PGE2 were significantly 
196 
 
increased (Figures 6.1 and 6.4). This is in agreement with other reports showing 
that an increased PGE2 level was found in HaCaT cells exposed to 6 mJ/cm
2 
UVR (Judson et al., 2010). It has been reported that when HaCaT cells were 
exposed to 60 mJ/cm2 UVB, the level of PGE2 also increased compared to non-
irradiated cells. Another study reported increases in PGE2 levels when HaCaT 
cells were exposed to100mJ/cm2, and after 48h (Storey et al., 2007). PGE2 
concentration was also increased when HaCaT cells were exposed to 250J/m2 
(Chen et al., 2001). Buckman et al (1998) found increased PGE2 when primary 
adult human keratinocytes were irradiated with 30 mJ/cm2 UVB (Buckman et al., 
1998). Increase in PGE2 was also observed in normal human keratinocytes 
when were exposed to 32 mJ/cm2 UVB (Pupe et al., 2002). Furthermore, in a 
clinical study, the level of PGE2 was increased in association with increased 
COX-2 expression in 32 healthy volunteers exposed to 4-MED for 72 h (Rhodes 
et al., 2009). 
          It is possible that UVR increased levels of PGs found in skin may also 
reflect the reduced catabolism of these PGs in addition to an increase in their 
synthesis. This could be attributed to increased expression of COX-2, which 
plays a major role in PG synthesis, and a decrease or suppression of the 
expression of 15-PGDH, which plays a major role in PG catabolism.  Findings in 
the present study suggest that both PGE1 and PGE2 and their inactivation 
products, 13,14-dihydro-15-keto-PGE1, 13,14-dihydro-15-keto-PGE2 and 15-
keto-PGE2, were increased post UVR treatment. Increased levels of the 
inactivation products of PGE1 and PGE2 may be a normal result of the cell 
haemostasis. Increased levels of PG inactivation were reported by Rhodes et al 
(2009). They reported that 13,14-dihydro-15-keto-PGE1, 13,14-dihydro-15-keto-
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PGE2 and 15-keto-PGE2 were significantly increased post UVR in 32 healthy 
humans. However, Judson et al reported that UVR (6 mJ/cm2 UVB) decreased 
15-PGDH protein, mRNA and enzyme activity in HaCaT cells. (Judson et al., 
2010). We also found that PGE3 concentration was increased after UVR 
treatment, as also reported by Rhodes et al (2009). 
           The results suggest that treating HaCaT cells with OA had no effect in 
the production of COX mediators. According to the hypothesis and experimental 
design, this was expected. Furthermore, these results confirm that OA, which 
was chosen as a control in this study did not convert into EPA or DHA. 
Conversely, n-3 PUFA EPA and DHA increased PGE3 and decreased PGE1 
and PGE2 post 15 mJ/cm
2 UVR. Other studies are in agreement with our results; 
normal human keratinocyte treated with 50 µM EPA resulted in a marked 
decrease in PGE2 level post 32 mJ/cm
2 UVB, which was most apparent at     
24h post irradiation, and PGE2 levels were reduced four-fold compared to non-
irradiated cells (Pupe et al., 2002). In a study where HaCaT cells were treated 
with 50µM EPA and DHA this was found to inhibit UVB-induced inflammation by 
modulation the interleukin (IL)-8 but there was no such effect when the cells 
were treated with 50µM OA (Storey et al., 2007). In contrast, induced COX-2 
expression through increased activation of γPPAR was found when HaCaT 
cells were treated with DHA (Chene et al., 2007) 
          The results of this study show that treating 46BR.1N cell fibroblasts with 
OA, EPA and DHA had no effect on the baseline level of series-1 
prostaglandins (PGE1, PGD1 and 13,14-dihydro-15-ketoPGE1). Although the 
levels of these prostaglandins increased when 46BR.1N cell were exposed to 
15mJ/cm2, this was not affected by the OA, EPA and DHA treatment. Our 
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results also showed that there was no effect of these fatty acids on series-2 
prostaglandins at baseline (Figure 6.13-16). Exposing the cells to 15mJ/cm2 
showed statistically significant changes in the levels of PGE2. A similar increase 
in PGE2 level was observed when CCD922SK normal human breast skin 
fibroblasts were exposed to 100mJ/cm2 UVB (Storey et al., 2007), and when 
cultured human skin fibroblasts were treated with 150mJ/cm2 UVB (Filipe et al., 
1995).  
         Treatment of 46BR.1N with OA did not affect the UVB-induced PGE2 
production. EPA reduced the level of PGE2 but this was not statistically 
significant and only DHA had a significant effect and reduced the UVB-induced 
PGE2. Treating CCD922SK cells (skin fibroblasts) with 50µM EPA and DHA 
inhibited UVB induced inflammation by modulation of IL-8 (Storey et al., 2007). 
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Chapter 7. Effect of UVR and n-3 PUFA on hydroxy fatty 
acids production in skin cells  
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7.1 Introduction 
         Lipoxygenases found in  skin can metabolise C18 and C20 PUFA to 
produce predominantly monohydroxy fatty acids: AA is metabolised by  5-LOX 
to 5-HETE, by 12-LOX to 12-HETE and by 15-LOX to 15-HETE (Ziboh, 1992).       
It has been suggested that 5-HETE itself does not play a significant role in 
biological signalling, but it is further reduced by 5-hydroxyeicosatetraenoic acid 
dehydrogenase to form the bioactive 5-oxo-eicosatetraenoic acid (5-oxoETE) 
(Powell and Rokach, 2005). Studies in human neutrophil reported that 5-
oxoETE is a potent stimulator of calcium mobilisation and cell migration. 5-
HETE has a similar role to 5-oxoETE but it is as much as 100 times less (Powell 
et al., 1993). An in vivo study has shown that intradermal injection of 5-oxoETE 
in humans led to infiltration of neutrophils into the skin (Muro et al., 2003). 
Moreover, 5-oxoETE has been found to be a potent simulator of human 
eosinophil migration with a potency up to 30 times greater than LTB4 (Powell et 
al., 1995). These results suggest that 5-oxo-ETE may be an important mediator 
of inflammation. 
        12-HETE is the main AA metabolite found in skin (Ruzicka et al., 1983), 
and is believed to have both a physiologic role in the biology of cutaneous 
reparative processes and pathophysiologic effects in inflammatory skin 
diseases such as psoriasis, atopic eczema and contact dermatitis (Black et al., 
1985a, Dowd et al., 1987). intradermal injection of 12-HETE in guinea pigs  led 
to an increase in the number of infiltrated neutrophils and eosinophils into the 
skin (Waldman et al., 1989). It has also been reported that 12-HETE can be a 
chemo-attractant for lymphocytes in addition to neutrophils (Bacon et al., 1988). 
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          15-HETE and 15-HETrE are believed to have potent anti-inflammatory 
properties (Ziboh, 1992). The supplementation of diets with appropriate purified 
vegetable oil and/or fish oil may help to improve cutaneous inflammatory 
reactions and disorders (Ziboh, 1992). Many studies found that supplementation 
with DGLA (precursor of 15-HETrE) led to improvement in atopic dermatitis 
(Wright and Burton, 1982, Fiocchi et al., 1994) and eczema (Henz et al., 1999). 
It has been reported that LTB4 induced skin reaction which lasted up to 18 h 
after the injection. A significant decrease was observed when LTB4 was injected 
together with 300 ng of 15-HETE and the skin reaction was reduced 1 h after 
the injection. These results support the role of 15-HETE as a pro-inflammatory 
mediator (Ternowitz et al., 1989). Furthermore, dermis-derived 15-HETE inhibits 
epidermal 12-LOX activity (Kragballe et al., 1986), and significant inhibition of 
12-LOX expression was found when HaCaT cells were treated with 15-HETE 
(Yoo et al., 2008). 
         The lipid mediator system in the body depends on the presence of PUFA 
and the ratio of n-6 PUFA to n-3 PUFA. Supplementation with n-3 PUFA has 
been shown to increase the level of anti-inflammatory mediators (Yang et al., 
2004, Bagga et al., 2003). With the use of mass spectrometry, it has been 
shown that EPA and DHA generate potent anti-inflammatory mediators that are 
implicated in the resolution of inflammation. 18-HEPE and 17-HDHA have been 
identified as precursors of RvE and RvD respectively (Hong et al., 2003, 
Marcheselli et al., 2003, Arita et al., 2005). However, this has not yet been 
shown in the skin. 
          UVR is one of main factors capable of modulating various cell-surface 
molecules. It has been reported that treating HaCaT cells with 100, 200 and 
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300J/m2 UVB has produced a significant dose-dependent decrease of 12-LOX 
and a significant dose-dependent increase of 15-LOX expression (Yoo et al., 
2008). The same result was also found when HaCaT cells were exposed to 10, 
20 and 30 J/m2 UVA (Yoo et al., 2008). A study of 32 healthy adult subjects 
showed up-regulation of 12-HETE and 15-HETE production in human skin 
expression following UVR exposure (Nicolaou et al., 2012, Rhodes et al., 2009). 
Furthermore, exposure of the human epidermal cell line SCL-II to 100-300 J/m2 
UVB led to the modulation of 12-HETE receptors and a large decrease in 12-
HETE binding sites (Kemeny et al., 1991).  
          This part of the study aimed to study the hydroxy fatty acid  production by 
HaCaT keratinocytes and 46BR.1N fibroblasts, and anwser the following 
question: 
A) What kind of hydroxy fatty acids are produced by these cells? 
B) Is there any effect of UVR in hydroxy fatty acids  production? 
C) What is the effect of n-3PUFA in hydroxy fatty acid  production with and 
without UVR treatment? 
7.2. Methods 
         All information relevant to the experiments reported in this study is 
presented in section 2.2. Cell culture and passaging in section 2.2.3.2 and cell 
counting in section 2.2.3.2. Exposure of cells to UVR is in section 2.2.3.3.2. 
Section 2.2.3.4 describes the treatment of cells with fatty acids and section 
2.2.3.5 shows the collection of cells and media. Hydroxy fatty acid analysis is 
reported in section 2.4 including sample preparation and LC/ESI-MS/MS 
analysis.  
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7.3 Results 
7.3.1. Hydroxy fatty acid profile in HaCaT and 46BR.1N cells 
          In order to measure the baseline concentration of hydroxy fatty acids 
produced by HaCaT keratinocytes and 46BR.1N fibroblasts, the cells were 
cultured and medium was collected and analysed by LC/ESI-MS/MS. 25 
Hydroxy fatty acids were detected in both cells (Table 7.1). 
          Table 7.1 shows the concentration (pg/million cell) of the hydroxy fatty 
acids present in HaCaT keratinocytes and 46BR.1N fibroblasts. It is clear that 
46BR.1N produce more hydroxy fatty acids than HaCaT cells. HODE are 
formed from LA. The concentration of 13-HODE was high than 9-HODE and 
this was found to be the most abundant hydroxy fatty acid in HaCaT (15.7%) 
and 46BR.1N (28.3%) cells. EPA is the precursor of HEPE. Seven types of 
HEPE were found in both cells with 15-HEPE being the main HEPE followed by 
9-HEPE. 15-HEPE was the third abundant hydroxy fatty acid in HaCaT (9.3%) 
and 46BR.1N cells (8%). By the action of lipoxygenases AA is converted to 
HETE. 12-HETE which is generated by the action of 12-LOX was found at 
higher concentration in HaCaT (12%) and 46BR.1N (11%). 15-HETE which is 
generated by 15-LOX was found at lower concentration on 3.3% and 3.1%, 
respectively. DHA is the precursor of the HDHA. 17-HDHA is generated by the 
action of 15-LOX and was found in both HaCaT (7.3%) and 46BR.1N (4.9%). 
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Table 7.1. Profile of hydroxy fatty acids produced by HaCaT and 46BR.1N. 
 HaCaT HaCaT 46BR.1N 46BR.1N 
 pg/million cell % of total 
pg/million cell % of total 
9-HODE 10.78 ± 5.0 9.1 33.7 ± 11.7 5.4 
13-HODE 18.52 ± 6.8 15.7 188.1 ± 18.7 28.3 
5-HEPE 1.47 ± 0.1 1.2 2.9  ± 1.0 0.4 
18-HEPE 2.32 ± 1.3 2.0 20.0 ± 1.7 3.0 
9-HEPE 3.83 ± 2.1 3.3 50.4 ± 24.4 7.6 
8-HEPE 3.83 ± 1.9 3.3 3.8 ± 0.9 0.6 
11-HEPE 3.19 ± 0.6 2.7 34.7 ± 15.2 5.2 
15-HEPE 11.00 ± 2.7 9.3 52.9 ± 14.9 8.0 
12-HEPE 1.79 ± 0.6 1.5 8.1 ± 2.4 1.2 
5-OXOETE 3.98 ± 1.6 3.4 4.2 ± 3.8 0.6 
14(15)EET 2.51 ± 0.9 2.1 4.2 ± 3.8 0.6 
5-HETE 2.45 ± 0.6 2.1 6.1 ±0.3 0.9 
9-HETE 2.88 ± 1.0 2.4 2.5 ± 0.7 0.4 
8-HETE 1.78 ± 0.7 1.5 3.3 ± 1.2 0.5 
11-HETE 1.12 ± 0.3 1.0 24.0 ± 5.1 3.6 
15-HETE 3.94 ± 1.0 3.3 20.5 ± 4.4 3.1 
12-HETE 13.57 ± 8.6 11.5 73.4 ± 9.6 11.0 
15-HETrE 0.65 ± 0.2 0.5 8.2 ± 1.9 1.2 
14,15-DHET 1.78 ± 0.5 1.5 3.9 ± 2.0 0.6 
10-HDHA 2.39 ± 1.6 2.0 2.7 ± 0.6 0.4 
14-HDHA 5.33 ± 3.5 4.5 10.3 ± 4.4 1.6 
13-HDHA 1.79 ± 1.4 1.5 23.1 ± 3.1 3.5 
17-HDHA 8.37 ± 2.3 7.1 32.6 ± 10.6 4.9 
20-HDHA 8.65 ± 3.2 7.3 8.5 ± 1.3 1.3 
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7.3.2. The effect of fatty acid and UVR treatment on hydroxy fatty acids 
produced by HaCaT keratinocytes 
7.3.2.1. The effect of fatty acid and UVR treatment on HODE 
          As shown in Figure 7.1 the levels of 9-HODE and 13-HODE appeared 
increased when HaCaT cells were exposed to 15mJ/cm2 UVR. However, this 
was statistically significantly (p≤0.05 and p≤0.05, respectively) when compared 
to non-irradiated control (FA(-)/UVR(-)).  
          In order to assess the effect of FA treatment on HODE production by 
HaCaT cells, cells were treated with 10 and 50µM of OA, EPA and DHA and 
exposed to UVR. Media were collected and analysed. HaCaT cells treated with 
OA 10 and 50µM showed no significant effect on 9-, 13-HODE at baseline or 
post UVR when compared to corresponding control (Figures 7.1). 
         HaCaT treated with 10 and 50µM EPA showed no significant decreased 
on 9-HODE and 13-HODE at baseline compared to non-irradiated control (FA(-
)/UVR(-)). Significant decrease in 9-,13-HODE (p≤0.01, p≤0.05, respectively) 
levels was when HaCaT cells were treated with 50µM EPA and exposed to 
15mJ/cm2 compared to irradiated control (FA (-)/UVR(+)).(Figures7.1)  
          Finally, HaCaT cells treated with 10 and 50µM DHA showed no 
significant decreased on 9-,13-HODE at the baseline compared to non-
irradiated control (FA(-)/UVR(-)). Significant decrease in 9-HODE (p≤0.05, 
p≤0.01) level was observed when the cells were treated with 10 and 50µM DHA, 
respectively. While 13-HODE (p≤0.05) was significant decrease when the cells 
were treated with 50µM DHA compared to irradiated control (FA (-)/UVR(+)). 
Results are shown in Figures 7.1. 
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Figure 7.1. Effect of UVR and fatty acid treatment, oleic acid (OA), eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA) on HODE produced by HaCaT 
keratinocyte 24h post UVR (15 mJ/cm2). Cells were treated with two concentrations of 
each fatty acid (10µM and 50 µM) for 72h. Results are shown as mean ± SD for 3 
independent experiments (each one performed in duplicate). *∆p≤0.05, **Δ∆p≤0.01, 
*=compared to non-irradiated control (FA(-)/UVR(-)). ∆=compared to irradiated control 
(FA (-)/UVR(+)). 
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7.3.2.2. The effect of UVR and fatty acid treatment on HEPE 
                    Seven HEPE were detected in HaCaT. However, 5 mediators were 
significantly increased 5-,9-,11-,12- and 18-HEPE (p≤0.05, p≤0.01,p≤0.001, 
p≤0.05 and p≤0.01; respectively) when cells were exposure to 15mJ/cm2 UVR, 
compared to non-irradiated control (FA(-)/UVR(-)).Figure (7.2-4). 
        As shown in Figure 7.2, there was no effect of OA (10 and 50 µM) on the 
level of HEPE mediators at the baseline when compared to non-irradiated 
control (FA(-)/UVR(-)). Also no significant difference on HEPE mediators was 
found when 10, 50 µM OA treated HaCaT were exposed to 15mJ/cm2 
compared to irradiated control (FA (-)/UVR(+)). 
         Treated HaCaT cells with EPA (10 and 50 µM) showed significant 
increased on the level of 5-, 9-, 12-, 15- and 18-HEPE ((p≤0.05,0.01), 
(p≤0.01,0.01), (p≤0.05,0.05), (p≤0.05,0.05) and (p≤0.05, 0.05), respectively), 
when compared to non-irradiated control (FA(-)/UVR(-)). An increase in these 
mediators was also observed when HaCaT cells treated with 10 and 50 µM of 
EPA were exposed to 15 mJ/cm2 UVR, but only 5-,15-HEPE were statistically 
significant (p≤0.05 and 0.005) after 50 µM of EPA. (Figure 7.3) 
        HaCaT treated with 10 µM of DHA showed no significant increase in HEPE 
mediators. However, treated with 50 µM DHA showed significant increase in    
5-,9-,11-,12-,15- and 18-HEPE (p≤0.01, p≤0.01, p=0.05, p≤0.05, p≤0.05 and 
p≤0.01; respectively) compared to non-irradiated control (FA(-)/UVR(-)). Also, 8-
,12-HEPE were significant increase (p≤0.01 and p≤0.05; respectively) when 
HaCaT treated with 50 µM of DHA exposed to 15mJ/cm2 UVR and compared to 
irradiated control (FA (-)/UVR(+)). (Figure 7.4). 
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Figure 7.2. Effect of UVR and oleic acid (OA) treatment on hydroxy-eicosapentaenoic 
acid (HEPE) mediators produced by HaCaT keratinocytes 24h post UVR (15 mJ/cm2). 
Cells were treated with two concentrations of each fatty acid (10µM and 50 µM) for 
72h. Results are shown as mean ± SD for 3 independent experiments (each one 
performed in duplicate). *p≤0.05, **p≤0.01, *=compared to non-irradiated control (FA(-
)/UVR(-)). ∆=compared to irradiated control (FA (-)/UVR(+)). 
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Figure 7.3. Effect of UVR and eicosapentaenoic acid (EPA) treatment on hydroxy-
eicosapentaenoic acid (HEPE) mediators produced by HaCaT keratinocytes 24h post 
UVR (15 mJ/cm2). Cells were treated with two concentrations of each fatty acid (10µM 
and 50 µM) for 72h. Results are shown as mean ± SD for 3 independent experiments 
(each one performed in duplicate). *p≤0.05, **,∆∆p≤0.01 *=compared to non-irradiated 
control (FA(-)/UVR(-)). ∆=compared to irradiated control (FA (-)/UVR(+)). 
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Figure 7.4. Effect of UVR and docosahexaenoic acid (DHA) treatment on hydroxy-
eicosapentaenoic acid (HEPE) mediators produced by HaCaT keratinocytes 24h post 
UVR (15 mJ/cm2). Cells were treated with two concentrations of each fatty acid (10µM 
and 50 µM) for 72h. Results are shown as mean ± SD for 3 independent experiments 
(each one performed in duplicate). *p≤0.05, **,∆∆p≤0.01 *=compared to non-irradiated 
control (FA(-)/UVR(-)). ∆=compared to irradiated control (FA (-)/UVR(+)). 
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7.3.2.3. The effect of UVR and fatty acid treatment on HETE 
          Six HETE were detected in HaCaT keratinocytes. Exposure to15mJ/cm2 
UVR shown significant increase in the level of 5-HETE (p≤0.05), 8-HETE 
(p≤0.05), 9-HETE (p≤0.05), 11-HETE (p≤0.01), 12-HETE (p≤0.01) and 15-
HETE (p≤0.01) when compared to non-irradiated control (FA(-)/UVR(-)). 
         Figure 7.5 shows the effect of OA (10 and 50 µM) on the level of HETE at 
baseline, there was no significant difference when compared to non-irradiated 
control (FA(-)/UVR(-)). Also no significant difference on HETE was found when 
OA (10 and 50 µM) treated HaCaT were exposed to 15mJ/cm2, compared to 
irradiated control (FA (-)/UVR(+)).  
         Although there was a decrease in the level of HETE mediators after 
treatment with 10 and 50 µM EPA, this was not statistically significant when 
compared to non-irradiated control (FA(-)/UVR(-)).(Figure 7.6). Significant 
decreased in 9-HETE (p≤0.05,0.05) and 11-HETE (p≤0.05,0.05) was observed 
when HaCaT cells were treated with 10 and 50 µM of EPA and exposed to 15 
mJ/cm2 UVR. Also, significant decreased in the level of 5-HETE (p≤0.05) and 8-
HETE (p≤0.05) was noted after treatment with 50 µM of EPA. Compared to 
irradiated control (FA (-)/UVR(+)) (Figure 7.6). No significant decrease in HETE 
was observed when the cells were treated with 10 and 50 µM of DHA compared 
to non-irradiated control (FA(-)/UVR(-)). Significant decreased in 5-HETE 
(p≤0.05,0.05), 11-HETE (p≤0.01,0.05) and 15-HETE (p≤0.05,0.01) was 
observed when HaCaT cells were treated with 10 and 50 µM of DHA and 
exposed to 15 mJ/cm2 UVR. Also, significant decreased in 8-HETE (p≤0.05) 
and 9-HETE (p≤0.05) was observed after treated with 50 µM of DHA. 
Compared to irradiated control (FA (-)/UVR(+)) (Figure 7.7). 
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Figure 7.5. Effect of UVR and oleic acid (OA) treatment on Hydroxy-eicosatetraenoic 
acids (HETE) mediators produced by HaCaT keratinocytes 24h post UVR (15 mJ/cm2). 
Cells were treated with two concentrations of each fatty acid (10µM and 50 µM) for 
72h. Results are shown as mean ± SD for 3 independent experiments (each one 
performed in duplicate). *p≤0.05, **p≤0.01, *=compared to non-irradiated control (FA(-
)/UVR(-)). ∆=compared to irradiated control (FA (-)/UVR(+)). 
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Figure 7.6. Effect of UVR and eicosapentaenoic acid (EPA) treatment on Hydroxy-
eicosatetraenoic acids (HETE) mediators produced by HaCaT keratinocytes 24h post 
UVR (15 mJ/cm2). Cells were treated with two concentrations of each fatty acid (10µM 
and 50 µM) for 72h. Results are shown as mean ± SD for 3 independent experiments 
(each one performed in duplicate). *p≤0.05, **,∆∆p≤0.01 *=compared to non-irradiated 
control (FA(-)/UVR(-)). ∆=compared to irradiated control (FA (-)/UVR(+)). 
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Figure 7.7. Effect of UVR and eicosatetraenoic acid (DHA) treatment on Hydroxy-
eicosatetraenoic acids (HETE) mediators produced by HaCaT keratinocytes 24h post 
UVR (15 mJ/cm2). Cells were treated with two concentrations of each fatty acid (10µM 
and 50 µM) for 72h. Results are shown as mean ± SD for 3 independent experiments 
(each one performed in duplicate). *p≤0.05, **,∆∆p≤0.01 *=compared to non-irradiated 
control (FA(-)/UVR(-)). ∆=compared to irradiated control (FA (-)/UVR(+)). 
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7.3.2.4. The effect of UVR and fatty acid treatment on HDHA 
          Five HDHA were detected in HaCaT cells. Exposing the cells to 
15mJ/cm2 UVR showed significant increased in the level of 13-HDHA (p≤0.05), 
14-HDHA (p≤0.01), 17-HDHA (p≤0.01) and 20-HDHA (p≤0.01) when compared 
to non-irradiated control (FA(-)/UVR(-)). 
          Figure 7.8 shows the effect of OA (10 and 50 µM) on the levels of HDHA 
mediators at the baseline, there was no significant difference when compared to 
non-irradiated control (FA(-)/UVR(-)). Also no significant difference was found 
when HaCaT treated with OA (10 and 50 µM) were exposed to 15mJ/cm2 and 
the result were compared to irradiated control (FA (-)/UVR(+)). 
       Statistically significant increase in the level of 13-HDHA (p≤0.001), 17-
HDHA (p≤0.05) and 20-HDHA (p≤0.01) was observed when HaCaT cell were 
treat with 50 µM EPA and compared to non-irradiated control (FA(-)/UVR(-)) 
(Figure 7.9). Moreover, an increase on these mediators was observed when 
HaCaT cells were treated with 10 and 50 µM of EPA and exposed to 15 mJ/cm2 
UVR but this was not statistically significant compared to irradiated control (FA 
(-)/UVR(+)). 
         Treated HaCaT cell with 10 and 50 µM DHA showed significant increased 
in 10-, 13-, 14-, 17- and 20-HDHA (p≤0.05,0.01), (p≤0.05,0.001), (p≤0.05, 0.05), 
(p≤0.05,0.01) and (p≤0.05,0.01),respectively, compared to non-irradiated 
control (FA(-)/UVR(-)). Also, significant increase in 10-HDHA (p≤0.01),13-HDHA 
(p≤0.001),14-HDHA (p≤0.01) and 17-HDHA (p≤0.01) was noted when HaCaT 
cells were treated with  50 µM DHA and exposed to 15mJ/cm2 compared to 
non-irradiated control (FA(-)/UVR(-)) (Figure 7.10). 
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Figure 7.8. Effect of UVR and oleic acid (OA) treatment on hydroxy-docosahexaenoic 
acid (HDHA) mediators produced by HaCaT keratinocytes 24h post UVR (15 mJ/cm2). 
Cells were treated with two concentrations of each fatty acid (10µM and 50 µM) for 
72h. Results are shown as mean ± SD for 3 independent experiments (each one 
performed in duplicate). *p≤0.05, **p≤0.01, *=compared to non-irradiated control (FA(-
)/UVR(-)). ∆=compared to irradiated control (FA (-)/UVR(+)). 
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Figure 7.9. Effect of UVR and eicosapentaenoic acid (EPA) treatment on hydroxy-
docosahexaenoic acid (HDHA) mediators produced by HaCaT keratinocytes 24h post 
UVR (15 mJ/cm2). Cells were treated with two concentrations of each fatty acid (10µM 
and 50 µM) for 72h. Results are shown as mean ± SD for 3 independent experiments 
(each one performed in duplicate). *p≤0.05, **p≤0.01, *=compared to non-irradiated 
control (FA(-)/UVR(-)). ∆=compared to irradiated control (FA (-)/UVR(+)). 
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Figure 7.10. Effect of UVR and docosahexaenoic acid (DHA) treatment on hydroxy-
docosahexaenoic acid (HDHA) mediators produced by HaCaT keratinocytes 24h post 
UVR (15 mJ/cm2). Cells were treated with two concentrations of each fatty acid (10µM 
and 50 µM) for 72h. Results are shown as mean ± SD for 3 independent experiments 
(each one performed in duplicate). *p≤0.05, **p≤0.01, *=compared to non-irradiated 
control (FA(-)/UVR(-)). ∆=compared to irradiated control (FA (-)/UVR(+)). 
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7.3.2.5. The effect of UVR and fatty acid treatment on 14(15)-EET and       
14, 15-DHET  
          As shown in Figure 7.12, the level of 14,15-EET and 14,15-DHET did not 
change when HaCaT cells were exposed to 15mJ/cm2 UVR and compared to 
non-irradiated control (FA(-)/UVR(-)). 
         HaCaT cells treated with OA (10 and 50µM) showed no significant effect 
in 14(15)-EET and 14,15-DHET levels at baseline when compared to non-
irradiated control (FA(-)/UVR(-)). Also OA had no effect on 14,(15)-EET and 
14,15-DHET post UVR compared to irradiated control (FA (-)/UVR(+)).(Figures 
7.11). 
         HaCaT treated with 10 and 50µM EPA did not have significantly different 
levels of 14(15)-EET and 14,15-DHET at baseline, compared to non-irradiated 
control (FA(-)/UVR(-)). Also no significant increase in 14(15)-EET and 14,15-
DHET was found when HaCaT were treated to EPA and exposed to 15mJ/cm2, 
compared to irradiated control (FA (-)/UVR(+)).(Figures 7.11). 
          Finally, HaCaT treated with 10 and 50µM DHA showed no effect on 
14(15)-EET and 14,15-DHET at baseline compared to non-irradiated control 
(FA(-)/UVR(-)). Also, when exposed to 15mJ/cm2 compared to irradiated control 
(FA (-)/UVR(+)).Result are shows in Figure 7.11. 
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Figure 7.11. Effect of UVR and fatty acid treatment, oleic acid (OA), eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA) on 14(15)EET AND 14,15-DHET 
produced by HaCaT keratinocytes 24h post UVR (15 mJ/cm2). Cells were treated with 
two concentrations of each fatty acid (10µM and 50 µM) for 72h. Results are shown as 
mean ± SD for 3 independent experiments (each one performed in duplicate).  
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7.3.2.6. The effect of UVR and fatty acid treatment on 5-oxo-ETE and 15-
HETrE 
          As shown in Figure 7.12, the levels of 5-oxo-ETE were not statistically 
different when HaCaT cells were exposed to 15mJ/cm2 UVR. While a significant 
increased of 15-HETrE (p≤0.05) was observed when compared to non-
irradiated control (FA(-)/UVR(-)). 
          HaCaT cells treated with OA 10 and 50 µM did not show any significant 
change on 5-oxo-ETE levels at baseline or post UVR when compared to 
corresponding control groups. Also, OA had no significant effect on 15-HETrE 
(Figure 7.13). 
         HaCaT treated with 10 and 50µM EPA, showed some increase in 5-oxo-
ETE at the baseline and post UVR, but this was not statistically significant. Also 
no significant changes in 15-HETrE levels at baseline. 50 µM EPA shown 
significant decreased in 15-HETrE (p≤0.05) post UVR compared to irradiated 
control (FA (-)/UVR(+)).Figure 7.13. 
         Finally HaCaT treated with 10 and 50µM DHA showed no significant 
difference on 5-oxo-ETE and 15-HETrE at baseline when compared to non-
irradiated control (FA(-)/UVR(-)). While 50 µM DHA shown significant decreased 
in 15-HETrE (p≤0.05) post UVR compared to irradiated exposed to 15mJ/cm2 
compared to irradiated control (FA (-)/UVR(+)).Figure 7.13. 
            Summary of the effect of UVR and n-3 PUFA treatment on the hydroxy 
fatty acids mediators produced by HaCaT keratinocyte is shown in Table (7.2). 
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Figure 7.12. Effect of UVR and fatty acid treatment, oleic acid (OA), eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA) treatment on 5-oxoETE and 15-HETrE 
produced by HaCaT keratinocytes 24h post UVR (15 mJ/cm2). Cells were treated with 
two concentrations of each fatty acid (10µM and 50 µM) for 72h. Results are shown as 
mean ± SD for 3 independent experiments (each one performed in duplicate).  
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Table 7.2 Summary of the effect of UVR and n-3 PUFA treatment on the 
hydroxy fatty acids mediators produced by HaCaT keratinocyte 
 
 
UVR 
(15mJ/cm2) 
No UVR UVR (15mJ/cm2) 
 EPA DHA EPA DHA 
9- HODE * ــــــ ــــــ Δ Δ 
13-HODE * ــــــ  ــــــ Δ Δ 
5- HEPE * * * Δ ــــــ 
12- HEPE * * * ــــــ Δ 
15- HEPE * ــــــ ــــــ Δ ــــــ 
18- HEPE * * * ــــــ ــــــ 
5- HETE * ــــــ * Δ Δ 
12- HETE * ــــــ ــــــ ــــــ ــــــ 
15- HETE * ــــــ ــــــ ــــــ Δ 
14- HDHA * ــــــ * ــــــ Δ 
17- HDHA * * * ــــــ Δ 
 
ــــــ= No significant effect 
  = Significant decrease 
  = Significant increase 
*= compared to untreated cells (FA(-)/UVR (-)) 
Δ= compared to untreated irradiated cells (FA(-)/UVR (+)) 
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7.3.3. The effect of UVR and fatty acid treatment on prostanoids produced 
by 46BR.1N fibroblasts 
7.3.3.1. The effect of UVR and fatty acid treatment on HEPE 
        46BR.1N cells treated with 15mJ/cm2 UVR showed significant increased in 
the level of 9-HODE (p≤0.01) and 13-HODE (p≤0.05) when compared to non-
irradiated control (FA(-)/UVR(-)).Results are shown in Figure 7.13. 
               46.BR.1N cells treated with OA 10 and 50µM showed no significant 
changes in 9- and 13-HODE production at the baseline when compared to non-
irradiated control (FA(-)/UVR(-)). Also, OA had no effect on 9-HODE and 13-
HODE levels post UVR, compared to irradiated control (FA (-)/UVR(+)).(Figure 
7.13). 
         46BR.1N treated with 10 and 50µM EPA showed no significant decrease 
on 9-HODE and 13-HODE levels at baseline compared to non-irradiated control 
(FA(-)/UVR(-)). Also, no significant decreased on 9-HODE or 13-HODE was 
found when 46.BR.1N were treated with 10 and 50µM EPA and exposed to 
15mJ/cm2 compared to irradiated control (FA (-)/UVR(+)).(Figures 7.13). 
          Finally, 46.BR.1N treated with 10 and 50µM DHA showed no significant 
decreased of 9-HODE. However, the level of 13-HODE was significant 
decreased (P≤0.05) when cells were treated with 50µM DHA at baseline 
compared, to non-irradiated control (FA(-)/UVR(-)). Also, 10 and 50µM DHA 
shown significant decrease of 9-HODE (p≤0.05, p≤0.05, respectively) and 13-
HODE (p≤0.05, p≤0.05, respectively) levels  post 15mJ/cm2 compared to 
irradiated control (FA (-)/UVR(+)).Result shown in Figures 7.13. 
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Figure 7.13. Effect of UVR and fatty acid treatment, oleic acid (OA),  eicosapentaenoic 
acid(EPA) and docosahexaenoic acid (DHA) on HODE produced by 46BR.1N 
fibroblasts 24h post UVR (15 mJ/cm2). Cells were treated with two concentrations of 
each fatty acid (10µM and 50 µM) for 72h. Results are shown as mean ± SD for 3 
independent experiments (each one performed in duplicate). *∆p≤0.05, *=compared to 
non-irradiated control (FA(-)/UVR(-)). ∆=compared to irradiated control (FA (-)/ UVR(+)). 
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7.3.3.2. The effect of UVR and fatty acid treatment on HEPE  
          Exposure of the 46BR.1N cells to 15mJ/cm2 UVR showed significant 
increase in the level of 5-,8-,9-,11-,12,15 and 18-HEPE (p≤0.05, 0.05, 0.001, 
0.01, 0.01, 0.05 and 0.01; respectively) when compared to non-irradiated 
control (FA(-)/UVR(-)). 
         As shown in Figure 7.14 there was no effect of OA (10 and 50 µM) on the 
level of HEPE mediators at the baseline or post UVR when compared to 
corresponding control  
         46BR.1N treated with 10 and 50µM EPA showed significant increase of  
5-,8-, 9-,11-,12-,15- and 18-HEPE ((p≤0.05,0.05), (p≤0.01, 0.01), (p≤0.01, 0.01), 
(p≤01,0.01), (p≤0.05, 0.001), (p≤0.05, 0.001) and (p≤0.01, 0.001);respectively). 
Also significant increase of 5-, 8-, 9-,11, 12-, 15- and 18-HEPA (p≤0.05,0.01, 
p≤0.05,0.001, p≤0.01, 0.001, p≤0.01,0.01, p≤0.01, 0.001, p≤0.01, 0.01, and 
p≤0.05,0.001; respectively) was observed when 46BR.1N cells were treated 
with 10 and 50 µM of EPA and exposed to 15 mJ/cm2 UVR compared to 
corresponding control.(Figure 7.14). 
         46BR.1N treated with 10 and 50µM DHA showed significant increase of  
5-,8-,11-,12- and 18-HEPE (p≤0.05,0.01, p≤0.01,0.01 p≤0.01, 0.01, p≤0.05,0.01 
and p≤0.05,0.01;respectively). While, 9- and 15-HEPE  (p≤0.01 and p≤0.01; 
respectively)  was significant increase post 50µM DHA. Also The level of 8-,12- 
and 18-HEBE (p≤0.01,0.01, p≤0.01,0.01 and p≤0.05,0.01; respectively) was 
significant increase when cells treated with 10 and 50µM post 15mJ/cm2. 5- and 
15-HEBE (p≤0.01) was significant increase post 50 µM compared to non-
irradiated control (FA(-)/UVR(-)) (Figure 7.22).  
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Figure 7.14. Effect of UVR and oleic acid (OA) treatment on hydroxy-eicosapentaenoic 
acid (HEPE) produced by 46BR.1N fibroblasts 24h post UVR (15 mJ/cm2). Cells were 
treated with two concentrations of each fatty acid (10µM and 50 µM) for 72h. Results 
are shown as mean ± SD for 3 independent experiments (each one performed in 
duplicate). *p≤0.05, **p≤0.01, *=compared to non-irradiated control (FA(-)/UVR(-)). 
∆=compared to irradiated control (FA (-)/UVR(+)). 
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Figure 7.15. Effect of UVR and eicosapentaenoic acid (EPA) treatment on hydroxy-
eicosapentaenoic acid (HEPE) mediators produced by 46BR.1N fibroblasts 24h post 
UVR (15 mJ/cm2). Cells were treated with two concentrations of each fatty acid (10µM 
and 50 µM) for 72h. Results are shown as mean ± SD for 3 independent experiments 
(each one performed in duplicate). *Δp≤0.05, **ΔΔp≤0.01, ***ΔΔΔp≤0.001 *=compared 
to non-irradiated control (FA(-)/UVR(-)). ∆=compared to irradiated control (FA (-
)/UVR(+)). 
0 
1000 
2000 
3000 
4000 
5000 
%
C
O
N
TR
O
L 
5-HEPE 
* 
ΔΔ 
        EPA     -          -       10µM   10µM    50µM  50µM 
        UVR    -          +          -            +            -          + 
* 
* Δ 
0 
1000 
2000 
3000 
%
C
O
N
TR
O
L 
8-HEPE 
** 
* 
** 
ΔΔΔ 
         EPA       -           -      10µM   10µM  50µM  50µM 
         UVR       -           +          -            +            -          + 
Δ 
0 
500 
1000 
1500 
2000 
2500 
%
C
O
N
TR
O
L 
9-HEPE 
** 
** 
ΔΔΔ 
** 
      EPA         -        -       10µM   10µM    50µM  50µM 
      UVR        -        +          -            +            -          + 
ΔΔ 
0 
200 
400 
600 
800 
1000 
%
C
O
N
TR
O
L 
11-HEPE 
** 
** 
ΔΔ ΔΔ 
** 
  EPA         -           -       10µM   10µM    50µM  50µM 
  UVR        -           +          -            +            -          + 
0 
500 
1000 
1500 
2000 
%
C
O
N
TR
O
L 
12-HEPE 
* 
*** 
* 
ΔΔΔ 
ΔΔ 
       EPA       -           -       10µM   10µM   50µM 50µM 
      UVR        -           +          -            +            -          + 
0 
500 
1000 
1500 
2000 
%
C
O
N
TR
O
L 
15-HEPE 
*** ΔΔ 
* * 
ΔΔ 
            EPA    -         -      10µM   10µM   50µM 50µM 
           UVR    -         +          -            +           -          + 
0 
1000 
2000 
3000 
%
C
O
N
TR
O
L 
18-HEPE 
** 
*** 
ΔΔΔ 
      EPA         -         -       10µM   10µM   50µM 50µM 
      UVR        -           +          -            +            -          + 
** 
Δ 
229 
 
     
     
     
                                                    
Figure 7.16. Effect of UVR and docosahexaenoic acid (DHA) treatment on hydroxy-
eicosapentaenoic acid (HEPE) mediators produced by 46BR.1N fibroblasts 24h post 
UVR (15 mJ/cm2). Cells were treated with two concentrations of each fatty acid (10µM 
and 50 µM) for 72h. Results are shown as mean ± SD for 3 independent experiments 
(each one performed in duplicate). *Δp≤0.05, **ΔΔp≤0.01, ***ΔΔΔp≤0.001 *=compared 
to non-irradiated control (FA(-)/UVR(-)). ∆=compared to irradiated control (FA (-
)/UVR(+)). 
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7.3.3.3. The effect of UVR and fatty acid treatment on HETE 
          Six HETE mediators were detected in 46BR.1N cells. Exposure of  the 
cells to 15mJ/cm2 UVR resulted in a significant increase in 5-, 8-, 9-, 11-, 12- 
and 15-HETE (p≤0.01, 0.05, 0.01, 0.01, 0.05 and 0.05; respectively) when 
compared to non-irradiated control (FA(-)/UVR(-)). 
         Figure 7.17 showed the effect of OA (10 and 50 µM) on the levels of 
HETE mediators at baseline, and following exposure to UVR. No statistically 
significant changes were observed when the data was compared to irradiated 
control (FA (-)/UVR(+)). 
         No significant decrease in 46BR.1N cell HETE mediators was observed 
when the cells were treated with 10 and 50 µM of EPA compared to non-
irradiated control (FA(-)/UVR(-)). Moreover, a significant decrease in 12-HETE 
(p≤0.05) and 15-HETE, (p≤0.05) was observed when 46BR.1N cells were 
treated with 50 µM of EPA and exposed to 15 mJ/cm2 UVR. Compared to 
irradiated control (FA (-)/UVR(+)).(Figure 7.18) 
          Finally 46BR.1N treated with 10 and 50µM DHA showed no significant 
decreased in HETE mediators at baseline when compared to non-irradiated 
control (FA(-)/UVR(-)).  Moreover, significant decrease in 9-, 11-, 12- and 15-
HETE (p≤0.01, 0.01, p≤0.01, 0.01, p≤0.05, 0.01 and p≤0.01, 0.01; respectively) 
was observed when 46BR.1N cells were treated with 10 and 50 µM of DHA, 
exposed to 15 mJ/cm2 UVR and compared to irradiated control (FA (-)/UVR(+)). 
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Figure 7.17. Effect of UVR and oleic acid (OA) treatment on hydroxy-eicosatetraenoic 
acid (HETE) mediators produced by 46BR.1N fibroblasts 24h post UVR (15 mJ/cm2). 
Cells were treated with two concentrations of each fatty acid (10µM and 50 µM) for 
72h. Results are shown as mean ± SD for 3 independent experiments (each one 
performed in duplicate). *p≤0.05, **p≤0.01, *=compared to non-irradiated control (FA(-
)/UVR(-)). ∆=compared to irradiated control (FA (-)/UVR(+)). 
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Figure 7.18. Effect of UVR and eicosapentaenoic acid (EPA) treatment on hydroxy-
eicosatetraenoic acid (HETE) mediators produced by 46BR.1N fibroblasts 24h post 
UVR (15 mJ/cm2). Cells were treated with two concentrations of each fatty acid (10µM 
and 50 µM) for 72h. Results are shown as mean ± SD for 3 independent experiments 
(each one performed in duplicate). *Δp≤0.05, **p≤0.01, *=compared to non-irradiated 
control (FA(-)/UVR(-)). ∆=compared to irradiated control (FA (-)/UVR(+)). 
0 
100 
200 
300 
400 
500 
600 
%
 C
O
N
TR
O
L 
5-HETE 
** 
      EPA         -         -       10µM   10µM   50µM 50µM 
      UVR        -         +          -            +            -          + 
0 
50 
100 
150 
200 
250 
300 
350 
400 
%
 C
O
N
TR
O
L 
8-HETE 
* 
      EPA         -         -       10µM   10µM   50µM 50µM 
      UVR        -         +          -            +            -          + 
0 
100 
200 
300 
400 
500 
%
 C
O
N
TR
O
L 
9-HETE 
** 
      EPA         -         -       10µM   10µM   50µM 50µM 
      UVR        -         +          -            +            -          + 
0 
100 
200 
300 
400 
500 
600 
700 
%
 C
O
N
TR
O
L 
11-HETE 
** 
      EPA         -         -       10µM   10µM   50µM 50µM 
      UVR        -         +          -            +            -          + 
0 
50 
100 
150 
200 
250 
300 
350 
%
 C
O
N
TR
O
L 
12-HETE 
* 
      EPA         -         -       10µM   10µM   50µM 50µM 
      UVR        -         +          -            +            -          + 
Δ 
0 
50 
100 
150 
200 
250 
300 
350 
400 
%
 C
O
N
TR
O
L 
15-HETE 
Δ 
* 
      EPA         -         -       10µM   10µM   50µM 50µM 
      UVR        -         +          -            +            -          + 
233 
 
      
     
     
Figure 7.19. Effect of UVR and docosahexaenoic acid (DHA) treatment on hydroxy-
eicosatetraenoic acid (HETE) mediators produced by 46BR.1N fibroblasts 24h post 
UVR (15 mJ/cm2). Cells were treated with two concentrations of each fatty acid (10µM 
and 50 µM) for 72h. Results are shown as mean ± SD for 3 independent experiments 
(each one performed in duplicate). *Δp≤0.05, **ΔΔp≤0.01, *=compared to non-
irradiated control (FA(-)/UVR(-)). ∆=compared to irradiated control (FA (-)/UVR(+)). 
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7.3.3.4. The effect of UVR and fatty acid treatment on HDHA 
          Five HDHA mediators were detected in 46BR.1N cells. Following 
exposure to 15mJ/cm2 UVR, significant increase in the level of 10-, 13-,14-,17- 
and 20-HDHA (p≤0.05, p≤0.05, p≤0.05, p≤0.05 and p≤0.01; respectively) were 
detected when compared to non-irradiated control (FA(-)/UVR(-)). 
        Figure 7.20 shows the effect of OA (10 and 50 µM) on the level of HDHA 
mediators at baseline, and there was no significant difference when compared 
to non-irradiated control (FA(-)/UVR(-)). Also no significant difference on HDHA 
mediators was found when 46BR.1N cells that were treated with OA (10 and 50 
µM) were exposed to 15mJ/cm2 compared to irradiated control (FA (-)/UVR(+)). 
         The results shown in Figure 7.21 present the effect of EPA treatment (10 
and 50 µM) on the level of HDHA mediators on 46BR.1N cells. Although there 
was increase in the level of these mediators after the treatment, this was not 
statistically significant when compared to non-irradiated control (FA(-)/UVR(-)). 
Moreover, an increase these  mediators was observed when 46BR.1N  cells 
were treated with 10 and 50 µM of EPA and exposed to 15 mJ/cm2 UVR but this 
was not statistically significant compared to irradiated control (FA (-)/UVR(+)). 
          The level of 10-, 13-,14-,17- and 20-HDHA were significant increased 
(P≤0.01, 0.001, P≤0.05, 0.001, P≤0.05, 0.01, P≤0.05, 0.001 and P≤0.01, 0.001; 
respectively) when 46BR.1N  cells were treated with 10 and 50 µM of DHA 
compared to non-irradiated control (FA(-)/UVR(-)). Also, the level of 10-,14-,17- 
and 20-HDHA (P≤0.01, 0.001, P≤0.01, 0.01, P≤0.05, 0.01 and P≤0.01, 0.01; 
respectively)  was significant increase post 15mJ/cm2 compared to non-
irradiated control (FA(-)/UVR(-)) (Figure 7.22). 
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Figure 7.20. Effect of UVR and oleic acid (OA) treatment on hydroxy-docosahexaenoic 
acid (HDHA) mediators produced by 46BR.1N fibroblasts 24h post UVR (15 mJ/cm2). 
Cells were treated with two concentrations of each fatty acid (10µM and 50 µM) for 
72h. Results are shown as mean ± SD for 3 independent experiments (each one 
performed in duplicate). *p≤0.05, **p≤0.01, *=compared to non-irradiated control (FA(-
)/UVR(-)).  
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Figure 7.21. Effect of UVR and eicosapentaenoic acid (EPA) treatment on hydroxy-
docosahexaenoic acid (HDHA) mediators produced by 46BR.1N fibroblasts 24h post 
UVR (15 mJ/cm2). Cells were treated with two concentrations of each fatty acid (10µM 
and 50 µM) for 72h. Results are shown as mean ± SD for 3 independent experiments 
(each one performed in duplicate). *p≤0.05, **p≤0.01, *=compared to non-irradiated 
control (FA(-)/UVR(-)). ∆=compared to irradiated control (FA (-)/UVR(+)). 
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Figure 7.22. Effect of UVR and docosahexaenoic acid (DHA) treatment on hydroxy-
docosahexaenoic acid (HDHA) mediators produced by 46BR.1N fibroblasts 24h post 
UVR (15 mJ/cm2). Cells were treated with two concentrations of each fatty acid (10µM 
and 50 µM) for 72h. Results are shown as mean ± SD for 3 independent experiments 
(each one performed in duplicate). *Δp≤0.05, **ΔΔp≤0.01, ***ΔΔΔp≤0.001 *=compared 
to non-irradiated control (FA(-)/UVR(-)). ∆=compared to irradiated control (FA (-
)/UVR(+)). 
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7.3.3.5. The effect of UVR and fatty acid treatment on 14(15)-EET and 14, 
15-DHET  
          As shown in Figure 7.23, the level of 14(15)-EET (p≤0.05) and 14,15-DHET 
(p≤0.05) were significantly increased when HaCaT cells were exposed to 
15mJ/cm2 UVR and compared to non-irradiated control (FA(-)/UVR(-)). 
         46BR.1N cells treated with OA (10 and 50µM) showed no significant 
change in 14(15)-EET and 14,15-DHET levels at baseline when compared to 
non-irradiated control (FA(-)/UVR(-)). Also OA had no effect on 14,(15)-EET and 
14,15-DHET post UVR compared to irradiated control (FA (-)/UVR(+)).(Figures 
7.23). 
         46BR.1N treated with 10 and 50µM EPA did not have significantly 
different levels of 14(15)-EET and 14,15-DHET at baseline, compared to non-
irradiated control (FA(-)/UVR(-)). Also no significant increase in 14(15)-EET and 
14,15-DHET was found when 46BR.1N  were treated to EPA and exposed to 
15mJ/cm2, compared to irradiated control (FA (-)/UVR(+)).(Figure 7.23). 
          Finally, 46BR.1N treated with 10 and 50µM DHA showed no change in 
14(15)-EET and 14,15-DHET at baseline compared to non-irradiated control 
(FA(-)/UVR(-)). Also, when exposed to 15mJ/cm2 compared to irradiated control 
(FA (-)/UVR(+)). Results are shown in Figure 7.23. 
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Figure 7.23. Effect of UVR and fatty acid treatment, oleic acid (OA),  eicosapentaenoic 
acid(EPA) and docosahexaenoic acid (DHA) on 14(15)EET and 14,15-DHET produced 
by 46BR.1N fibroblasts 24h post UVR (15 mJ/cm2). Cells were treated with two 
concentrations of each fatty acid (10µM and 50 µM) for 72h. Results are shown as 
mean ± SD for 3 independent experiments (each one performed in duplicate). *p≤0.001 
*=compared to non-irradiated control (FA(-)/UVR(-)).  
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7.3.3.6. The effect of UVR and fatty acid treatment on 5-OXO-ETE and 15-
HETrE 
                    As shown in Figure 7.12, the levels of 5-oxo-ETE (p=0.013) and 15-
HETrE (p=0.03) were statistically increased when 46BR.1N cells were exposed 
to 15mJ/cm2 UVR and compared to non-irradiated control (FA(-)/UVR(-)). 
           46BR.1N cells treated with OA 10 and 50µM did not shown any 
significant increase on 5-oxo-ETE levels at baseline or post UVR when 
compared to corresponding control groups. Also OA had no significant effect on 
15-HETrE (Figures 7.24). 
         46BR.1N treated with 10 and 50µM EPA, showed some increase in        5-
oxo-ETE at the baseline and post UVR, but this was not statistically significant. 
Also there were no significant changes in 15-HETrE levels at baseline. 50µM 
EPA showed significant decreased in 15-HETrE (p≤0.05) post UVR compared 
to irradiated control (FA (-)/UVR(+)).Figures 7.24. 
         Finally 46BR.1N treated with 10 and 50µM DHA showed no significant 
difference on 5-oxo-ETE and 15-HETrE at baseline when compared to non-
irradiated control (FA(-)/UVR(-)). A significant decrease in 15-HETrE (p≤0.05) 
was observed when cells treated with 50µM DHA, were exposed to 15 mJ/cm2 
and compared to irradiated control (FA (-)/UVR(+)). Figure 7.24. 
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Figure 7.24. Effect of UVR and fatty acid treatment, oleic acid (OA),  eicosapentaenoic 
acid(EPA) and docosahexaenoic acid (DHA) on 5oxoETE and 15-HETrE produced by 
46BR.1N fibroblasts 24h post UVR (15 mJ/cm2). Cells were treated with two 
concentrations of each fatty acid (10µM and 50 µM) for 72h. Results are shown as 
mean ± SD for 3 independent experiments (each one performed in duplicate). 
*Δp≤0.05 *=compared to non-irradiated control (FA(-)/UVR(-)). ∆=compared to 
irradiated control (FA (-)/UVR(+)). 
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Table 7.3. Summary of the effect of UVR and n-3 PUFA treatment on the 
hydroxy fatty acids mediators produced by 46BR.1N fibroblasts. 
 
 
UVR 
(15mJ/cm2) 
No UVR UVR (15mJ/cm2) 
 EPA DHA EPA DHA 
9- HODE * ــــــ ــــــ ــــــ Δ 
13-HODE * ــــــ * ــــــ Δ 
5- HEPE * * * Δ Δ 
12- HEPE * * * Δ Δ 
15- HEPE * * * Δ Δ 
18- HEPE * * * Δ Δ 
5- HETE * ــــــ ــــــ ــــــ ــــــ 
12- HETE * ــــــ ــــــ Δ Δ 
15- HETE * ــــــ ــــــ Δ Δ 
14- HDHA * ــــــ * ــــــ Δ 
17- HDHA * ــــــ * ــــــ Δ 
 
ــــــ= No significant effect 
  = Significant decrease 
  = Significant increase 
*= compared to untreated cells (FA(-)/UVR (-)) 
Δ= compared to untreated irradiated cells (FA(-)/UVR (+)) 
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7.4. Discussion  
          Data in this study have shown that a range of hydroxy fatty acids were 
produced from different fatty acid precursors, including LA, AA, EPA, DHA and 
DGLA in HaCaT and 46BR.1N. At baseline and in both cell lines, 13-HODE was 
the main hydroxy fatty acid generated from LA, 15-HEPE was the main HEPE 
generated form EPA, 12-HETE was the highest AA metabolite, and 17-HDHA 
was the main hydroxy fatty acid generated from DHA. Other hydroxy fatty acids 
were detected including 5-oxoETE, a product of dehydrogenation of 5-HETE 
and 15-HETrE from DGLA. In addition, the epoxide 14(15) EET and its 
metabolite 14,15-DHET were detected in both HaCaT and 46BR.1N cells. 
Overall, 13-HODE (15.7%, 28.3%) was found to be the most abundant hydroxy 
fatty acid in HaCaT and 46BR.1N cells followed by 12-HETE (12%, 11%) and 
15-HEPE (9.3%, 8%). In agreement with this study 13-HODE  was reported to 
be the main hydroxy fatty acid in epidermal guinea pigs (Miller et al., 1990). 
Many studies have reported that 12- HETE is the main pro-inflammatory 
mediator produced from AA in the skin (Rhodes et al., 2009). Moreover, 12-
HETE has been found to be the main hydroxy fatty acid in human epidermal 
cells (Henneickevonzepelin et al., 1991). A study in human skin fibroblasts 
reported that only 4.5% of the lipid extract was monohydroxy fatty acids and this 
fraction contained 12-hydroxy-5,8,10-heptadecatrienoic acid (HHT) 33%, 15-
HETE 31% and  11-HETE 22%. No other monohydroxy fatty acids were 
detected in that study, but this was an old paper whose method may not have 
been very sensitive (Mayer et al., 1984). The paper concluded that 15-HETE is 
the main LOX product in human skin fibroblasts, where 12-HETE is the main 
LOX product found in this study. The high levels of 13-HODE and 12-HETE 
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may reflect their precursors LA and AA, respectively, which are the most 
abundant PUFAs in the skin (Tables 3.2 and 5.1). 
         The epoxy fatty acid 14,(15)-EET was detected in HaCaT and 46BR.1N 
cells at low levels (2% and 0.6% respectively).  The dihydroxy fatty acid 14, 15-
DHET was also detected in HaCaT and 46BR.1N cells at 2% and 0.6% 
respectively. It is known that EETs are hydrated by the cytosolic epoxide 
hydrolase to give the inactive DHET (Zeldin et al., 1995). A study on human 
skin fibroblasts reported another metabolic pathway for 11,12- and 14,15-EET: 
EETs are converted to the chain-shortened epoxy-fatty acids of DHET by β-
oxidation. They are produced when the fibroblasts are exposed to a relatively 
high concentration of EET. This suggests that partial β-oxidation, rather than 
hydration by epoxide hydrolase, is the main pathway for EET metabolism in 
human fibroblasts (Fang et al., 2000). 
           The present study has shown that exposing HaCaT and 46BR.1N cells 
to 15mJ/cm2 UVR produced significant increases in most hydroxy fatty acids at 
24h post UVR. Rhodes et al (2009) reported that 8, 11, 12 and 15-HETE were 
significantly increased post UVR in the skin of 32 healthy human volunteers 
(Rhodes et al., 2009). 12-HETE has also been found to be increased after UV 
exposure in a study of skin blister fluid in six subjects (Black et al., 1985) and in 
dermal microdialysate in three subjects (Grundmann et al., 2004). 12-LOX is the 
key enzyme producing 12-HETE. Exposure of HaCaT cells to UVB and UVA 
showed a dose-dependent decrease in the level of 12-LOX expression in 
HaCaT keratinocytes (Yoo et al., 2008). 
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          The results of this study show that treatment of HaCaT and 46BR.1N with 
EPA led to an increase of most HEPE mediators and some HDHA mediators, 
and decreased HODE and HETE production, especially post UVR. EPA is the 
precursor of HEPE, and the increase in these mediators after EPA treatment 
reflects the increase in EPA content in HaCaT and 46BR.1N. Meanwhile, 
increased HDHA mediators after EPA treatment may reflect the conversion of 
EPA to DHA. Furthermore, we found an increase in both HDHA and HEPE after 
treatment with DHA which reflects the increase of DHA content or conversion of 
DHA to EPA in HaCaT and 46BR.1N. The effect of PUFA on LOX products has 
also been studied in guinea pigs. Increased 15-HEPE was noted in animals fed 
with fish oil and increases in 15-HETrE was noted in animals fed with GLA 
(Miller et al., 1990). Another animal study shows increase EPA and DHA in 
epidermal phospholipids and their mediators, 15-HEPE and 17-HDHA, after 
supplementation with n-3 PUFA ethyl esters (Miller et al., 1991) 
          The results of this study show that both cells HaCaT keratinocytes and 
46BR.1N fibroblasts can produce high levels of hydroxy fatty acids. However, 
46BR.1N fibroblasts produce more of these than HaCaT keratinocytes do. 
Exposure of HaCaT and 46BR.1N to 15mJ/cm2 UVR showed significant 
increases in HODE, HEPE, HETE and HDHA. Cells treated with EPA and DHA 
showed a significant decrease in the level of HODE and HETE mediators. 
Meanwhile, significant increases were found in HEPA and HDHA mediators 
post UVR and FA treatment. As a result, it seems that increased HODE and 
HETE may result from the effect of UVR on the LOX, while the increase in 
HEPE and HDHA may be a result not only of the effect of UVR on LOX, but also 
of the presence of their precursors (EPA and DHA respectively).   
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8.1. Discussion  
          The human skin is a complex multilayered organ with several specialised 
appendages   (Freinkel and Woodley, 2001). It is identified as the largest and 
one of the most important organs in the body (Bos, 2005), and it acts as a 
barrier between the body and external environment. The skin plays an important 
role in regulating body homeostasis by minimising water loss and regulating 
body temperature. Moreover, the nerve endings in the skin react to pain and 
temperature, and skin is an essential part of the immune system (Katunina, 
2011). Skin condition and functioning are affected by environmental factors, 
such as UVR, free radicals, and toxic and allergic compounds, and by 
endogenous factors, such as genetic predisposition, immune and hormone 
status, and stress. Fatty acids and their derivates are considered important 
cellular structural and functional components. In the skin, fatty acids are 
important for the multilamellar lipid bilayer which regulates the permeability 
barrier and prevents excessive water loss and the entry of harmful substances 
into the skin (Proksck, 1999). 
          In this study, as shown in Table 5.1, the fatty acid profile of HaCaT 
epidermal keratinocytes (human cell line) and 46BR.1N dermal fibroblasts 
(human cell line) showed differences in their fatty acids composition; MUFA 
(54.22%) was the main group followed by SFA (37.11%), while OA (26.47%) 
was the main fatty acid followed by palmitic acid (18.96%) in HaCaT 
keratinocytes. Meanwhile, in 46BR.1N the SFA (51.94%) was the main group 
followed by MUFA (27.07%), and stearic acid (26.83%) was the main fatty acid 
followed by palmitic acid (20.68%). AA was the main n-6 PUFA and it was 
higher in 46BR.1N (8.40%) than in HaCaT (3.04%). Finally, DHA was found to 
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be the main n-3 PUFA and it was higher in 46BR.1N (2.68%) than in HaCaT 
(1.13%). These differences in the fatty acid composition of the epidermal and 
dermal cells could be quite useful for understanding the function and 
biochemistry of these histologically different regions of the skin (Uchida et al., 
1988). However, more is known about the composition of fatty acids in human 
skin tissue and skin cell lines or about any changes in this composition during 
disease and cancer development (Mahadik et al., 1996). 
          We know that skin is the foremost organ protecting the body against 
environmental injuries, especially UVR in sun-light. It has been shown that UVR 
can damage biological macromolecules such as nucleic acids, lipids and 
proteins (Tsoyi et al., 2008). Furthermore, immune-suppression, carcinogenesis 
and apoptotic skin cell death are the result of chronic exposure to UVB. The 
inflammatory changes in response to acute UVB exposure on the skin include 
up-regulation of pro-inflammatory enzymes and their products. Numerous 
studies have shown that UVB irradiation significantly increased both mRNA and 
protein levels of COX-2 (Isoherranen et al., 1999, Rhodes et al., 2009, Lee et 
al., 2013b, Buckman et al., 1998). This in turn increases the production of pro-
inflammatory mediators such as cytokines and PGs, specifically PGE2 which 
has been reported to cause pain, oedema and vasodilatation in the inflamed 
regions (Mitchell et al., 1995, Siqueira et al., 2002).  
          Recently, attention has been focused on administering natural materials 
to protect skin against UV radiation. Diet has been recognised as a safe method 
of protecting the skin. Anti-inflammatory n-3 PUFAs have been suggested to 
have a beneficial role in keeping skin healthy and preventing disease. The 
purpose of this study was to measure and evaluate the protective effect of n-3 
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PUFAs, especially EPA and DHA, on skin cells against UVR, using a model 
system comprising HaCaT keratinocytes and 46BR.1N fibroblastic cells. Cells 
were treated with EPA, DHA and OA, and were exposed to UVR.  
          Competition with n-6 PUFA is one of the mechanisms behind the             
n-3 PUFA mediated protection. The result of this study showed that, treating 
HaCaT and 46BR.1N cells with EPA and DHA increased their cellular 
concentrations (chapter 5). More specifically, HaCaT cells treated with EPA 
resulted in significant increases of EPA, DPA and DHA, but AA was not affected 
by the EPA treatment. Increased EPA, DPA and DHA and decreased AA were 
observed when HaCaT cells were treated with DHA. Treating 46BR.1N cells 
with EPA resulted in significant increases of EPA, DPA and DHA but no 
significant decrease of AA. Increases of EPA, DPA and DHA and decrease of 
AA were observed when 46BR.1N cells were treated with DHA. Increased DPA 
and DHA after EPA treatment reflect its further metabolism by elongation 
enzymes. Unexpectedly, an increase of EPA and DPA content after DHA 
treatment not only indicates that DHA was incorporated into the cells, but also 
demonstrates the ability of these cells to retro-convert DHA to EPA and DPA. 
Conversion of DHA to EPA takes place in peroxisomes by the action of Δ4 
enoyl reductase and Δ2, Δ3 enoyl CoA isomerise enzymes (Vidgren et al., 
1997). In addition, an increase in the concentration of DPA after DHA treatment 
could be a result of saturation of DHA (Vidgren et al., 1997).  
         N-3 PUFA can alter signal transduction. When humans ingest up to 1.6 
gm of EPA per day, a dose-related replacement of membrane PUFAs occurs. 
According to Flower and Perretti (2005), this result is achieved more effectively 
when the amount of AA in the diet is simultaneously reduced (Flower and 
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Perretti, 2005). Further to the above, when n-3 PUFAs are incorporated into 
membrane lipids, membrane composition is altered leading to increased 
viscosity and minor changes in osmotic cell weakness (Fischer and Black, 
1991).  
          Here, the composition of fatty acids in HaCaT and 46BR.1N was studied 
only after EPA and DHA treatment and was not studied post UVR. The 
hypothesised that there would be a normal physiological replacement of fatty 
acids in the cells.  Other studies have shown the effect of UVR on EPA and 
DHA levels in keratinocytes. Initially, the concentration of EPA and DHA in 
HaCaT cells was 0%. Following treatment with 50µM of fatty acid the content of 
EPA and DHA was increased to 3.4% and 6.3%, respectively, and then 
decreased to 2% and 5.4% after cells were exposed to 100mJ/cm2UVB. (Storey 
et al., 2005). The concentration of EPA and DHA in CCD922SK fibroblasts 
increased from 5.7% and 3.2% in un-treated cells to 11.1% and 17.4% following 
EPA and DHA supplementation. This was then reduced to 10.3% and 14.8% 
after 100mJ/cm2 UVB (Storey et al., 2005). We found that 50mJ/cm2 decreased 
the viability of HaCaT and 46BR.1N to 50%, and this dose was considered toxic 
in our study. 
       UV irradiation had a negative effect on both the morphology of the cells and 
the growth parameters of the whole cell population. Many studies have reported 
that cell viability is reduced after exposure to UVR. The results of this study 
showed that HaCaT and 46BR.1N cell viability was decreased when these cells 
were exposed to various doses of UVR. Further decreases occurred when the 
cells were treated with EPA and DHA. On that basis, we hypothesised that this 
reduction in the cell viability may be due to induction of apoptosis. Apoptosis is 
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a controlled way used by tissues to remove abnormal cells. Deregulation of 
apoptosis is a hallmark of all cancer cells and can be considered a target for 
cancer therapeutics (Fadeel, 2004). PUFAs can regulate cellular proliferation 
and apoptosis through different mechanisms including gene expression, 
eicosanoid formation, signal transduction and lipid peroxidation (Field et al., 
2002). Findings from this study show that there is an increase in cell apoptosis 
post UVR when the cells are treated with EPA and DHA. Long-chain n-3 PUFAs 
have a highly unsaturated structure. This property makes them the target of 
oxidation by free radicals, resulting in the formation of lipid peroxides. This lipid 
peroxidation is thought to be the mechanism for n-3 PUFA-induced apoptosis 
and prevention of the growth of tumour cells (Albino et al., 2000). A highly 
unsaturated structure of n-3 PUFA may explain our finding that, DHA which has 
more double bonds than EPA, induced more apoptosis than EPA. It has been 
reported that supplementation of humans with fish oil at 2g/day (18%EPA and 
12%DHA) increased UV-induced production of lipid peroxidation. An increase in 
lipid peroxidation leads to a decrease in the ability of UV to induce erythema, 
which is partly mediated by ROS production. This suggests that the cellular 
structure is protected against oxidative damage by n-3 PUFA, which may act as 
oxidisable buffers (Rhodes et al., 1994). Moreover, apoptosis is also 
characterised by increased DNA fragmentation, decrease in nuclear size and 
translocation of the phosphatidyl serine phospholipid from inner to outer cell 
membrane. The ability of DHA to induce apoptosis to a greater extent than EPA 
may be a result of its ability to be incorporated in the phospholipid bilayer. The 
results show that HaCaT cells treated with 50 µM showed increased levels of 
DHA (7.20%) compared to EPA (3.02%) (Appendices 3.2 and 3.3). Moreover, 
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the level of DHA (15.06%) was greater than that of EPA (7.56%) in 46BR.1N 
after treatment with 50µM (Appendices 3.5 and 3.6). It has been reported that 
the effect of DHA in apoptosis could be due to its incorporation in the 
phospholipid bilayer, while EPA contributes to the formation of lipid bodies 
within the cell (Rudolph et al., 2001). Additionally, it was found that EPA and 
DHA induced the death of apoptotic cells in various cancer cell lines (Mund et 
al., 2007). This resulted in the increase of membrane unsaturation and fluidity 
with relocalisation of membrane signalling proteins followed by alteration in 
signal transduction and intracellular signalling pathways (Simopoulos, 2002). 
PUFAs have anti-carcinogenic properties facilitated via a reduced cancer cell 
growth, partly by cell signalling modification. Aspects of cellular development, 
growth and proliferation are mediated by the EGFR signalling pathway. Cancer 
development has been associated with mutations causing an increased 
expression or activation of EGFR. It has been reported that DHA 
supplementation consequently modulates EGFR phosphorylation, localisation 
and signalling. Further to the above, combining DHA with the EGFR inhibitor 
PD153035 was found to improve its actions (Rogers et al., 2010). Recently, it 
has been reported that both EPA and DHA can inhibit the growth of oral 
squamous cell carcinoma (SCC) cell lines but not normal keratinocytes. Low 
doses of EPA, in particular, inhibited the growth of pre-malignant and malignant 
keratinocytes by a combination of cell cycle arrest and apoptosis. Moreover, this 
was associated with the  auto-phosphorylation of EGFR and the sustained 
phosphorylation of extracellular signal-regulated protein kinases 1 and 2 
(ERK1/2) (Nikolakopoulou et al., 2013).  
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          N-3 PUFA can also act through an alteration of cytokine expression; the 
overproduction of pro-inflammatory cytokines is caused by an imbalance of n-6 
and n-3 PUFAs. IL-1 and TNF are major proinflammatory cytokines. The impact 
of fish oil supplementation on the monocyte production of IL-1β and TNF-α was 
studied in nine healthy volunteers ingesting 16gm/day of fish oil. Six weeks after 
supplementation, reduction in IL-1β, IL- α and TNF-α cytokines was found 
(Endres, 1993). Furthermore, the long chain n-3 PUFAs, EPA and DHA 
decreased the baseline secretion of another pro-inflammatory mediator IL-8 and 
they decreased the post-UV release of IL-8 from keratinocytes and fibroblast 
cell lines. EPA and DHA also reduced the expected TNF-α stimulation of IL-8 
secretion (Storey et al., 2005). In addition, studies have shown that n-3 PUFAs 
can modulate the expression of various genes as well as influencing the 
activation of numerous transcription factors. Changes in a cell’s PUFA content 
influences a significant transcription factor such as NFkB. Increased regulation 
of NFkB is seen in response to stress and inflammation and has been known to 
activate numerous genes involved in carcinogenesis. Hardman (2002) reported 
that n-3 PUFAs were shown to prevent COX-2 gene expression by inhibition of 
NFkB (Hardman, 2002). The suppression of AA metabolism inhibited the 
activation of NFkB. Moreover, NFkB was found to be activated by PGE2 and 
inhibited by EPA; this may indicate that possibility of a balancing role for an n-3: 
n-6 PUFA ratio in the important control of NFkB expression (Camandola et al., 
1996). The peroxisome proliferator activated receptors (PPAR) are also affected 
by the n-3: n-6 PUFA ratio. These PPARs are nuclear receptors that regulate 
gene activity. PPAR-γ can be activated by metabolites of n-6 PUFA such as 
PGE2, which induce COX-2 expression. COX-2 expression can be deregulated 
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by the n-3 PUFA, EPA, in human keratinocytes via the PPAR-γ receptor. This 
indicates that a ratio of n-6: n-3 PUFA in the diet may regulate gene expression 
(Chene et al., 2007).  
            In order to measure the eicosanoids and related mediators produced by 
HaCaT and 46BR.1N cells, the cell culture media were analysed by LC/ESI-
MS/MS. Results from HaCaT keratinocyte showed that the amount of 
prostaglandins, hydroxy fatty acids and epoxy fatty acids was 68, 109 and 4 
pg/million cells (or 37.5%, 60.0% and 2.5% of total lipid extract) respectively.  
Analysis of 46BR.1N showed that the amount of prostaglandins, hydroxy fatty 
acids and epoxy fatty acids was 174, 614 and 8 pg/million cells (or 22%, 77.0% 
and 1% of total lipid extract) respectively.  All mediators were found at higher 
levels in 46BR.1N than in HaCaT. The results also show that 13-HODE, PGE2 
and 12-HETE were the main mediators produced by HaCaT and 46BR.1N at 
baseline and post UVR. The level of these mediators decreased when the cells 
were treated with EPA and DHA, with or without UVR. PGE3, 15-HEPE and 17-
HDHA were the main n-3PUFA mediators. The levels of these mediators 
increased post UVR, and after EPA and DHA treatment. It has been known that 
PGE2 has an important role in keratinocyte proliferation and apoptosis during 
homeostasis (Chun et al., 2007, Chun et al., 2010).  Furthermore, PGE2 had 
been mediating the vasodilatation of UVR inducing an inflammatory response in 
humans. 12-HETE has chemoattractant properties that have been important in 
some skin diseases such as psoriasis (Barr et al., 1984) and inflamed skin 
(Black et al., 1985). The actions of anti-inflammatory mediators in the skin are 
not completely known, but increasing the level of anti-inflammatory mediators 
and inducing a significant reduction in inflammatory mediators following UVR 
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exposure, suggests that increased content of EPA and DHA may contribute to 
the regulation of cutaneous inflammatory responses. The UVR increases the 
liberation of AA and other PUFAs from membrane phospholipids. EPA 
competes with AA, and although it is no better than AA substrate for COX, EPA 
produces PGE3, which is markedly less effective than PGE2. The results of this 
study, as expected, showed a potentially protective effect of n-3 PUFAs against 
UVR, but the study was not expected to find that DHA had a more potent role 
than EPA. Specifically: DHA decreases cell viability, increases cell apoptosis 
and decreases pro-inflammatory mediators such as PGE2 post UVR more than 
EPA.  
          Overall, this study suggests that the protective role of n-3 PUFAs may be 
the result of inhibiting the activity of COX and LOX. Our results show that the 
epoxy fatty acid 14,(15)-EET was detected in HaCaT and 46BR.1N cells.  
Furthermore, the dihydroxy fatty acid 14, 15-DHET was detected in HaCaT and 
46BR.1N cells. The levels of these mediators were increased post UVR and 
were not affected by the n-3 PUFA treatment.  
          As a conclusion from the above, the in vitro experiments suggest that n-3 
PUFAs have a beneficial role when incorporated in cells and increase their 
concentration. This result in increased cell death post UVR, decreased 
inflammatory mediators such as PGE2 and increased anti-inflammatory 
mediators such as PEG3, HEPE and HDHA. The next question should be as 
follows: Do the n-3 PUFAs have the same effect in vivo? In order to answer this 
question a clinical study was performed using healthy volunteers. The active 
group was supplemented with 4g/day n-3 PUFAs. The content of fatty acid in 
RBC was analysed to show the compliance, and skin (dermal) fatty acid was 
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used to assess the target system. The content of EPA, DPA and DAH in RBC 
increased after n-3 PUFA supplementation while only EPA in dermal tissue was 
significantly increased after n-3PUFA supplementation. Although the aim of this 
study was achieved when by monitored the increase in the content of EPA in 
the skin, but there was no big change in the amount of EPA. This may because 
the baseline EPA was lower in this group of volunteers (Wallingford et al., 2012).               
8.2. Future work 
                      Many of the results of this study were in agreement with other 
studies in that a decrease in cell viability was observed when cells were treated 
with n-3 PUFAs and exposed to UVR. The results also suggest that both UVR 
and the n-3 PUFA EPA and DHA increase apoptosis in HaCaT and 46BR.1N 
cells in a dose-dependent manner. Moreover, further increases in apoptosis 
were observed when cells were treated with n-3 PUFAs and exposed to UVR. 
More studies are needed to fully understand the mechanism of this action and 
to assess the effect of UVR and n-3 PUFAs in the extrinsic and intrinsic 
pathways of apoptosis. 
           Caspases are central components for apoptosis. Caspases involved in 
apoptosis are generally divided into two groups, the initiator caspases, which 
include caspase-2, -8, -9, and -10, and the effector caspases, which include 
caspase-3, -6, and -7. It will be useful to assess the capacity of n-3 PUFA to 
activate the caspases. This can be achieved by treating the HaCaT 
keratinocytes and 46BR.1N fibroblasts cells with and without n-3 PUFA in the 
presence and absence of specific inhibitors of the different caspases. Changes 
in levels of caspase expression can be measured using western blotting and 
changes in activity by specific ELISAs. These experiments will clarify which 
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caspases important in apoptosis are modulated by n-3 PUFA. Also in parallel 
with this, it will be useful to compare other compounds which play an important 
role in modulating the apoptosis pathways such as cytochrome c, BAX and tBid. 
A better understanding of how n3 PUFA modulates apoptosis may help to 
explain the mechanisms of action for these fatty acids in the skin. 
          Activation of the extrinsic apoptosis pathway may also be a mechanism of 
n-3 PUFA action to induce apoptosis. This pathway is commonly activated by 
death receptors. Death receptors may be activated directly by the fatty acids or 
their bioactive mediators. This could be assessed by treating the HaCaT 
keratinocytes and 46BR.1N fibroblasts cells with n-3 PUFA in the presence and 
absence of specific inhibitors of the death receptors. 
          The intracellular concentration of ROS appears to dictate stress survival 
apoptotic responses. Low levels of ROS are utilised within the cells as signalling 
intermediates for normal homeostasis. However, high levels of ROS directly 
damages cellular structural components and can induce apoptosis. Furthermore, 
it has been reported that n-3 PUFA produces ROS resulting in the formation of 
lipid peroxides. According to this, production of ROS can be a mechanism for n-
3 PUFA-induced apoptosis and prevention of the growth of cancer cells. This 
mechanism can be followed by treating the HaCaT keratinocyte and 46BR.1N 
fibroblasts cells with or without n-3 PUFA and with or without a ROS 
inhibiter such as diphenyleneiodoniuma and N-acetyl-L-cysteine. 
              Analysis of fatty acid profile on HaCaT and 46BR.1N with and without 
n-3 PUFA treatment showed an increase in the content of these fatty acids in 
the cells. It may be better to analyse the fatty acid profile in these cells post 
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UVR with and without n-3 PUFA treatment. This may help to explain and 
provide an understanding of the effect of UVR on the fatty acid profile of these 
cells, PUFAs in prostanoids and hydroxy fatty acids. 
          The results in this study showed an increase in inflammatory mediators 
such as PGE2 post UVR and showed that n-3PUFA reduced pro-inflammatory 
and increased anti-inflammatory mediators such as PGE3. To fully understand 
these findings, we must explore their mechanism of action so that we can 
understand how they work. Further studies are needed to investigate the 
relationship between n-3 PUFA mediators and gene expression and protein 
expression of lipid enzymes such as COX and LOX. All the experiments in this 
study were performed at 24h post UVR. It would be beneficial to repeat these 
experiments with more time points before and after 24h to investigate the up or 
down-regulation of COX and LOX expression and their bioactive lipids.  
          Studies with EPA and DHA suggest that their effect of protecting the skin 
against UVR may be related to their direct action, or to the action of their 
metabolites. More experiments are needed to investigate which of these fatty 
acids performs best in protecting skin and treating skin disorders. Moreover, the 
results showed an increase in the level of DPA post EPA and DHA treatment. 
More studies are needed to investigate the specific biological properties and 
active biological mediators of DPA. It will be more useful to treat the HaCaT 
keratinocytes and 46BR.1N with DPA to investigate; A) The effect of DPA on 
HaCaT and 46BR.1N cells viability and apoptosis, B) The effect of DPA on the 
eicosanoids produced by HaCaT and 46BR.1N cells, C) The effect of DPA on 
COX and LOX expression. This can be achieved by treating the cells with DPA 
and then comparing the viability and apoptosis of cells that have been exposed 
259 
 
to UVR with those that have not. Also the effects of DPA on the production of 
eicosanoids can be assessed by analysis of the cell medium by LC/ESI-MS/MS.    
          Finally, all in vitro experiments in this study were performed on HaCaT 
and 46BR.1N cells which are cell lines. It would be more beneficial to the 
understanding of the effect of n-3PUFA on skin cells to repeat these 
experiments on primary human skin cells such as primary keratinocytes and 
primary fibroblasts. Skin punch biopsies should take from a site that has not 
been exposed to UVR, to avoid any cellular changes induced by UVR. 
Moreover, the clinical study was performed in order to assess the effect of n-3 
PUFA on skin fatty acids profile. After three months of EPA ethyl ester (~72%) 
and DHA ethyl ester (10%) 4g daily supplementation only the composition of 
EPA was slightly increased in skin post supplementation. It will be useful to 
design and apply a new clinical study which increases the amount of DHA in the 
supplementation and the daily dose. This will increase the composition of n-3 
PUFA in skin which has a role of protecting it against UVR.   
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APPENDIX.1 
APPENDIX 1.1 
Complete RPMI 1640 medium 
RPMI 1640 media 450ml  
Fetal calf serum 50ml 
Penicillin (10,000U/ml) Streptomycin (10mg/ml)  
Amphotericin B (2.5ng/ml) 
RPMI 1640 serum free medium 
RPMI 1640 media 500ml 
Penicillin (10,000U/ml) Streptomycin (10mg/ml)  
Amphotericin B (2.5ng/ml) 
Complete Dulbecco’s Modified Eagle Medium (DMEM) 
DMEM media 450ml 
Fetal calf serum 50ml  
Sodium Pyruvate 1mM 
Penicillin (10,000U/ml) Streptomycin (10mg/ml)  
Amphotericin B (2.5ng/ml) 
Dulbecco’s Modified Eagle (DMEM) serum free Medium 
DMEM media 500ml 
Sodium Pyruvate 1mM 
Penicillin (10,000U/ml) Streptomycin (10mg/ml) Amphotericin B (2.5ng/ml) 
Complete Minimum Essential Medium Eagle (MEME) 
MEME media 425ml 
L-glutamine 2mM 
Non Essential Amino acids 1% 
Sodium Pyruvate 1mM 
Fetal Bovine serum 75ml 
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Penicillin (10,000U/ml) Streptomycin (10mg/ml)  
Amphotericin B (2.5ng/ml) 
Complete Minimum Essential Medium Eagle (MEME) serum free Medium 
MEME media 500ml 
L-glutamine 2mM 
Non Essential Amino acids 1% 
Sodium Pyruvate 1mM 
Penicillin (10,000U/ml) Streptomycin (10mg/ml)  
Amphotericin B (2.5ng/ml) 
Oleic Acid stock solution (50mM) 
Oleic acid 26 mg 
Dimethyl sulfoxide (DMSO) 1.84 ml 
Aliquoted (55µl each) and stored at -20°C. Each aliquot is used only once. 
Eicosapentaenoic Acid stock solution (50mM) 
Eicosapentaenoic Acid 10 mg 
Dimethyl sulfoxide (DMSO) 0.66 ml 
Aliquoted (55µl each) and stored at -20°C. Each aliquot is used only once. 
Docosahexaenoic Acid stock solution (50mM) 
Docosahexaenoic acid 25 mg 
Dimethyl sulfoxide (DMSO) 1.5 ml 
Aliquoted (55µl each) and stored at -20°C. Each aliquot is used only once. 
10mM H2O2 
100µl H2O2 1M 
900 µl media 
5%V/V Dye 
500µl APOPercentage Dye 
9500 µl cell culture media 
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Reagent A and B 
 Reagent A 500 µl/well Reagent B 500 µl/well 
Reagent Blank  Culture media Reagent A 
Negative control Culture media Reagent A + 5%V/V Dye 
Positive control Culture media+ reference 
apoptotic agent 
Reagent A + 5%V/V Dye 
Test samples Culture media + test 
apoptotic agent 
Reagent A + 5%V/V Dye 
 
APPENDIX 1.2 
0.01% (w/v) BHT in 2:1 chloroform: methanol  
0.030 g BHT dissolved in 200ml chloroform and 100ml methanol and stored at 
room temperature for a month.   
0.5M Potassium chloride (KCL) in 50% methanol  
7.455 g potassium chloride dissolved in 100ml water and 100ml methanol and 
stored at room temperature for a month   
Toluene: Methanol (50/50) (v/v) 
10 ml toluene mixed with 10 ml methanol. Stored in a clean glass container at 
4°C. 
10% (w/v) Potassium Carbonate (K2CO3) solution:  
10.0 g potassium carbonate dissolved in 100ml deionised water and stored at 
room temperature for a month.   
APPENDIX 1.3 
Hydrochloric acid (HCl) 1M 
8.5 ml HCl 
100ml water 
Methanol 15% 
45ml methanol 
255ml water 
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APPENDIX. 2 
Appendix 2.1 Fatty acid profile of RBC pre and post n-3PUFA supplementation in 
Placebo and Active groups. Results are expressed as % weight of total fatty acid 
(mean ± SEM).  
FATTY 
ACID 
Placebo PRE 
n=33 
Placebo POST 
n=33 
Active PRE 
n=35 
Active POST 
n=35 
C12:0 0.08 ± 0.01 0.10 ± 0.02 0.11± 0.02 0.10 ±0.02 
C14:0 0.62 ± 0.11 0.63 ±0.11 0.70 ± 0.12 0.63 ± 0.11 
C15:0 0.16 ± 0.03 0.15 ±0.03 0.15 ± 0.03 0.15 ± 0.03 
C16:0 26.19 ± 4.56 25.18 ± 4.38 24.93 ± 4.15 24.44 ± 4.13 
C17:0 0.31 ± 0.05 0.28 ± 0.05 0.32 ± 0.05 0.31± 0.05 
C18:0 15.30 ± 2.66 14.81± 2.58 14.51 ± 2.42 14.41± 2.44 
C20:0 0.30 ± 0.05 0.25 ± 0.04 0.247 ± 0.04 0.23± 0.04 
C22:0 0.62 ± 0.11 0.48 ± 0.08 0.57 ± 0.09 0.54 ± 0.09 
C23:0 0.10 ± 0.02 0.07 ± 0.01 0.0744 ± 0.01 0.08 ± 0.01 
C24:0 1.71 ± 0.30 1.46 ± 0.25 1.6672 ± 0.28 1.36 ± 0.23 
ΣSFA 45.38 ± 7.90 43.41 ± 7.56 43.25 ± 7.21 42.26 ± 7.14 
C14:1 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 0.01 ± 0.01 
C15:1 0.01 ± 0.01 0.01 ±0.01 0.01 ± 0.01 0.01 ± 0.01 
C16:1 0.80 ± 0.14 1.05 ±0.18 0.87 ± 0.15 0.71 ±0.12 
C17:1 0.01 ±0.01 0.01 ± 0.01 0.01 ± 0.01 0.03 ±0.01 
C18:1n-9t 0.12 ±0.02 0.09 ± 0.02 0.14 ± 0.02 0.06 ±0.01 
C18:1n-9c 16.58 ±2.89 16.57 ±2.88 16.67 ± 2.78 16.67 ± 2.82 
C18:1n-7 1.19 ±0.21 1.13 ±0.20 1.12 ± 0.19 1.44 ± 0.24 
C20:1n-9 0.37 ±0.06 0.45 ±0.08 0.54 ± 0.09 0.31 ± 0.05 
C22:1n-9 0.10 ± 0.02 0.09 ±.0.02 0.09 ± 0.01 0.11±0.02 
C24:1 1.73 ±.30 1.40 ±.0.24 1.49 ± 0.25 1.49 ± 0.25 
ΣMUFA 20.93 ± 3.64 20.79 ± 3.62 20.94 ± 3.49 20.84 ± 3.52 
C18:2n-6t 0.06 ± 0.01 0.06±0.01 0.06 ± 0.01 0.03 ± 0.01 
C18:2n-6c 15.05 ± 2.62 15.51± 2.70 14.23 ± 2.37 13.73 ± 2.32 
C18:3n-6 0.17 ± 0.03 0.16 ±.0.03 0.21 ± 0.03 0.11 ± 0.02 
C20:3n-6 1.96 ± 0.34 1.97 ± 0.34 1.80 ± 0.30 1.56 ± 0.26 
C20:4n-6 13.45 ± 2.34 12.77 ± 2.22 12.31 ± 2.05 11.84 ± 2.00 
ΣN-6PUFA 30.69 ± 5.34 30.46 ± 5.30 28.61 ± 4.77 27.28 ± 4.61 
C18:3n-3 0.34 ±.0.06 0.37 ±.0.07 0.46 ±.0.08 0.31 ± 0.05 
C20:3n-3 0.01 ± 0.01 0.03±.0.01 0.02 ±0.001 0.02 ± 0.001 
C20:5n-3 0.90 ± 0.16 0.92 ±0.16 0.93 ±.0.15 3.61 ± 0.61 
C22:5n-3 1.98 ± 0.35 1.93 ±.0.34 1.85 ±0.3 3.19 ± 0.54 
C22:6n-3 3.53 ±.0.62 3.53 ±0.61 3.61 ±0.60 4.20 ± 0.71 
ΣN-3PUFA 6.76 ± 1.18 6.79 ± 1.18 6.88 ± 1.15 11.34 ±1.92  
C20:2 0.18 ± 0.03 0.26 ± 0.05 0.19 ±0.03 0.20 ±0.03 
C22:2 0.06 ±0.01 0.04 ± 0.01 0.07 ±0.01 0.06 ±0.01 
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Appendix 2.2 Fatty acid profile of dermis pre and post supplementation, in the Placebo 
and Active groups. Results are expressed as % weight of total fatty acid (mean ± SEM).  
 
FATTY  
ACID 
Placebo PRE 
n=14 
Placebo POST 
n=14 
Active PRE 
n=19 
Active POST 
n=19 
C12:0 0.18 ± 0.05 0.21 ± 0.05 0.18 ± 0.04 0.17 ± 0.04 
C14:0 1.82 ± 0.49 1.82 ± 0.49 1.84 ± 0.42 1.76 ± 0.40 
C15:0 0.22 ± 0.06 0.24 ± 0.06 0.24 ± 0.05 0.21 ±  0.05 
C16:0 19.97 ± 5.34 20.52 ± 5.48 21.85 ± 5.01 19.06 ± 4.37 
C17:0 0.19 ± 0.05 0.23 ± 0.06 0.21 ± 0.05 0.13 ± 0.03 
C18:0 2.75 ± 0.73 3.72 ± 0.99 3.66 ± 0.84 2.57 ± 0.59 
C20:0 0.16 ± 0.04 0.13 ± 0.03 0.20 ± 0.05 0.16 ± 0.04 
C22:0 0.02 ± 0.01 0.04 ± 0.01 0.04 ± 0.01 0.01 ±0.01 
C23:0 0.01 ± 0.01 0.01 ± 0.01 0.03 ± 0.01 0.00 ±0.00 
C24:0 0.07 ± 0.02 0.07 ± 0.02 0.06 ± 0.01 0.05 ± 0.01 
ΣSFA 25.38 ± 6.78 26.97 ± 7.71 28.31 ± 6.50 24.13 ± 5.54 
C14:1 0.52 ± 0.14 0.49 ± 0.13 0.52 ± 0.12 0.57 ± 0.13 
C15:1 0.03 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.01 ± 0.01 
C16:1 9.76 ± 2.61 8.21 ± 2.19 10.13 ± 2.23 10.38 ± 2.38 
C17:1 0.17 ± 0.05 0.17 ± 0.04 0.19 ± 0.04 0.21 ± 0.05 
C18:1n-9t 0.92 ± 0.25 0.72 ± 0.19 0.80 ± 0.18 0.34 ± 0.08 
C18:1n-9c 45.81 ± 12.24 46.01 ±12.30 42.28 ± 9.70 46.82 ± 10.74 
C18:1n-7 2.93 ± 0.78 3.28 ± 0.88 3.20 ± 0.73 2.75 ± 0.63 
C20:1n-9 0.45 ± 0.12 0.44 ±0.12 0.37 ± 0.08 0.39 ± 0.09 
C22:1n-9 0.05 ± 0.01 0.06 ± 0.02 0.07 ± 0.02 0.03 ± 0.01 
C24:1 0.03 ± 0.01 0.04 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 
ΣMUFA 60.66 ± 16.21 59.43 ± 15.88 57.61 ± 13.22 61.52 ± 14.11 
C18:2n-6t 0.14 ±0.04 0.14 ± 0.04 0.14 ± 0.03 0.10 ± 0.02 
C18:2n-6c 11.04 ± 3.07 10.99 ± 2.94 10.58 ± 2.43 11.63 ± 2.67 
C18:3n-6 0.07 ± 0.02 0.08 ± 0.02 0.06 ± 0.01 0.07 ± 0.02 
C20:3n-6 0.21 ± 0.06 0.22 ± 0.06 0.22 ± 0.05 0.19 ± 0.04 
C20:4n-6 0.57± 0.15 0.66 ± 0.18 0.73 ± 0.17 0.61 ± 0.14 
ΣN-6PUFA 12.47 ± 3.33 12.08 ± 3.23 11.74 ± 2.69 12.60 ± 2.89 
C18:3n-3 0.76 ± 0.20 0.69 ± 0.19 0.74 ± 0.17 0.81 ± 0.19 
C20:3n-3 0.04 ± 0.01 0.04 ± 0.01 0.04 ± 0.01 0.04 ± 0.01 
C20:5n-3 0.05 ± 0.01 0.06 ± 0.02 0.08 ± 0.02 0.12 ± 0.03 a,b 
C22:5n-3 0.18 ± 0.05 0.19 ±0.05 0.21 ± 0.05 0.24 ± 0.05 
C22:6n-3 0.14 ± 0.04 0.16 ± 0.04 0.20 ± 0.05 0.21 ± 0.05 
ΣN-3PUFA 1.17 ± 0.31 1.14 ±0.31 1.27 ±0.29 1.42 ±0.33 
C20:2 0.31 ± 0.08 0.36 ± 0.10 1.05 ± 0.24 0.32 ± 0.07 
C22:2 0.01 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.01 ± 0.01 
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Appendix 2.3 Fatty acid profile of human epidermis, dermis and RBC. Results are 
expressed as % weight of total fatty acid (mean ± SD) 
Fatty 
acid 
Epidermis  
n=5 
Dermis 
n=5 
RBC 
n=5 
C12:0 0.43 ± 0.20 0.18 ± 0.05 0.06 ± 0.06 
C14:0 3.03 ±1.24 1.86 ± 0.43 0.62 ± 0.13 
C15:0 0.96 ± 0.73 0.25 ± 0.05 0.15 ± 0.04 
C16:0 20.97 ±1.61 19.73 ± 6.69 24.81 ± 1.01 
C17:0 0.50 ± 0.05 0.16 ± 0.12 0.31 ± 0.08 
C18:0 10.65 ± 0.76 2.83 ± 1.35 13.52 ± 0.90 
C20:0 0.28 ± 0.06 0.17 ± 0.09 0.30 ± 0.09 
C22:0 0.00 ± 0.00 0.02 ± 0.01 0.68 ± 0.15 
C23:0 0.15 ± 0.01 0.01 ± 0.01 0.11 ± 0.03 
C24:0 0.34 ± 0.12 0.03 ± 0.02 1.50 ± 0.53 
ΣSFA 37.29 ± 4.52 25.24 ± 8.03 42.08 ± 1.11 
C14:1 0.31 ± 0.12 0.68 ± 0.35 0.01 ± 0.01 
C15:1 0.00 ± 0.00 0.05 ± 0.03 0.01 ± 0.01 
C16:1 6.36 ± 1.28 11.38 ± 3.66 0.99 ± 0.53 
C17:1 0.30 ± 0.01 0.23 ± 0.15 0.01 ± 0.03 
C18:1n-9t 0.17± 0.02 0.40 ± 0.25 0.03 ±0.02 
C18:1n-9c 35.09 ± 3.25 44.93 ± 7.53 17.58 ± 1.49 
C18:1n-7 2.73 ± 0.56 3.22 ± 0.69 1.27 ± 0.22 
C20:1n-9 0.43 ± 0.08 0.41 ± 0.05 0.25 ± 0.03 
C22:1n-9 0.35 ± 0.06 0.04 ± 0.02 0.08 ± 0.04 
C24:1 0.20 ± 0.07 0.03 ± 0.02 2.28 ± 0.69 
ΣMUFA 45.94 ± 4.99 61.36 ± 8.61 22.50 ± 2.04 
C18:2n-6t 0.45 ± 0.33 0.11 ± 0.07 0.02 ± 0.01 
C18:2n-6c 10.77± 0.62 10.85 ± 1.94 14.28 ± 3.38 
C18:3n-6 0.11 ± 0.05 0.09 ± 0.001 0.16 ± 0.03 
C20:3n-6 0.49 ± 0.16 0.18 ± 0.06 1.92 ± 0.50 
C20:4n-6 2.32 ± 0.23 0.69 ± 0.14 13.51 ± 1.32 
ΣN-6PUFA 14.13 ± 0.67 11.92 ± 1.98 29.89 ± 2.47 
C18:3n-3 0.47± 0.09 0.73 ± 0.29 0.39 ± 0.11 
C20:3n-3 0.42  ± 0.01 0.03 ± 0.01 0.00 ± 0.00 
C20:5n-3 0.61± 0.94 0.07 ± 0.02 0.77 ± 0.47 
C22:5n-3 0.41± 0.03 0.18 ± 0.05 1.78 ± 0.17 
C22:6n-3 0.38 ± 0.08 0.19 ± 0.07 3.83 ± 0.51 
ΣN-3PUFA 2.29 ± 1.00 1.20 ± 0.30 6.77 ± 0.93 
C20:2 0.16 ± 0.04 0.27 ± 0.25 0.26 ± 0.24 
C22:2 0.18 ±0.16 0.01 ± 0.01 0.06 ± 0.01 
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Appendix 2.4 Sample GC-FID chromatogram of cocktail FAME standard 
(SIGMA). 
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APPENDIX .3 
 Appendix.3.1. Fatty acid profile of HaCaT cells before (control) and after treatment 
with OA 10µM and 50µM. Results are expressed as % weight of total fatty acids (mean 
± SD) of n=3 independent experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FATTY ACID Control OA 10M OA 50M 
C12:0 0.05 ± 0.04 0.11 ± 0.06 0.15 ± 0.06 
C14:0 1.52 ± 0.32 1.71 ± 0.22 1.82 ± 0.26 
C15:0 0.11 ± 0.07 0.14 ± 0.04 0.15 ± 0.04 
C16:0 18.96 ± 2.48 17.58 ± 1.22 18.29 ± 1.52 
C17:0 0.26 ± 0.12 0.16 ± 0.05 0.19 ± 0.07 
C18:0 15.32 ± 8.09 9.19 ± 2.94 9.99 ± 3.76 
C20:0 0.23 ± 0.08 0.27 ± 0.09 0.29 ± 0.10 
C22:0 1.0 ± 001 0.00 ± 00. 0.00 ± 00 
C23:0 0.03 ± 0.01 0.04 ± 0.001 0.04 ± 0.02 
C24:0 0.64 ± 0.53 0.42 ± 0.30 0.41 ± 0.28 
ΣSFA 37.11 ± 9.16 29.62 ± 4.93 31.31 ± 6.11 
C14:1 0.03 ± 0.10 0.16 ± 0.08 0.15 ± 0.11 
C16:1 9.85 ± 4.90 10.90 ± 3.88 10.44 ± 3.85 
C17:1 0.53 ± 0.08 0.46 ± 0.34 0.39 ± 0.26 
C18:1n-9t 0.09 ± 0.03 0.14 ± 0.03 0.32 ± 0.27 
C18:1n-9c 26.47 ± 1.77 31.53 ± 5.00 31.55 ± 4.11 
C18:1n-7 14.85 ± 5.17 16.42 ± 3.77 15.75 ± 4.26 
C20:1n-9 1.51 ± 0.39 1.96 ± 0.16 1.97 ± 0.16 
C22:1n-9 0.48 ± 0.32 0.69 ± 0.06 0.73 ± 0.34 
C24:1 0.35 ± 0.24 0.83 ± 0.68 0.47 ± 0.36 
ΣMUFA 54.22 ± 8.82 63.10 ± 14.01 61.76 ± 13.73 
C18:2n-6t 0.10 ± 0.09 0.16 ± 0.22 0.05 ± 0.02 
C18:2n-6c 2.19 ± 1.00 1.61 ± 0.49 1.56 ± 0.43 
C18:3n-6 0.13 ± 0.25 0.06 ± 0.05 0.06 ± 0.05 
C20:3n-6 0.43 ± 0.15 0.55 ± 0.34 0.40 ± 0.08 
C20:4n-6 3.04 ± 1.69 2.25 ± 0.80 2.08 ± 0.58 
ΣN-6PUFA 5.88 ± 2.64 4.62 ± 1.89 4.15 ± 1.15 
C18:3n-3 0.03 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 
C20:3n-3 0.33 ± 0.08 0.37 ± 0.14 0.42 ± 0.11 
C20:5n-3 0.25 ± 0.09 0.33 ± 0.07 0.32 ± 0.07 
C22:5n-3 1.00 ± 0.26 0.94 ± 0.11 0.97 ± 0.19 
C22:6n-3 1.13 ± 0.23 1.09 ± 0.12 1.09 ± 0.28 
ΣN-3PUFA 2.72 ± 0.49 2.75 ± 0.45 2.83 ± 0.66 
C20:2 0.18 ± 0.09 0.13 ± 0.06 0.14 ± 0.05 
C22:2 0.04 ± 0.02 0.02 ± 0.01 0.07 ± 0.06 
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Appendix.3.2. Fatty acid profile of HaCaT cells before (control) and after treatment 
with EPA 10µM and 50µM. Results are expressed as % weight of total fatty acid (mean 
± SD) of n=3 independent experiments. (a) comparing control to EPA10µM group and 
(b) comparing control to EPA 50µM group. a,b=p≤0.05, aa,bb=p≤0.001,aaa,bbb=p≤0.001.  
 
FATTY ACID Control EPA 10M EPA 50M 
C12:0 0.05 ± 0.04 0.11 ± 0.01 0.12 ± 0.07 
C14:0 1.52 ± 0.32 2.13 ± 0.33 1.97 ± 0.35 
C15:0 0.11 ± 0.07 0.21 ± 0.05 0.21 ± 0.06 
C16:0 18.96 ± 2.48 19.34 ± 0.64 19.20 ± 1.30 
C17:0 0.26 ± 0.12 0.19 ± 0.03 0.19 ± 0.03 
C18:0 15.32 ± 8.09 9.67± 1.21 10.95 ± 1.30 
C20:0 0.23 ± 0.08 0.21± 0.04 0.22 ± 0.02 
C22:0 0.0 001 0000 ± 000 0.00  ± 0.001 
C23:0 0.03 ± 0.01 0.03  ± 0.02 0.03 ± 0.001 
C24:0 0.64 ± 0.53 0.96 ± 0.26 0.72 ± 0.16 
ΣSFA 37.11 ± 9.16 32.85 ± 2.59 33.62 ± 3.29 
C14:1 0.03 ± 0.10 0.17 ± 0.09 0.14 ± 0.02 
C16:1 9.85 ± 4.90 11.39 ± 2.64 10.47 ± 1.44 
C17:1 0.53 ± 0.08 0.43 ± 0.38 0.48 ± 0.42 
C18:1n-9t 0.09 ± 0.03 0.08 ± 0.01 0.08 ± 0.02 
C18:1n-9c 26.47 ± 1.77 25.65 ± 0.87 24.63 ± 1.82 
C18:1n-7 14.85 ± 5.17 14.48 ± 3.08 10.09 ± 1.89 
C20:1n-9 1.51 ± 0.39 1.31 ± 0.46 0.83 ±  0.33 
C22:1n-9 0.48 ± 0.32 0.32 ± 0.29 0.26 ± 0.28 
C24:1 0.35 ± 0.24 0.19 ± 0.01 0.16 ± 0.02 
ΣMUFA 54.22 ± 8.82 54.02 ± 7.83 47.14 ±  6.23 
C18:2n-6t 0.10 ± 0.09 0.09 ± 0.03 0.09 ± 0.03 
C18:2n-6c 2.19 ± 1.00 2.79 ± 0.84 2.84 ± 0.76 
C18:3n-6 0.13 ± 0.25 0.08 ± 0.07 0.14 ± 0.02 
C20:3n-6 0.43 ± 0.15 0.67 ± 0.24 1.86 ± 0.34 
C20:4n-6 3.04 ± 1.69 4.44 ± 1.42 3.07 ± 1.19 
ΣN-6PUFA 5.88 ± 2.64 8.07 ± 2.60 8.09 ± 2.33
 
C18:3n-3 0.03 ± 0.01 0.04 ± 0.02 0.13 ± 0.08 
C20:3n-3 0.33 ± 0.08 0.34 ± 0.08 0.38 ± 0.02 
C20:5n-3 0.25 ± 0.09 0.65 ± 0.07 3.02 ± 0.44
bbb 
C22:5n-3 1.00 ± 0.26 2.62 ± 0.63
aa 6.00 ± 1.18bbb 
C22:6n-3 1.13 ± 0.23 1.24 ± 0.36 1.48 ± 0.26 
ΣN-3PUFA 2.72 ± 0.49 4.89 ± 1.16 11.02 ± 1.98
bbb 
C20:2 0.18 ± 0.09 0.22 ± 0.04 0.16 ± 0.01 
C22:2 0.04 ± 0.02 0.03 ± 0.00 0.02 ± 0.001 
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Appendix.3.3. Fatty acid profile of HaCaT cells before (control) and after treatment 
with DHA 10µM and 50µM. Results are expressed as % weight of total fatty acid (mean 
± SD) of n=3 independent experiments. (a) comparing control to DHA10µM group and 
(b) comparing control to DHA50µM group. a,b=p≤0.05, aa,bb=p≤0.001.   
 
FATTY ACID Control DHA 10M DHA 50M 
C12:0 0.05 ± 0.04 0.15 ±0.12 0.08 ± 0.04 
C14:0 1.52 ± 0.32 1.60 ±0.10 1.28 ± 0.12 
C15:0 0.11 ± 0.07 0.15 ±0.03 0.15 ± 0.03 
C16:0 18.96 ± 2.48 17.02 ±2.50 16.85 ± 1.10 
C17:0 0.26 ± 0.12 0.19 ±0.08 0.23 ± 0.06 
C18:0 15.32 ± 8.09 10.45 ±4.28 13.03 ± 2.49 
C20:0 0.23 ± 0.08 0.24 ±012 0.31 ± 0.07 
C22:0 1.0 ± 001 0.01 ±001 0.00 ± 0.001 
C23:0 0.03 ± 0.01 0.03 ±0.01 0.01 ± 0.05 
C24:0 0.64 ± 0.53 0.40 ±0.28 0.28 ± 0.21 
ΣSFA 37.11 ± 9.16 30.22 ±7.53 32.29 ± 4.18 
C14:1 0.03 ± 0.10 0.17 ±0.13 0.09 ± 0.05 
C16:1 9.85 ± 4.90 10.96 ±4.76 8.37 ± 2.43 
C17:1 0.53 ± 0.08 0.32 ±0.28 0.36 ± 0.24 
C18:1n-9t 0.09 ± 0.03 0.13 ±0.05 0.12 ± 0.05 
C18:1n-9c 26.47 ± 1.77 30.19 ±4.43 31.74 ± 3.09 
C18:1n-7 14.85 ± 5.17 15.74 ±5.33 9.86 ± 2.71 
C20:1n-9 1.51 ± 0.39 1.88 ±0.28 1.21 ± 0.44 
C22:1n-9 0.48 ± 0.32 0.64 ±0.06 0.60 ± 0.14 
C24:1 0.35 ± 0.24 0.47 ±0.26 0.51 ± 0.46 
ΣMUFA 54.22 ± 8.82 60.51 ±15.59 52.87 ± 0.61 
C18:2n-6t 0.10 ± 0.09 0.19 ±0.24 0.17 ± 0.18 
C18:2n-6c 2.19 ± 1.00 2.16 ±1.26 2.21 ± 1.05 
C18:3n-6 0.13 ± 0.25 0.03 ±0.01 0.07 ± 0.09 
C20:3n-6 0.43 ± 0.15 0.47 ±0.09 0.79 ± 0.14 
C20:4n-6 3.04 ± 1.69 2.51 ±1.18 2.44 ± 1.06 
ΣN-6PUFA 5.88 ± 2.64 5.36 ±2.78 5.68 ± 2.52 
C18:3n-3 0.03 ± 0.01 0.03 ±0.01 0.08 ± 0.05 
C20:3n-3 0.33 ± 0.08 0.33 ±0.14 0.54 ± 0.20 
C20:5n-3 0.25 ± 0.09 0.38 ±0.18 1.36 ± 1.11
b 
C22:5n-3 1.00 ± 0.26 1.10 ±0.09 1.46 ± 0.34 
C22:6n-3 1.13 ± 0.23 2.08 ±0.97 7.20 ± 3.26
bb 
ΣN-3PUFA 2.72 ± 0.49 3.93 ±1.39 10.63 ± 4.96
bb 
C20:2 0.18 ± 0.09 0.19 ±0.11 0.16 ± 0.09 
C22:2 0.04 ± 0.02 0.05 ±0.05 0.03 ± 0.02 
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Appendix.3.4. Fatty acid profile of 46BR.1Ncells before (control) and after treatment 
with OA 10µM and 50µM. Results are expressed as % weight of total fatty acid (mean 
± SD) of n=3 independent experiments. (a) comparing control to OA10µM group and (b) 
comparing control to OA 50µM group. a,b=p≤0.05. 
FATTY ACID Control OA 10M OA 50M 
C12:0 0.16 ± 0.11 0.22 ± 0.11 0.15 ± 0.04 
C14:0 1.00 ± 0.93 1.29 ± 0.25 1.23 ± 0.34 
C15:0 0.41 ± 0.05 0.43 ± 0.05 0.41 ± 0.05 
C16:0 00.68 ± 2.36 17.89 ± 0.88 17.05 ± 2.90 
C17:0 1.17 ± 0.13 1.01 ± 0.09 0.97 ± 0.16 
C18:0 26.83 ± 5.30 20.59 ± 2.27 18.50 ± 3.76 
C20:0 0.42 ± 0.05 0.35 ± 0.05 0.31 ± 0.08 
C23:0 0.05 ± 0.02 0.06 ± 0.02 0.06 ± 0.02 
C24:0 0.72 ± 0.26 1.03 ± 0.34 1.07 ± 0.37 
ΣSFA 51.94 ± 8.68 42.87 ± 2.93 39.75 ± 7.40 
C14:1 0.04 ± 0.03 0.02 ± 0.02 0.02 ± 0.02 
C16:1 1.79 ± 0.33 1.76 ± 0.48 1.68 ± 0.30 
C17:1 0.46 ± 0.31 0.58 ± 0.36 0.60 ± 0.34 
C18:1n-9t 0.23 ± 0.10 0.16 ± 0.11 0.09 ± 0.03 
C18:1n-9c 18.23 ± 2.98 24.47 ± 5.42 29.53 ± 9.06
b 
C18:1n-7 5.24 ±0.73 5.40 ±1.02 5.35 ± 0.57 
C20:1n-9 0.34 ± 0.08 0.42  ±0.12 0.49 ± 0.15 
C22:1n-9 0.35 ± 0.03 0.50 ± 0.22 0.43 ± 0.37 
C24:1 0.39 ± 0.21 0.38 ± 0.24 0.64 ± 0.17 
ΣMUFA 27.07 ± 4.79 33.69 ± 4.09 38.83 ± 8.82 
C18:2n-6t 0.23 ± 0.04 0.22 ± 0.07 0.21 ± 0.07 
C18:2n-6c 4.25 ±1.10 5.29 ± 1.76 5.17 ± 1.13 
C18:3n-6 0.08 ± 0.08 0.15 ± 0.13 0.15 ± 0.13 
C20:3n-6 0.65 ± 0.08 0.81 ± 0.10 0.77 ± 0.18 
C20:4n-6 9.40 ± 3.61 9.30 ± 3.46 8.29 ± 2.19 
ΣN-6PUFA 14.62 ± 5.10 15.76 ±5.00 14.58 ± 3.01 
C18:3n-3 0.19 ± 0.04 0.18 ± 0.06 0.18 ± 0.04 
C20:3n-3 0.49 ± 0.10 0.47 ± 0.12 0.45 ± 0.06 
C20:5n-3 0.94 ± 0.34 1.15 ± 0.60 0.85 ± 0.25 
C22:5n-3 1.82 ± 0.45 2.47 ± 0.96 2.00 ± 1.01 
C22:6n-3 2.68 ± 0.47 3.16 ±1.59 3.11 ± 0.74 
ΣN-3PUFA 6.11 ± 1.40 7.43 ± 1.94 6.59 ± 1.93 
C20:2 0.19 ± 0.04 0.21 ± 0.05 0.21 ± 0.04 
C22:2 0.04 ± 0.01 0.04 ± 0.01 0.04 ± 0.02 
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Appendix.3.5. Fatty acid profile of 46BR.1Ncell before (control) and before treatment 
with EPA 10µM and 50µM. Results are expressed as % weight of total fatty acid (mean 
± SD) of n=3 independent experiments. (a) comparing control to EPA10µM group and 
(b) comparing control to EPA 50µM group. a,b=p≤0.05, aa,bb=p≤0.001,aaa,bbb=p≤0.001. 
 
FATTY ACID Control EPA 10M EPA 50M 
C12:0 0.16 ± 0.11 0.14 ± 0.07 0.14 ± 0.07 
C14:0 1.00 ± 0.93 1.15 ± 0.26 1.20 ± 0.20 
C15:0 0.41 ± 0.05 0.38 ± 0.03 0.37 ± 0.03 
C16:0 00.68 ± 2.36 18.37 ± 0.94 17.37 ± 0.91 
C17:0 1.17 ± 0.13 1.07 ±  0.14 0.98 ± 0.11 
C18:0 26.83 ± 5.30 21.33 ± 1.49 19.57 ± 1.04 
C20:0 0.42 ± 0.05 0.37 ± 0.05 0.34 ± 0.08 
C23:0 0.05 ± 0.02 0.07 ± 0.05 0.03 ± 0.02 
C24:0 0.72 ± 0.26 0.86  ± 0.27 0.68 ± 0.06 
ΣSFA 51.94 ± 8.68 43.73  ± 3.31 40.68 ± 2.52 
C14:1 0.04 ± 0.03 0.04  ± 0.01 0.03 ± 0.01 
C16:1 1.79 ± 0.33 2.00  ± 0.13 1.98 ± 0.14 
C17:1 0.46 ± 0.31 0.42  ± 0.28 0.41 ± 0.31 
C18:1n-9t 0.23 ± 0.10 0.20  ± 0.08 0.14 ± 0.03 
C18:1n-9c 18.23 ± 2.98 19.45  ± 1.86 18.01 ± 0.95 
C18:1n-7 5.24 ±0.73 5.47 ± 0.26 4.85 ± 0.09 
C20:1n-9 0.34 ± 0.08 0.31 ± 0.08 0.24 ± 0.03 
C22:1n-9 0.35 ± 0.03 0.43 ± 0.06 0.52 ± 0.21 
C24:1 0.39 ± 0.21 0.50 ± 0.05 0.43 ± 0.25 
ΣMUFA 27.07 ± 4.79 28.83 ± 2.81 26.62 ± 2.01 
C18:2n-6t 0.23 ± 0.04 0.24 ± 0.06 0.20 ± 0.03 
C18:2n-6c 4.25 ±1.10 5.73 ± 0.93 5.27 ± 1.09 
C18:3n-6 0.08 ± 0.08 0.07 ± 0.05 0.07 ± 0.09 
C20:3n-6 0.65 ± 0.08 0.78 ± 0.19 0.74 ± 0.12
 
C20:4n-6 9.40 ± 3.61 9.88 ± 4.26 8.38 ± 3.08 
ΣN-6PUFA 14.62 ± 5.10 16.70 ± 5.49 14.67 ± 4.40 
C18:3n-3 0.19 ± 0.04 0.24 ± 0.02 0.31 ± 0.03
b 
C20:3n-3 0.49 ± 0.10 0.57 ± 0.09 0.45 ± 0.11 
C20:5n-3 0.94 ± 0.34 2.67 ± 0.19
aaa 6.57 ± 0.42bbb 
C22:5n-3 1.82 ± 0.45 4.03 ± 0.75
a 7.34 ± 1.49bbb 
C22:6n-3 2.68 ± 0.47 2.96 ±  0.59 3.20 ± 0.51 
ΣN-3PUFA 6.11 ± 1.40 10.47 ± 1.64 17.86 ± 2.57
bb 
C20:2 0.19 ± 0.04 0.18 ± 0.02 0.14 ± 0.01 
C22:2 0.04 ± 0.01 0.04 ± 0.01 0.03 ± 0.01 
ΣN-9PUFA 0.23 ± 0.05 0.22 ± 0.04 0.17 ± 0.02 
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Appendix.3.6. Fatty acid profile of 46BR.1Ncells before (control) and post treatment 
with DHA 10µM and 50µM. Results are expressed as % weight of total fatty acid (mean 
± SD) of n=3 independent experiments. (a) comparing control to DHA10µM group and 
(b) comparing control to DHA 50µM group. a,b=p≤0.05, aa,bb=p≤0.001,aaa,bbb=p≤0.001,   
 
FATTY ACID Control DHA 10M DHA 50M 
C12:0 0.16 ± 0.11 0.13 ± 0.05 0.12 ± 0.03 
C14:0 1.00 ± 0.93 1.31 ± 0.17 1.29 ± 0.23 
C15:0 0.41 ± 0.05 0.43 ± 0.07 0.43 ± 0.11 
C16:0 00.68 ± 2.36 18.27 ± 1.37 17.10 ± 1.11 
C17:0 1.17 ± 0.13 1.08 ± 0.09 0.75 ± 0.46 
C18:0 26.83 ± 5.30 21.14 ± 1.60 19.91 ± 1.00 
C20:0 0.42 ± 0.05 0.37 ± 0.05 0.31 ± 0.07 
C23:0 0.05 ± 0.02 0.06 ± 0.03 0.04 ± 0.02 
C24:0 0.72 ± 0.26 1.09 ± 0.40 0.93 ± 0.49 
ΣSFA 51.94 ± 8.68 43.88 ± 3.36 40.88 ± 2.92 
C14:1 0.04 ± 0.03 0.02 ± 0.03 0.02 ± 0.02 
C16:1 1.79 ± 0.33 2.03 ± 0.24 2.01 ± 0.10 
C17:1 0.46 ± 0.31 0.60 ± 0.43 0.54 ± 0.39 
C18:1n-9t 0.23 ± 0.10 0.14 ± 0.07 0.12 ± 0.05 
C18:1n-9c 18.23 ± 2.98 19.53 ± 1.61 17.82 ± 1.52 
C18:1n-7 5.24 ±0.73 5.65 ± 0.39 5.12 ± 0.56 
C20:1n-9 0.34 ± 0.08 0.42 ± 0.25 0.27 ± 0.07 
C22:1n-9 0.35 ± 0.03 0.34 ± 0.09 0.52 ± 0.10 
C24:1 0.39 ± 0.21 0.31 ± 0.19 0.30 ± 0.12 
ΣMUFA 27.07 ± 4.79 29.05 ± 2.31 26.72 ± 2.22 
C18:2n-6t 0.23 ± 0.04 0.22 ± 0.04 0.21 ± 0.03 
C18:2n-6c 4.25 ±1.10 5.75 ± 1.30 6.06 ± 1.38 
C18:3n-6 0.08 ± 0.08 0.22 ± 0.24 0.15 ± 0.11 
C20:3n-6 0.65 ± 0.08 0.99 ± 0.12a 0.98 ± 0.12a 
C20:4n-6 9.40 ± 3.61 9.49 ± 2.79 8.27 ± 2.50 
ΣN-6PUFA 14.62 ± 5.10 16.68 ± 3.65 15.66 ± 3.42 
C18:3n-3 0.19 ± 0.04 0.21 ± 0.05 0.26 ± 0.05 
C20:3n-3 0.49 ± 0.10 0.48 ± 0.11 0.40 ± 0.08 
C20:5n-3 0.94 ± 0.34 1.32 ± 0.19 1.38 ± 0.36 
C22:5n-3 1.82 ± 0.45 2.27 ± 0.96 2.08 ± 0.64 
C22:6n-3 2.68 ± 0.47 5.88 ± 2.51 15.06 ± 7.29bbb 
ΣN-3PUFA 6.11 ± 1.40 10.16 ± 3.19 19.17 ± 7.29bb 
C20:2 0.19 ± 0.04 0.21 ± 0.04 0.20 ± 0.07 
C22:2 0.04 ± 0.01 0.04 ± 0.02 0.04 ± 0.02 
